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I 
Introduction 
2 Chapter 1.1 
1.1 General Introduction 
In the early 1980's the treatment and prevention of pain in children, especially in 
newborns and infants, did not have a high priority in daily clinical practice. Following 
the pioneer work done both outside the Netherlands by Anand, Aynsley-Green, 
McGrath PA, and McGrath PJ and in our country by Boelen-van del' Loo, Huijer-Abu 
Saad, de Kuiper and various support groups the scope has changed. 
Infants, even prematurely born ones, are capable of feeling pain. I ,2.3 Cutaneous pain 
receptors are present over the whole body at 20 weeks post-conceptional age. By 30 
weeks myelinization of nerve tracts in the spinal cord, the brain stem and the thalamus 
is complete and the cerebral cortex is functionally prematlU'e in infants as well. I Due to 
the itmnatlU'e organisation of cOimections within the dorsal hom of the spitlal cord,4 
and the not yet fully develo~ed it,h,ibititlg processes pain thresholds itl neonates are 
lower than they are in adults. This pain threshold is lower itl pretenn ituants than it is 
itl full-term infants, and is presumed to increase after a number of painful procedures, 
and with postnatal age.6 However, contradicting these fmditlgs, recent research shows 
that tiu'esholds remaitllow after injmy to the contralateral leg even itl ituants who were 
tenn takillg conceptional age as a reference poin!.7 This suggests tilat exposure to 
frequent and multiple procedures in the neonatal intensive care writ (NICUl, which is 
very conunon especially itl the velY pretenn infant,' increases paitl awareness.' 
Thus newborn infants in fact are not only capable of feeling pain, but even seem to 
experience more pain than do older children and adults. 
Paitl results in stress, and this in its tum results itl metabolic instability. Primary stress 
responses to surgely were found to be significarltly greater itl ituants who did not 
receive analgesic drugs as compar'ed to tilOse who did receive analgesics, and tilese 
iluarlts were more susceptible to circulatolY arId metabolic complications 
. I 9·11 postoperative y, 
hI two classical papers, pnblished in the Lancet arId the New England Journal of 
Medicine, Anand and colleagues showed that preemptive anal\\esia following cardiac 
surgery dramatically decreased mortality and morbidity rates. II. 2 
The first studies of long-tenn effects of ear'ly pain experience show tilat neonatal pain 
leads to different responses to subsequent painful events. D.ll 
Despite convincing evidence from basic resear'ch, arId despite tile fact tilat more arId 
more nurses and doctors realize that preventing and treatitlg pain will improve 
outcome, many neonates are nowadays still subjected to umlecessary pain. 16.1• 
Followitlg new insights into the negative effects of pain and stress in newbol1ls, the 
prescription of systemic opioids for major surgery in newborn infants itlcreased from 
10% of infarllS in 1988 to 91% itl 1995.1' For neonates, 92% of anaestilesists used 
opioids in 1995 as compared Witil 18% in 1988." A survey of the use of analgesics for 
postoperative arId non-operative purposes in NICUs itl tile Ulrited Kingdom showed 
that 59% of these units used drugs for pain relief more than once a week, and 26% 
more than once a month. 19 A comparable study itl the USA revealed a 28.6-fold 
variation among NICUs in narcotic adnrinistration itl velY low-birth-weight neonates.20 
The ten NICUs in the Netherlands give analgesia in 40% of ventilated infants, in 80% 
after trawnatic delivery and before intubation, arId in 100% before chest draitl insertion 
or postoperatively.21 
Despite the increased awareness of the problem of procedural paitl itl infants, 
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clinicians generally believed that neither pharmacological agents nor comf01i measures 
were frequently used to manage infant pain,22 This is partly due to ignorance about the 
pharmacokinetics and phar'lnacodynamics of dlUgs; the lack of validated pain 
assessment instruments and finally the lack of proper training in pain assessment and 
management. Lack of readily available infonnation in the paediatric literature is a 
contributing factor as well,23 
Several editorials in the past 15 years pointed out that premature and newbom babies 
do feel pain and that it is time for a change in our attitude towards the prescription of 
analgesia in this age group, but unfortunatell the message had to be repeated over all 
tllese years, as attitude changes slowly,3,5,24,3 
Assessment of pain in neonates is hard to measure objectively, Several par'arneters 
have been used to measure pain, but these are mostly used in c01mection with acute 
sharp pain (Table I), Combining several of these parameters in both clinical and 
research Settlll§ has resulted in the development of a range of pain assessment 
instruments.33.3 
Several multicenter trials ar'e now in progress to validate and evaluate these 
instruments for specific conditions in pretenn, full-term, and surgical newbol1ls arId 
infants, 
Parameters used for pain assessment 
Behavioural 
Physiological 
Honnonal 
- Changes in facial expression, as 
brow bulge, nasolabial furrow 
-Cry 
- Flexor withdrawal of limb 
- Increase in heart rate 
- Increase in respirat01Y rate 
- Increase in blood pressure 
- Decrease in oxygen saturation 
- Increase in palmar sweating" 
- Increase in intracranial pressure 
- Increased plasma concentrations 
of catecholamines, cortisol, 
growth hormone, and glucagon 
- Decrease in insulin concentration 
Table J Parameters usedfor pain assessment in infants and children . • Not in preterlll ill/allIS; 
illler/U iI!lantspreselll after several days. 
In children, analgesia is generally provided by morphine and paracetamol and to a 
lesser extent by fentanyl. 
On the basis of the concept that neonates indeed can feel pain, several authors studied 
tlle effect on stress parameters,40.41 However, single dose effects were mostly 
investigated, whereas often data on multiple doses or continuous infusion are needed, 
Opiates are widely used, WiOl a wide range of doses, and adverse effects are commonly 
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reported,I',,, Paracetamol is Ule most commonly used non-opioid analgesic dmg; of 
which adverse effects are rarely repOlied,19 
In adults and older children pain relief is considered the most impOliant target in the 
adnllnistration of analgesia, and side effects are of secondary importance,32 The same 
should apply to infants and newborns, 
As they can feel pain, and invasive procedures resulting in pain or distress m'e 
frequently perfonned in infmlts admitted to the NICU,' studies evaluating the effects 
of morphine mid pm'acetamol in this age group are wan-anted, 
Of the drugs that have been approved by the Food and Drug Administration (FDA) in 
the past 30 years 80% may not be administered officially to newboms and validated 
data are lacking,43,44 In a recent survey in European paediatric hospitals, over half of 
Ule patients were given unlicensed or off-label drugs, among which morphine and the 
most widely prescribed dl1lg and analgesic paracetamol. 4S 
Phanllacokinetic and phm'macodynamic data are essential in Ule first few days after 
birth, as during transition mmry metabolic processes Imdergo rapid chmlges, Several 
factors affectinll pharmacokiuetics and drug metabolism change during the last weeks 
of gestatiOlI:,,4 and during the first days of life, In view of different body condition 
and composition in pretenll infants there are both arguments for better analgesia and 
m'guments for Ule opposite (Table 2)," 
Sensitivity to dmgs might be different as the effects of nm'cotics in infmlts of mothers 
who used narcotics dwing labour, wear off rapidly after hand bagging or low doses of 
naloxone, An interesting observation relates to infmlts whose moUlers had ingested a 
paracetamol overdose, They had toxic serum concentrations without apparent hepatic 
or renal toxicity,49,so 
As the above mentioned factors are influenced by gestational age, hUihweight, the 
presence of edema, inflammation, or oUler factors such as severity of illness, studies on 
boUI phmll1acokinetics and dynmnics of regularly used analgetic chugs are wml'mlted, 
in order to stmt mid adjust mlalgesics, 
Better mlalgesia 
- Reduced plasma albumin resultulg in 
more free, active circulating drug 
" Greater pelmeability of the blood braul 
bml'ier 
" Immature liver and kidney, resulting UI 
slower elimination 
Worse mlalgesia 
- Larger volume of distribution, leading 
to lower peak drug levels 
- Reduced number of receptors 
Table 2 FaCial'S Ihalmighl improve or dimillish allalgesia ill Ihe lIewho/'ll illjalll as compared 
10 older childrell alld adults 
1.1.1 Scope of the thesis 
This thesis described the use of Ule two most often used analgesic chugs, paracetamol 
(acetmllinophen) and morphine focussing on the phru1l1acokinetics and 
pharmacodynamics of Ulese chugs during the first days of life in relation to the use of 
pain assessment ulstruments, 
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The general development of the fctus' senses, touch, pain, hearing, smell and taste, and 
sight, is discussed in chapter 1.2, in the light of the fact that leaming abilities of the 
newborn organism increasingly prove to reflect continuity from prenatal life. 
A literature review on paracetamol, a dmg known for over a centmy after its fll'St 
introduction by Von Mering," is given in chapter II.!, concentrating on the relevance 
of therapeutic concentrations. 
Chapter 11.2 describes the method we developed to determine concentrations of 
paracetamol in serum, and of paracetamol and its metabolites in urine. Because an 
analgesic for moderate pain is not available for pre term neonates, we were prompted to 
investigate the phal1nacokinetics, metabolism, and pharmacodynamics of a single dose 
of paracetamol, as described in chapter 11.3. 
In daily practice, however, paracetamol is given as single dose and multiple dose 
therapy in case of suspected pain or fever in full teon infants, though always off-label, 
as label instmctions are only given for infants over 3 months of age. Consequently in 
chapter 11.4 multiple dose phal111aCokinetics and pharmacodynamics on the fIrst day of 
life are discussed. 
Multiple doses of paracetamol after an invasive procedure e.g. vacuum extraction have 
been given for suspected'pain to selected infants. We, therefore, studied the effIcacy of 
multiple doses of paracetamol following vacuum extraction, which is described in 
chapter 11.5 
Chapter IlL! describes the validation of a method to detennine morphine-
concentrations in neonatal serum, and discusses the possibilities to adjusttlle dose 
based on morphine concentration and a pain assessment instmment. 
As the morphine metabolites, morphine-3-glucuronide and morphine-6-glucul'Onide, 
are known to have an important effect on respiration and analgesia, and morphine is 
nsed in ventilated preteon infants for several days to weeks, the effects of two different 
dose regimens on phannacokinetics and phanllacodynamics were studied as reported 
in chapter 1II.2. 
Chapter IV contains a general discussion, as well as several options and wishes for 
future pain management and flUther studies. 
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1.2.1 Introduction 
The development of senses is a multidimensional process incorporating sensmy, 
emotional, affective, cognitive and evaluative abilities. For a long time it was rather a 
philosophical than a scientific question how early such abilities are acquired. Aristotle 
ah'eady anticipated tlle phenomenon that the sensOlY development is a quiet process of 
tlre prenate gradually responding to the extrauterine world. However, negative thinking 
about prenatal sensOlY capabilities was more common: Rousseau refened to the fetus 
as a "witless tadpole" isolated from the agitation of the world. Even first scientific 
approaches by Preyer in 1885 led to doubtful conclusions about fetal sensmy 
capacities l • The advent of technical advances allowed access to the unbom in the 
womb and the study mainly behavioural responses. Prechtl2 can be regarded as the 
pioneer of integrating observations of endogenously evoked behaviour into neonatal 
and prenatal surveillance. He stressed tlle clinical imporlance and provided us with a 
tool appropriate for the investigation of developmental responses towards internal and 
external stimuli. Reactive behavioural patterns towards touch, sound (including 
maternal noise), vibration, light, taste and odor have been observed and may be 
integrated into a cohesive whole, to describe developmental sensitivity. Besides 
behavioural reactions, responses may be mediated by physiological, honnonal or 
metabolic processes. Although tlle fetal brain can organize and elaborate stimulus 
infonnation and encode in memory the activation of reflex responses, it is still difficult 
to defme in how far tlle "memories" are 01' become conscious, reflect tlle present or 
contribute to future sensmy development. 
Tlris chapter tries to summarize some essential aspects and eventual clinical 
implications. 
1.2.2 Sensitivity and experience of pain 
Anatomy, sensmy physiology and responsiveness 
Cutaneous sensory receptors appeal' in the perioral area of the human fetus in the 7th 
week, spread to tlle face, hands and feet at around 11 weeks, to the tnmk, anns and 
legs at arornld 15 weeks and to all cutaneous and mucous surfaces at around 20 weeks. 
The spread of cutaneous receptors is accompalried by the development of synapses 
between sensmy fibers in tlle dorsal hom of the spinal cord, which first appear at 
aI'olUJd 6 weeks. Sensmy nerves first grow into the spinal cord at 14 weeks' gestation. 
Development of the fetal neocortex begins at 8 weeks. Most sensmy pathways to the 
neocmiex have synapses in the thalamus. Between 20 and 24 weeks thalamocortical 
fibers establish synaptic connections with dentritic processes of neocmiical neurons. 
After that time it is more likely that the fetus nright not only react towards but also 
"expedence" touch alld pain. In vivo measurements of glucose utilization have shown 
that maximal metabolic activity is located in sensOlY aI'eas of tlle neonatal brain, 
suggesting tlle Mlctional matrn·ity. The existence of neurotransmitters, endogenous 
opioids released pre- and perinatally in response to fetal stress and of stereospecific 
opiate receptors at spinal and supraspinal levels as well as behavioural reactions have 
fmiher increased our knowledge of sensory or painful sensation and offered 
implications for t:reatment. 3 
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As supposed for motor activities4 sensitivity to touch may develop before the response 
to relevant biological or psychological sensOlY input. Hooker was the fIrst to descdbe 
reactions towards cutaneous stimulation of embryos after therapeutic terminations of 
pregnancy by hysterotomy, maintaining them in an isotonic fluid bath,' With the 
inh'oduction of real-time ulh'asound, it became possible to observe early prenatal 
movements and behaviour,6 To shldy reactions of single fehlses towards touch iI/litera 
would be combined with ethical and practical restraints, However, twins are nahlrally 
exposed to cutaneous stimulations of the co-twin, enabling us to shldy the onset of 
reactions towards touch ill vivo, 
Touch, no reaction **~ First reaction 
** 
StOll' bodr contact 
:1 I I L: StOll' head contact I StOll' arm conlact I I 
Slow leg contact 1** I I~ Fast bod)' contact *~ 
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COIl1!Jlex contact 
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Figure 1 Onset of prenatal contacts in 20 dichorionic and 5 monochorionic diamlliotic twins 
flvin pairs (Box-Whisker plots) compared to two cases of mOl1oGnmiotic twins (.J , ultrasound 
observations at 1 week-intel1'ols 
Multiple pregnancies to shldv reactions to cutaneous stimulation ill vivo 
The onset of reactions towards touch can ideally be investigated in monoamniotic 
multiplets, since fIrst reactions towards touch are observed earlier than in 
monochOilonic diamniotic multiplets and again earlier than in dichorionic multiplets 
(Figure I). As described ill vitro' we found ill vivo that monoamniotic lI1ultiplets 
responded to tactile stimulation between 8 and 9 weeks,6 Early contacts in 
monoamniotic and monochorionic twin pregnancies are also more numerous compared 
to dichorionic ,pregnancies because the membranes may prevent early reaching and 
touch ill litera. The development of reactions towards cutaneous stimulations of a co-
twin in utero reveals different qualities. Up to 16 weeks, we have meanwhile analyzed 
several contact ~attems according to the speed of initiatives and reactions or part of the 
body involved, In advanced pregnancy, it is more difficult to differentiate fetal 
reactions to touch by conventional ultrasOJUld methods, Three-dimensional real-time 
ultrasOlUld may facilitate observations in the future. From early fetal heart rate 
(FHR)/fetalmovement analysis of singletons compared to twins, one can conclude that 
inter-twin reactions contribute to an increased munber of simultaneous FHR 
accelerations. 
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Gender differences have been reported for cognition, aggression and sociability in 
humans. Explanations have focused on nemoanatomic differences and exposure to 
steroid honnones. We have analyzed twin pairs with different gender combinations 
between 8 and 16 weeks. In the group of only male twins, fast initiatives combined 
with fast reactions and the lIIunber of complex contacts were significantly increased 
compared to only female or mixed twin pairs.7 It is suggested that differences of 
testosterone levels might have an impact on early development ill liteI'D. 
Limitations in the intelJlretation of our twin studies include difficulties in 
differentiating reactions to touch from a parallel onset of endogenously evoked 
movements, and passive from active reactions. 
It was speculated that the tactile stimuli of multiplets might improve their development 
during early follow-up examinations up to the age of 6 years, when multiplets scored 
better than singletons,7 and that not only activity that promotes growth and dendritic 
branching of individual neurons, but similarly, that sensation from receptor cells might 
promote the development of the nemal system.8 
1.2.3 Fetal pain 
Pain includes feeling, suffering and leaming (memory). The increasing number of 
prenatal techniques and of operations in premature neonates has given rise to 
controversial discussions how early and in how far fetuses and neonates feel pain. This 
has implications for professionals who provide abortions. Fetal responses to invasive 
teclmiques were observed as blood flow redistribution from 18 weeks9 and as an 
increase of cortisol and p-endolJlhin from at least 23 weeks of gestation. 10 
Nevertheless, the most rational approach is to make an informed guess based on 
knowledge of the development of the nervous system or measurements and 
obsetvations in preteI'm infants. Some authors argue for placing the onset of pain 
sensation at somewhere between 6 and 12 weeks after conception." Others define 
recorded responses before 26 weeks as reflexes without conscious appreciation, 
suggesting that, only then, it is likely that the fetus not only reacts towards a stimulus 
but also experiences pain. 12 It seems to be accepted that the thalamus may assume 
some functions to contribute to fetal awareness of pain, but it is still not known when 
the brain is mature enough to register pain. 
To avoid suffering and long-term effects, it is considered advisable to provide the fetus 
with analgesia. Suffering during termination of pregnancy is also a question of 
concem. The Royal College of Obstetricians and Gynaecologists recommends that 
practitioners who undertake diagnostic 01' therapeutic smgical procedures upon the 
fetus at or after 24 weeks consider the requirements of fetal analgesia and sedation, 
either by agents given to the mother or directly.l3 Before petfonning late tenninations 
of pregnancy it is suggested that fetocide be considered. Matemal analgesia which 
transfers across the placenta is supposed to be sufficient in cases with early 
tenninations of pregnancy. Research is needed to detennine how the detection and 
treatment of pain can be extended to the fetal patient in a direct way. 
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The preteml infant of 23 weeks' gestation shows reflex responses to noxious stimuli. A 
variety of physiological, hormonal, metabolic and behavioural changes have been 
observed after painful procedures; these include cardiovascular variables, palmar 
sweating, increase of renin, epinephrine (adrenaline), norepinephrine (noradrenaline), 
catecholamines and glucocorticoids, which are related to the intensity of the stimulus6. 
Stimulation of the cutaneous flexor reflex showed that reflex thresholds were 
proportionally related to increasing gestational age. 14 Therefore, infants under 32 
weeks might need even more analgesia to avoid stress responses and pain experience. 
In our group we score neonates from 24 weeks onwards according to the neonatal 
infant pain score (NIPS) looking at cry patteolS, breathing, body language and facial 
expressions. IS If we suspect Ulat infants experience pain from ventilation or invasive 
procedures we start treatment with morphine or acetaminophen (APAP). In a recent 
study we found significant higher concentrations with lower gestational age, two hours 
after administration of paracetamoL 16 We take advantage of the increased half-life due 
to decreased clearance of the drug in preteon infants to reach higher concentrations 
according to Ule supposed lower pain Ull'eshold (Figure 2). Little attention is given to 
the experience of pain during vacuum or forceps delivery. Newborns born by either of 
these procedmes in om mtit receive pain treatment directly aftcr birU!. 
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Figure 2 Lineal' regression analysis with confidence limits oj gestatiollal age 011 
acetalllillophell (APAP), cOllcelltratiolls at 120 lIIilllltes (16). 
},2,4 Hearing 
The onset and development of fetal hearing are dated by extrapolation from animal 
studies or from measurements in prematme babies and by studying prenatal reactions 
to acoustic stimuli. References to the extensive detailed literature on fetal hearing 
development can be obtained in a previous publication. 17 
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Anatomy. acoustic physiology 
From 10 weeks onwards the extemal ear and later even the tympanic membrane are 
visualized by ultrasolllld. The outer ear collects sound energy and shapes it towards the 
tympanic membrane. The ossicles of the middle ear develop between 4 and 6 
gestational weeks and reach full size by 18 weeks. Only then they become ossified; 
they are of adult size by 8 months of gestation. At 7 weeks, the Eustachian tube and 
the tympanic cavity are formed. In the middle ear, acoustic energy is transduced into 
mechanical energy. The hmer ear consists of a membranous labyrinth inside a bony 
labyrinth. Ossification does not occur until each portion has attained adult size. Hair 
cell differentiation, sYllaptogenesis and ciliogenesis of the membranous labyrinth are 
completed at around 24 weeks. The basis of the frequency-related regional 
displacement of the entire cochlear partition was revealed by the classic Nobel laureate 
von Bekesy. With the entty of the acoustic nelve into the brainstem, auditOlY neurons 
multiply and project the information to the auditOlY cortex. Many auditOlY abilities are 
atttibutable to subcOltical processing. Therefore, decOliicated anhnals are capable of 
detecting intensity and frequency of SOllllds, and anencephalic fetuses demonstrate 
behavioural reactions to extemal stimnli. 
Sound is created by a vibratOlY source, can sing molecules to be displaced. The 
amplitude is measured in pascals (Pa). Sound pressure level and frequencies is given in 
decibels (dB) and hel1z (Hz), respectively. The range of 20-20000 Hz is the bandwidth 
of human hearhlg. Information about intrauterhle heming conditions are obtahJed from 
sheep experiments or from pregnancies with mpttrred membranes: a bone conduction 
route is asslllned, whereby SOtUld energy is dimhushed by 10-20 dB for frequencies 
<250 Hz and by 40-50 dB for >500 Hz. 
A second reason for fetal "sound isolation" is the sound pressure attenuation. Thereby, 
transmission losses range froUl 39 dB at 500 Hz to 85 dB at 5000 Hz. It has been 
shown that sound attenuation decreases durhlg late gestation. In humans, sound of at 
least 65-70 dB is transmitted with attenuation of 30 dB hI SOtUld pressure level for 
tones of up to 12 kHz. Frequencies of 200 Hz are even enhanced. The SOlUld 
environment in IIfero is dominated by fi'equencies <500 Hz and mean sound pressure 
levels of 90 dB caused by vessel pulsations, intclvillous htiections and maternal 
digestion or breathing. It might have an "imprinting" and a masking effect for the 
fettls. "Intelligibility" reflects the ability to distinguish complex sounds: music and 
voices are disthlguishable fi'om the basal noise by 8-12 dB. The male voice with a 
mean fi'equency of 125 Hz is better transnutted, but emerges in the range with high 
intemal noise. Female voices with an average of 220 Hz receive greater attenuation, 
but emerge hI a range with low intemal noise. 
Prenatal and postnatal auditOlY responsiveness 
Studies of fetal response to sound have used a vadety of stimuli, not always with 
rationale. Sttldies with airbome and vibroacoustie stimuli (VAS) providing vibration 
and airbome sOluld should be differentiated. The eleetralue artificial lalynx used for 
VAS has a spectrum between 0.5 and I kHz and a sound pressure level averaging 135 
dB. The fU'st responsiveness to pure tones was detected at 23 weeks at 500 Hz, by 27 
weeks to up to 500 Hz and only at 31 weeks responses were observed to 1000 - 3000 
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Hz, The sound preSSlU'e level required is 20-30 dB less at 35 than at 23 weeks, With 
the use of a habituation-dishabituation teclmique, a fehls aged 35 weeks was found to 
discriminate between frequencies of 250 and 500 Hz and different speech sounds; 
fetuses of 27 weeks were unable to make this differentiation, 
Non-invasive recordings of auditOlY responses are based on compound potentials 
representing the activity of many cells; these recordings use the 
electroencephalographic (EEG) and magnetoencephalographic (MEG) methods, 
Human EEG responses to acoustic signals have been obtained after mphlred 
membranes, In MEG recordings neuromagnetic auditOlY brain stem responses are 
measured with intact membranes, Short stimuli are perfol1ned in a room guaranteeing 
electrical radio frequency shielding, Thus, we succeeded in recording stimulus-related 
auditolY evoked neuromagnetic fields through the mothers' abdomen at 34 weeks 
(Figure 3), Latency shifts of brainstem components are proposed to reflect early brain 
maturation, Use of multi-channel magnetoencephalography specifically designed for 
the prenate might be expected to extend the window of observation, 
TLI 
TL2 
TL2 
o , 250 , 
Figllre 3 Wavejorms oblailled jrom braillslem recordillgs ajler click slillllliolioll 01 34 weeks 
usillg olle-chollllelllloglleloellcephalagraphy (17), TL ~ lelllparalialeral, jl~ jellioiesla, 
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Fetal auditory abilities can be examined by behavioural reactions. Problems arise when 
the felns does not react, since we cannot say that the stimulus is not sensed. In general, 
reactions towards acoustic stimuli do not occur before 24 weeks. Fetal movement and 
FHR responses may be classified into immediate short (blinking, reflex movements) 
and long-tenn changes of activity and FHR pattems. With increasing gestational age, 
an increasing number of long reactions are observed after VAS. FHR baseline changes 
more dramatically than FHR vadability. Fetal responses to speech were studied at 26-
34 weeks' gestation, during pedods of low FER vadability. A decrease in FHR was 
found, as the only demonstration of prenatal responses to speech stimuli. Female 
fetuses responded earlier than males. Twins are ideal models to differentiate the 
simultaneous influence of gestational age, state before stimulation, individual 
disposition (zygosity), position and sex of the prenates by analyzing inter-twin 
differences of FHR/fetalmovement patterns towards vibroacoustic stimulation (VAS). 
The detection of cortical potentials and auditolY evoked potentials as early as 25 weeks 
before birth indicates functional maturity of the auditOlY pathway. 
Electrophysiological responses from the cochlea, the eighth nerve and the auditOlY 
brainstem are similar to those of the adult by 32-36 weeks. In neonates, broadband 
sounds (speech) are likely to elicit responses depending on states of hunger and sleep-
wakefulness. Newboms differentiate band-width, dlU'ation, inter-stimulus interval, 
frequency and sound preSSlU'e: signals <4 kHz evoke responses more often than signals 
in the higher range. Lower frequencies generally evoke gross motor activity; high 
frequencies evoke freezing reactions. 
Effects of prenatal hearing on postnatal development 
While habituation reflects sholt-tenn melllOlY, there is also proof of long-term memOlY 
from pre- to postnatal life, as observed by studies of behaviolU'al modifications of 
neonates presented with stimuli with which they have been confronted prenatally. 
Newborns showed a preference for the voice of their mother and, with a baby's 
pacifier (dummy) cOlmected to a tape recorder, they where able to distinguish between 
their mother speaking in her native or an unfamiliar language, and they preferred a 
lullaby that had been read twice a day by the mother during the last weeks of 
pregnancy to a new stOlY. All tlus suggests tile possibility of prenatal acquisitions and 
antenatal discrimination, however elementary it might be. 
Settings of talking, music and meditation were perfonned during pregnancy. 
Postnatally, for talking only 58% of behavioural variables were identified as positive, 
!6% as ambiguous and 26% as negative (e.g. clying for obscure reasons, needing 
constant supervision). Music and meditation, however, cOlTelated in 90-100% with 
positive attitudes. It is speculated tllat vadations of timbre and honnona! changes 
associated witll tile content of speech may evoke associations in the infant. 
Hearing has a close relation to tlIe kinetic system: tile "auditory-vocal-kinetic 
channel". Vocal expression can been heard in immalnre newboms and follow 
unpleasant maneuvers. Newbom "cryprints" are as lIIuque as fingerprints. The fetus 
seems to store matemal speech features: even newborns bol'll at 28 weeks had similar 
voice perfonnance fealnres to those of their mothers. 
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Prenatal acoustical responsiveness as,a test for fetal well-being 
The ability of VAS to elicit FHR accelerations has 'well been established, In tlus 
context, VAS was proposed to assess fetal well being and to discriminate between 
"non-reactive" non-stress tests (NST) due to hypoxia and a quiet state, FHR-reactions 
are reduced afier VAS in fetuses with intrauterine growth restriction (IUGR), The 
conclusion, that nutritional deprivation is associated with delayed sensOlY maturation, 
is not necessarily true, since even when there is no reaction, the stimulus might well be 
received, 
We compared the clinical value of NST, a ratio of cerebral versus mnbilical blood 
flow, VAS and conb'action stress test (CST) to predict poor outcome for lUGR and 
post-term pregnancies: Doppler velocimelIY and the NST's were superior to VAS and 
the CST, In the only controlled trial, in wluch VAS was compared to NST, false-
positive tests were slightly lowered and performance reduced from a mean of 27 to 23 
min. The question remains of whether 4 min justifies frightening -or only wakening-
an innocently sleeping fetus. For the time being, we recommend VAS only under 
controlled conditions, but not for routine use, as proposed by others. 
Possible damage from environmental hazards during pregnancy 
Fetal noise-induced hearing loss has been a matter of concern regarding working or 
living conditions of pregnant women supposing that noise can adversely change fetal 
hearing. From sheep experiments it was found that noise sources with low-frequency 
components and high intensity impulses had temporillY effects, whereas long-term 
effects are still IUlknown. In summary, Ule Committee on Heilling, Bioacoustics illld 
Biomechanics attempting to protect fetal hearing suggested tl18t pregtlilllt women 
should avoid noise exposures greater than 90 dB. 
1.2.5 Olfaction and taste 
Anatomy illld physiology of nasal illld oral flavor reception 
About 1-2% of the human genome is allocated to receptors for the olfactOlY 
epithelium. 18 OlfactOlY receptors mediate the sense of flavor ill'ising from volatile 
substances pumped into the nasal cavity durinJl inhalation, swallowing or chewing. 
They also mediate neuroendocrine responses. 18.1 
The primary neuronal cells of the main olfactOlY system are embedded in the upper 
part of the nasal cavity. Their dendrites merge into the mucus and bear receptor-
binding compounds. The receptor binding elicits in the nemon illl elech'ical signal, 
which is transmitted along the axon penetrating the lamina cribrosa to meet in one of 
the paired olfactOlY bulbs, and via a neuronal network to the paleocortex including the 
luppocampus. 18 Impulses reaching the thalamic nuclei project to the frontal cOltex 
where the conscious perception of smell takes place; pathways to the limbic system 
mediate affective illld neuroendocrine responses. The vomeronasal organ with sensOlY 
cells on the nasal seplIun mediates endocline responses activated by pheromones. 
More studies are required to deteonine the specific fiUlction in humans. By tlle third 
trimester all chemosensory receptors seem ready to be functional. The nostrils have 
become patent and anUliotic fluid is swallowed and inhaled. Taste buds are found as 
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early as 12 weeks and displayed over the oral cavity, concentrating at buth on the 
tongue and on the anterior palate,20 
Prenatal and postnatal olfactolY responsiveness 
Olfactory responses have been demonstrated in premature babies of 6 months, In the 
sheep, intranasal injections of odorant components induce FHR changes. 19 Intra-
allliuotic injection of a saccharule solution led to increased swallowing; injection of 
bitter or acid solutions reduces fetal swallowing, signi~ing awareness of different 
tastes during pregnancy even uilluellCuIg fetal behaviour.2 
The newbom may retain an olfactolY memolY trace: During the initial attempt to 
locate the mother's nipple, newboms preferred a breast with the areola moistened with 
amniotic fluid over an untreated breast. 18 The scent of amniotic fluid even has a 
calming effect shortly after birth, as measured by infants' rate of crying." There is also 
evidence that babies recognize theu' mother by her scent, because 6-day-old infants 
tmlled preferentially in the direction of their own mother's odor pad rather than 
towards an alien breast odor. Neonates respond to scents by changes in respiration, 
facial expression and orientation. Even at less than 2 days old, they developed 
preferences (based on formation of new synapses) and oriented towards an odor that 
had been present in their nurselY for the preceding 24 h. This phenomenon was still 
evident 2 weeks after the exposure was discontinued. 18 
Knowledge about olfaction and taste may not only have diagnostic and but also 
therapeutic implications, such as the initiation and stabilization of breast-feeding, 
newbom adaptation, attachment and social interaction as well as the reduction of 
apneic episodes." We therefore by to provide the newboms adnutted to our intensive 
care unit with some accessories of theu' mothers. 
1,2,6 Vision 
Anatomy and physiology of visual function 
Different parts of the eye develop from different origins: the retina, iris and optic nerve 
are of neuroectodenllal origin; the lens and comea are of ectodermal origin; and the 
choroid, sclera, the ciliary body and ocular blood vessels are of mesodermal origin. 
Neuroblastic cells differentiate into photoreceptor cells, wluch later secrete interstitial 
retinol-binding protein, which plays a role UI the defense against free radicals by 
bUldulg vitamin E". After 18 weeks, synapses appear on the eye rods. From 20 to 24 
weeks, fetal eyelids may open. Macula and photoreceptors start development, which is 
not completed before birth and lasts for several postnatalmontlls. 20 The retinal smface 
ar'ea doubles between 6 months arId tenn." Birnholz was the first to describe prenatal 
ocular stmctures as seen by ultrasound." He described periods of active growth 
between 12 and 20 and between 28 and 32 weeks. At tenu, the eye is well developed, 
growing only three times compared to 20 times for the rest of the body to reach adult 
size. Myelination of the optic nelve starts between 6 and 8 months; mjelillation of the 
posterior visual pathway and superior colliculus start just before tenll.2 
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Prenatal and postnatal visual responsiveness 
More than SOIUld, light is attenuated by the matemal abdomen. Transmission of 
extemallight was detected to be around 2% at 550 nm and to reach 10% at around 650 
mn20. In addition, the fetal position might prevent even a limited amoUllt of light 
reaches the fetal retina. The restricted and inegular visual input impairs profound 
studies about behavioural responses to light ill 1/lero. Neveltheless, prenatal responses 
have been reported from 25 weeks onwards." We have observed movements of the 
bulbs ("twinkling") by ultrasound as well as reactions of FHR and fetal movements 
towards stimulation with a flashlijlht from 28 weeks onwards, comparable to 
behavioural patterns towards VAS. However, probably owing to the described 
problems, reactions of FHRJfetal movement pattems were recorded in only arOlUld 
10%. Stimulations with light that was introduced during amnioscopy directly into the 
uterine cavity were more successful. 20 
After delivery, the newborn is suddenly exposed to light, and we do not know how this 
sudden impression is experienced. Recordings of visual responses based on compound 
potentials can be applied in pretenn newboms such as the electroretinogram (ERG) or 
the visual evoked potential (YEP). The latter can be elicited even at 23 weeks; with 
increasing age the latency of Ule response signal decreases and its morphology gets 
more complex, signifying visual pathway maturation.23 Behavioural tests have been 
introduced, such as the blink response and the registration of awareness and fixation. 
Dubowitz and Dubowitz used the ability of the pretenn infant to focus, to follow and 
to track in order to draw conclusions about the developing visual system?' They also 
observed Ulat newboms frequently do not open their eyes in the presence of strong 
lighting.2' 
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Further studies have all used "preferential looking" -based tests of visual acuity 
measurement. Although the visual development of preterm infants at different 
gestational ages lags behind that of term infants, when tlus is corrected for ti,e degree 
of prematurity, both groups behave similarly. Pretenlls infants sometimes exhibit more 
rapid development tllan tenll infants.23 All in all, arowld 50% of infants of velY low 
bir1h weight show visual impairments across a range of functions.26 The highest 
incidence was found at around 6 month; beyond tlus age fewer deficits were observed, 
suggesting delayed rather than permanently impaired visual development. Visual 
abnonnality is frequently related to neurological impairment, suggesting that it is of 
cerebral rather tI,an of ophthalmological origin (Figure 4). Still, in time tI,ese irlfants 
may show progress, thanks to neural plasticity. 
Possible damage during and after pregnancy 
The velY small premature infant spends his/her fll'st weeks in a constantly illuminated 
environment. Light is transmitted even tllI'ough the eyelid at a rate of 1-10% 
predominantly at the red end of the spectnnn23 Exposme to light has been 
demonstrated to cause retirlal damage in atumals even at intensities encountered in 
neonatal intensive care units. It is atl intriguing question irl how far tllis can be 
extrapolated to humans, and nught require that light be reduced or adapted to the 
sleep-wakefulness rhythms of the neonates. Retinal photodamage mainly occurs by a 
raise of oxygen tension, occurrirlg Ulmaturally for the very premature infants. At 
present, retinopathy is the most common ocular disease beirlg characterized by 
abnormal proliferation of the immature retina, wluch catl progress to retirlal scanirlg 
and visual hatl(licap up to blindness (for review, see reference 24). 
1.2.7 Conclusions 
An increasing amount of data demonstrate that leaming abilities of the newborn 
organism reflect continuity from prenatal life. The long history of denial and the short 
histOIY of limited research relating to prenatal perception atld the implications for 
further life highlight Olll" ignorance of the effects of early senSOIY development. The 
use of modem technology in order to understand pathophysiological processes and to 
create stinmlative interventions, but even more important our own respect and 
awareness towards the unborn and newbol1l infant are prerequisite to discover that this 
topic represents a wealth for ongoing and future research. Early capabilities reflect 
complex neurological development and thus one of the most impoliant objectives of 
perinatal cat·e. It is our responsibility to avoid wwecessaty stress of the fetus atld 
newbol1l from overstimulation by IUlnatural exposure to light or sound atld to treat pain 
as effectively as we do in adult patients. However, health is IUlderstood as tile physical, 
mental and social well-being that goes much further than just the absence of sufferirlg 
or ilmess. As important as it is to teach children abilities at certain times, it might 
favor the development or prevent sensOlY retardation to create integrated stimulations 
for the unborn or newborn. This should be a matter of concern of public health 
projects. Encouragement atld avoidance of stinlUli have to be considered and balanced 
in observational or ioterventional projects according to critical developmental phases. 
Whetlwr we go so far as to fowld prenatal luuversities is of secondary importance, as 
long as we strive to understand physiology and pathophysiology of early sensOlY 
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development and to create designs suitable to induce a comprehensive expression of all 
our genetic potential. 
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II 
Paracetamol in Pain Management of the Newborn. 
"Even if we have no facts, observations, or theories to suggest that infants feel 
pain, we have nothing to lose by assuming that they do. " (Owens ME. A clying 
need. 1986) 
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II.1 Analgesic Therapeutic Range of Pal'acetamol and Correlation with 
Pain Assessment Instruments: Myth or Reality? 
Based on the atiicle: 
Analgesic therapeutic range o/paraeetamol and correlatioll with paill assessmellt 
illstruments: Myth or reality? 
RA van Lingen, JT Deinum, R vall Dicen, IN van den Anker, D Tibboel. 
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II.l.1 Abstract 
Objective: To test the evidence that blood concentrations of paracetamol between 10 
and 20 mgll represent therapeutic analgesic values, and to determine the correlation 
between dose and/or concentrations and validated pain assessment scores. 
Design: Meta-analysis of studies from the literature and an inquity among 
phal111aceutical companies. 
Results: Seventy-eight studies on paracetamol (43 on antipyretic, and 35 on analgesic 
effects) were fOlUld suitable to be included. Of the studies describing analgesic effects, 
9 contained data on infants, 21 on children aged 1-17 years, and 7 on adults. Fifteen 
studies were dose-effect studies, 10 dose-concentl'alion studies, and 10 dose-
concentration-effect studies. 
A wide range for mean maximum blood concentration was found; in infants and 
children doses of 7.5-40 mglkg resulted in mean maximulll blood concentrations 
rangrng from 5.5 to 22.5 mgll, while in adults single doses of 500-1500 mg resulted in 
mean maximum blood concentrations between 5.8 and 55.9 mgl!. 
The pain scores taken into consideration rely on self-reporting (>3 years of age) or on 
objective validated pain measurements. In the different studies, concentrations of 5.9 -
29.8 mgll in adults and of 7.5-22.5 mgll in infants and children were repolted to result 
in appropriate analgesia. 
Conclusion: The recommended therapeutic range from 10-20 mgll for ti,e' analgesic 
effect of paracetamol as reported itl the literature is not supported by well-designed 
clittical studies providing level I evidence. Recent reports indicate that analgesic 
efficacy may be obtained when blood concentrations range fi'om 5-25 mgll, and that 
these concentrations are related to adequate concentrations itl the cerebrospinal fluid. 
n.1.2 Introduction 
For over 100 years, paracetamol (acetaminophen, AP AP) has been used as an 
analgesic. It is the most commonly used over-the-colUlter medication in the USA, I and 
the most frequently prescribed medication in the UK and the Netllerlands.2•3 Although 
its efficacy itl antipyretic treatment has been shown in many studies,'·lo its analgesic 
efficacy in children has never been studied by detemlining the plasma or sennn 
concentration-effect relationship. In adults, two studies with intravenously 
admitlistered paracetamol and two studies with oral paracetamol have been performed, 
using the visual analog scale (VAS) or the nociceptive flexion reflex threshold (RIIJ) 
as an effect parameter for acute pain. 11·14 
Paracetamol is a typical example of a phannacologic agent that has been widely used 
for analgesia in the pediatric population based on data extrapolated from adults,15 as 
often occurS. 16 
Intemationally accepted dosages for paracetamol are 0.5-1 g for adults, with a 
maximum of 3 glday orally or 4 glday rectally, 90 mglkglday for c1tildren and infants 
from 3 months and older, and 60-90 mg/kg/day for infants from 1-3 monthsY7 In 
neonates single doses of 20 mglkg18,19 and multiple doses up to 80 mglkglday have 
been shown to be safe.2o 
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Prescribing habits in a children's hospital showed a trend in the use of a lower daily 
dose in the younger age group, while at the same time 17% of prescriptions were 
above 95 mg/kg/day. 21 
Recently, higher loading doses have been proposed for rectal administration in order to 
reach therapeutic concentrations for analgesia."'" 
Recent studies on the central analgesic effects in adults indicate that, after intravenous 
administration, concentrations from 6-24 mg/l result in appropriate analgesia, 
evaluated by VAS and R_m.II.12 
Many studies already refer to a range of 10-20 mg/l as therapeutic.9•26 Wilson et al 6 
showed that plasma concentrations between 4 and 18 mg/l are associated with an 
optimal antipyretic effect in children. 
To test the evidence that sermn or plasma concentrations of paracetamol between 10 
and 20 mg/l represent therapeutic analgesic values, both in children and adults, we 
conducted a systematic search for published reviews and reports of both randomised 
and non-randomised controlled or non-controlled trials on the use of paracetamol in 
adults, children and infants. hI palticular, we focussed on con'elation between dose 
and/or concentrations in relation to validated pain scores. 
For all therapeutic ranges given, we searched for the original research perf0J111ed or for 
the original guidelines. 
11.1.3 Methods 
A number of different search strategies in MEDLINE (1966 through October 1999), 
the Cochrane Librmy (1999, issue 4) and the World Wide Web were used, without 
restrictions. Keywords were paracetamol, acetaminophen, therapeutic concentrations, 
drug dose-response relationship and values. Additional publications were fOIUld by 
manually reviewing reference lists of reb'ieved ar1icles and reports. Original papers in 
English, French, German, Italian, and Dutch were included. Animal studies were 
excluded, as were studies on combination dmgs, such as paracod. 
Phannacokilletic data including peak semm concentration (Cm,,), area under the 
concenb'ation-time cmve (AVC), time to reach Cm" (Tm,,), and serum-half-life of the 
drllg (T y,), therapeutic ranges, and measures for pain were extracted from tlle articles. 
In cases that only a figure was given data were calculated from the figures arId when 
possible, the original author was consulted. 
Oral, rectal, or intravenous routes of administration were included in the search. 
The type of study was stratified into one of the following categories: Dose-Effect 
(DE), Dose-Concenb'ation (DC), or Dose-Concentration-Effect (DCE), in relation to 
age. 
Phannaceutical comparlies producing one or more forms of par'acetamol were asked 
for the primary SOmce of their therapeutic rarlges, as mentioned on their labeling 
insb·uctions. When a Ulerapeutic range was provided we evaluated Ule original 
reference. 

Table I Summary of demographic, pharmacokinetic, and pharmacodynamic data of 35 trials on analgesic effect of paracetamol. 'pretenn 
infants, d; days, m; months, y; years, i; at induction of anaesthesia, pre; pre operatively, post; post operatively, Cm~; peak serum/plasma 
concentration (mgll), A UC; area under the serum/plasma concentration-time curve (mg.hIL), Tmax: time to reach Cm~ (h), Tv,; 
serum/plasma half-life of the drug (h), OPS; objective pain score, FLACC; faces, legs, activity, cry, cansolability, VAS; visual analog 
scale, R-IIl,' nociceptionflerion reflex, pm; pain threshold difference, Pharmacokinetic data are given as mean, mean ± SD, or range, 
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11.1.4 Results 
Seventy-eight studies on paracetamol were included in our study, some studies 
rep0l1ed data of more than one age group. Eight out of these studies contained data on 
neonates, 16 on infants, 37 on children (>1 year of age), and 33 on adults (Appendix 1) 
(Figure 1). The majority of the studies employed a single dose design, only 10 (2 in 
adults) investigated multiple dose administration (Appendix 1). 
Of those 78 studies 43 studies (17 in children and 26 in adults) concemed trials in 
febrile patients or pharmacokinetic trials in volunteers. 
Out of the 35 trials describing an analgesic effect of paracetamol, 15 trials were dose-
effect (DE), 10 dose-concentration (DC), and 10 other dose-concentration-effect 
(DeE) studies (Table I, see page 32_33).11.14,18.20,22-49. 
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Paracetamol dose 
In children, single oral dose administration ranged from 8-40 mg/kg and multiple dose 
administration was 15 mg/kg every 6 hours for 24 homs27 or 17.6-18.0 mg/kg 5 
times/day.4s In adults, doses ranged from 0.33 to 1.5 g 11·14,4749 (Figure 2). 
For rectal administration in children, doses ran!i!ed from 10-45 mg/kg with either 
suppositories or a rectal solution,18.20,23.26,30,33,35,36,3 ,41,43,46 
Propacetamol, a fonnulation for intravenous use, available only in Belgium, France, 
and Switzerland was used in 3 studies in infants and children in doses ranging from 
15-30 mg/kg (equivalent to 7.5-15 mg ofparacetamol)29.32,44 and in 3 studies in adults 
with a dose of 1-4 g (0.5-2 g ofparacetamol):1.12,47 
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Figure 3 Mean Cmax in children in relation to paracetamol dose. 
Datafrom table 1.0 intravenolls, 0 rectal, II oral administration. 
Phannacokinetics 
Maximum serum or plasma concentrations (emox) in children in relation to either oral, 
rectal or intravenous application are shown in figme 3. 
Oral administration in children with 8-18 mg/kg led to a mean em" of 7.7 mg/I,41 40 
mg/kg to concentrations with a em"" between 7.5 and 22.5 mg/l.22 Mean em"" was 5.8 ± 
1.5 mffl in adult volunteers after a single 0.5 g dose,14 between 11.3 and 14 mg/I after 
I g!3, 4 and 21.4 ± 7.7 mg/l after 1.5 g ofparacetamo1.48 
Rectal adlninistration of 20 mg/kg in rreterm infants <32 weeks!8 and of 24.5-45 
mg/kg in children > I year of age, 2M ,30,35,41 usually resulted in serum or plasma 
concentrations with a mean em" between 10.7 and 22.5 mg/l. 
In pretenn infants >32 weeks, a dose of 20 mg/kg resulted in a mean em" between 7.5 
and 8.4 mg/I!' while in infants and children doses from 10-25 mg/kgI9,20,2S,26,41 and in 
one study a dose of 35 mg/kg38 led to a mean em"" between 5.5 and 10.9 mg/1. 
Intravenous administration of 7.5 mg/kg in infants resulted in a mean emox ranging 
from 8.9 to 13,2 mg/1.29 Doses of 0.5 to 1 g in adult volunteers gave mean em" ranging 
from 14.5 to 55.9 mg/I. II ,12 
None of the studies reported values close to or higher than the toxic range of 120 mg/1. 
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AVC was determined in 4 studies in children after rectal administration and varied 
between 71.7 and 97.3 mg.h/1,18.20.3S,41 After oral and intravenous administration in 
adults, values were 44.5 ± 10.413 and between 18.5 and 80.3 mg.h/l" respectively 
(Table 1). 
T max in infants and children has been studied by 10 authors, mostly after rectal 
administration, with doses ranging from 10 to 45 mg/kg. In these studies, Tmax between 
1.3 and 5.1 h were found in neonates, and between 0.25 and 4.8 h in children.(Table 1) 
Serum half-life of the dIllg (T%) was high in neonates (3.5-11 h); in infants, older 
children and adults it varied from 0.7-4.1 h (Table 1). 
Efficacy 
In 15 DE and in 10 DCE studies 13 different pain scores were used, the results were 
favourable in 8 out of 15 DE studies and in 6 out of 8 DCE shldies. As the design of 
these DE studies did not include serum concentrations, the paracetamol dose was 
related to 'therapeutic' antipyretic concenh·ations. 
Pain was scored by means of a variety of measures; objective pain score (OPS), VAS, 
faces, legs, activity, Cly, consolability (FLACC), Facies, Comfort, Poker Chip Tool, 
Oucher, RIll, pain threshold difference (PTD), and by behaviomal criteria (Table 1). 
One shldy related the relief of postoperative pain to the presence or absence of 
vomiting (Table I). 
Only in the studies using the R III score a comparison was made to another pain score, 
i.e. the VAS. II." 
In the DE studies, the concentrations expected to be reached with a certain dose, were 
presumed to fall within the therapeutic range as stated beforehand, based on antipyretic 
data or on dose recommendations,7.9 but an explanation was often lacking. 
There was no positive or no measurable effect of paracetamol in the shldies in infants 
with general painful procedures,18.20 after circumcision" or during heel prick" and in 
children with tonsillitis,37,42 regardless of dose, route or time of adminish·ation. 
Postoperative analgesia after orthopaedic or visceral surgelY was good after 
intravenous administration of 7.5-15 mg/kg postoperatively.32,44 In the remaining II 
DE and DCE studies tonsillectomy or myringotomy was used as a pain model. The 
outcome was favourable if oral doses li01n 15-40 mg/kg were given preoperatively or 
at induction of anaesthesia,"·31.34.36,4S and after a rectal dose of 40 mg/kg at inductioll.4s 
Rectal doses <40 nw/kg or postoperative administration of paracetamol did not 
provide analgesia.26.33,1'6.31;43.46 
Therapeutic concentrations 
In 24 articles on both analgesia and antipyresis (Appendix I), a therapeutic range was 
mentioned; in 21 cases the authors referred to a previous shldy. In two cases, the 
studies that were referred to did not even mention therapeutic values,26.31 or refened to 
earlier published shldies (5 times). 
In only 6 shldies (3 on antif,yresis) original results were used to determine or propose 
therapeutic leve!s.4.6,IO,18.20, 2 Of the 6 most cited publications, only the shldy by 
Wilson yielded an original therapeutic range,6 the others proposed a range without 
providing supporting data,7.s3 or did not mention a range at all. so.52 
All four DCE-shldies in adults showed good analgesia after doses of 0.5-1 g resulting 
in plasma concentrations between 5.8 and 29.8 mg/l (Table I). In children, good 
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analgesia was found with mean Cm~ concentrations between 7.5 and 22.5 mg/I, after 
single doses of20.40 mg/kg."·'6 
The proposed ranges are all close to the typically mentioned range of 10·20 mg/I, and 
vary from 4·25 mg/l. 
Therapeutic ranges in relation to pain scores revealed that satisfactory analgesia was 
achieved in 50 and 75% of children lIlldergoing tonsillectomy when blood 
concentrations were 10 mg/l or higher.22,45 A cut· off value (i.e.3 on a scale of 1·10) for 
good analgesia was often not given. 
All 5 pharmaceutical companies referred to the guidelines from the Dutch Council for 
Drug Administration (and the European Community), which are based on data from 
Temple, Rumack and Wilson,,·7.53 
11.1.5 Discussion 
Paracetamol has been known to be an effective antipyretic and analgesic drug for over 
100 years.54,55 It has been extensively used during the last 50 years, following renewed 
interest after the study of Brodie.56 Our study shows that, up till now, only 4 studies 
took into account the ultimate aim of the drug: to reach a therapeutic concentration 
after an appropriate dose, evaluated by means of a validated pain score. 
Several authors propose doses of 25·40 mg/kg followed by doses of 20 mg/kg every 4· 
8 hours in children,"·25.4o.41 and of 1000 mg q4 in adults to achieve blood 
concentrations between 10 and 25 mg/l.II,14 
Differences between rectal and oral administration are due to differences in absorption. 
However, different suppositories can not be compared as they are non.e~uivalent 
products due to the different components leading to different bioavailability.8. 1.57 Age 
influences the absorption from the rectum, and resorption from the gastrointestinal 
tract is fast, but the rate· limiting factor is the time needed for gastric emptying,58 which 
is slower in preterm infants. 
M b I· . I .. ., b' d d . d I" 8 18 59 eta 0 Ism IS sower 111 llllants, ut IS a equate ue to lllcrease su latton.' , 
Paracetamol is used extensively for both analgesia and antipyresis. However, only a 
few studies in infants and children have evaluated whether the administered doses 
result in the expected sermtl or plasma concentrations and the expected effect. This 
could lead to lUlderdosing.60 Especially when paracetamol is given for a period 
exceeding the 48 hours, and in the case of an underlying disease with decreased 
metabolism,61 this might lead to overdosing and subsequent toxicity. Recently, 
Anderson proposed a faster detemunation of paracetamollevels in case of suspected 
overdose" Although individual Cmox varied widely, a toxic level was not reached in 
any of the reviewed studies. In multiple dose studies on analgesic effects"o,4o and on 
antipyresis5o.63 no accumulation was found. However, none of these studies evaluated 
the effects of chronic use, i.e. for periods longer than 48·72 hours. 
Although no toxic ranges were found in a multiple dose study in 21 children aged 0.5· 
6.4 years,50 an increase in AVC suggested that paracetamol may accumulate 
substantially after repeated therapeutic doses over 2-3 days. 
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AUC was detenuined in a few studies only, which might be due to the fact Ulat blood 
sampling took place during such an inadequate shOl1 time span, that blood 
concentrations were not yet decreasing, 
T y, is longer when impaired liver function is present, as in pretenu or tenll infants 
where the liver nmction is not yet fully developed, Generally, T Yo increases WiOl size, 
which means that, except for Ute neonatal period, it is shorter in children than in 
adults,62 There is a lack of data regarding T y, in children, which might be due in part to 
the fact that it is impossible to calculate T Yo when elimination of the dmg is not yet 
apparent. T Yo seems to be independent of both dose and route of administration, 
It is difficult to believe that for an analgesic U,at has been used in such large quantities 
and for such a long time, so few data on analgesic effect have been collected, Tltis is 
partly due to its introduction at a time when dl1lg trials did not yet exist, From the few 
studies in adults and children, Ulat evaluated both concentration and effect, and from 
the majority of the dose concentration studies, it appears that oral doses of 15 mg/kg 
and rectal doses of 20 mg/kg 4 times a day after a loading dose of 30 mg/kg, are 
appropriate for analgesia, provided that blood concentrations are> I 0 mg/l. In pretenn 
infants, a dosing interval of 8-12 hours should be maintained, 18 
In adults, U,e first few studies on Ute analgesic effect have been published,11,12 
However, in bOUl adults and in cltildren, prospective studies with validated pain scores 
as Ule R II1NAS combination (in adults) and U,e VAS, NIPS," PIPP," and Comfort 
are needed to assess the tme analgesic value of paracetamol. 
After a heel prick and during circumcision no effect was observed, since paracetamol 
is effective for moderate pain and not for severe pain, From the studies with 
tonsillectomy as a pain model it is evident U,at paracetamol should be admittistered 
preoperatively or at induction, preferably by oral route, or rectally after a loading dose 
of 30 mg/kg, 
We agree with Anderson'6 that, as paracetamol has a central action for both antipyresis 
and analgesia, and Illaximum temperature decrease and peak analgesia are reported at 
1-2 hours after peak plasma concentration, APAP should be given 1-2 h before any 
painful procedure, 
The Ulerapeutic range for paracetamol seems to be 10-25 mg/l, based on a few studies 
WiOl propaeetamol. AuUlOrs, pharmaceutical companies and govellunental drug 
admittistration offices have been satisfied with data or references that are often not 
controlled, not tme or non-existent. 
In Illany studies, reference values were taken from the literature without checking the 
reference itself; some references quoted did not exist, did not mention the therapeutic 
concentrations,50-52 or were review articles.53,67.70 
The above-mentioned range applies to adults only, for children and infants it is not 
known; neonates may even have altered phalmacodynantics compared with older 
children,71 
In newborns and even in infants, lower concentrations may be effective as paracetamol 
might pass Ule blood-brain-barrier more easily, but appropriate research WiOl a 
Analgesic Therapeutic Range of Pal'acetamol and Correlatlon with Pain Assessment Instnnnents 39 
standard pain stimulus as RIll and studying levels in cerebrospinal fluid to confirm this 
hypothesis, is difficult to perfontl. 
As most dosing recommendations are based on either single dose studies or on 
computer data, and since more reports are published with toxicity after apparently 
nontlal doses in children, but used for a longer time, more DeE studies after repeated 
therapeutic doses are needed. 
We conclude that the therapeutic range from 10-20 mg/l for the analgetic effect of 
paracetamol as found in the literature is not supported by well-designed clinical 
studies, and in particular in children, does not correlate with pain assessment 
instruments. Recent repOlis indicate that analgesic efficacy might be obtained when 
blood concentrations are between 10 and 25 mg/I, in infants even from 5 to 25 mg/I, 
and that these concentrations are related to adequate concentrations in cerebrospinal 
fluid. 
A loading dose of30 mg/kg orally and 40 mg rectally followed by 15-20 mg/kg q6h in 
children, not exceeding 90 mg/kg/day and 4000 mg in adults is proposed. 
Future dose-concentration-effect studies are needed to reach conclusive data on 
therapeutic analgesic ranges, especially in children. 
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11.2.1 Summary 
Paracetamol is a widely-used analgetic and antipyretic drug. Its use in the first weeks 
of life in pretenn neonates is still a matter for debate, due to its unknown 
phannacokinetics, pharmacodynamics and metabolism in this age group. 
Analysis of plasma and urine of pretenu neonates who have received a dose of 
paracetamol can provide more insight into the metabolism and possible formation of 
toxic metabolites of paracetamol in pretenu neonates. 
Although several methods for analyzing paracetamol in mine have been published, the 
majority of these are quite labom-intensive. 
Tltis paper describes a ltigh-performance liquid chromatographic method for the 
determination of paracetamol and its metabolites in urine. 
Retention times of paracetamol and its metabolites varied from 1.6 to 8.0 minutes, and 
calibration curves showed good linearity. 
II.2.2 Introduction 
Paracetamol (acetaminophen) is a widely-used analgesic wltich has few side effects in 
therapeutic doses. It is metabolised in the liver, with the metabolic biotransfonnation 
involving capacity-limited pathways of paracetamol-glucuronidation and paracetamol-
sulphation. Taken together, these metabolites account for 82% and 68% of 
paracetamol excreted in urine for adults and children, respectively.' 
In adults, a small percentage of a tllerapeutic dose is metabolised by cytocln'ome P450 
to tile potentially toxic intennediate N-acetyl-p-benzoquinoneimine. Tltis reactive 
metabolite is subsequently conjugated WiOl glutathione and excreted in the urine as tile 
cysteine-conjugate or the mercaptlllic acid-conjugate. If the reactive intermediate is 
not immediately detoxified by conjugation (in the case of depletion of glutathione), it 
can bind covalently to essential hepatic cellular macromolecules and lltitiate cellular 
necrosis,2-5 
It is known tlmt the metabolism of paracetamol differs in adults, children and neonates; 
tile percentage paracetamol excreted in mine as tile glucmOltide-conjugate lllcreases 
Witll age. 6 Little is known about the metabolism of paracetamol III pretenn infants. 
Since we wanted to study the pharmacokinetics and metabolism of rectally 
admiItistered paracetamol in preterm infants, an analytical method for the 
detenniIlation of paracetamol iII serum and of paracetamol and its metabolites in mine 
was needed. 
Many different methods have been published already. For a rapid and sllnple 
detel1lllllatioll of paracetamol III senUll, an High Perf0I111anCe Liquid Chromatography 
(HPLC) method has been described by Stevens and Gil!.' 
Several methods have been described for the detenllination of paracetamol and its 
metabolites iII mine, but available assays are typically too labour-iIltensive, e.g. 
metabolites have to be hydrolyzed by enzymes before analysis,8,9 or fail to identify or 
resolve critical paracetamolmetabolites from endogenous peaks, '0 
We developed all HPLC method whereby paracetamol and its metabolites can be 
detennllled wiOllil 15 mlllUtes, 
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11.2.3 Materials and Methods 
Apparatus 
The H1'LC system consisted of a Waters 710 B autosampler (Waters, Etten-Leur, the 
Netherlands), a Thermo Separation Products S1' 8810 pump (Thermo Separation 
Products, Eindhoven, the Netherlands), a Thenllo Separation Products VV 2000 
detector and a Thenno Separation Products Chromjet integrator. 
The COllUlll1 used was a Licrospher RP C-18 (5 ~m) 12.5 cm x 4 mill J.D. (Merck 
50943). 
The mobile phase consisted of formic acid: isopropanol: O.lM potassium dihydrogen 
phosphate in water (0.1: l. 7:98.2, v/v/v), The flow rate was 1.8 ml/min. VV detection 
was achieved at 240 nm. 
The injection volume was 20 Ill. 
Reagents and chemicals 
Isopropanol and methanol (HPLC grade), formic acid and potassium dihydrogen 
phosphate were obtained from Merck (Darmstadt, Germany), paracetamol (1') from 
Bufa (Vitgeest, the Netherlands), paracetamol-glucuronide (P-G), paracetamol-sulfate 
(P-S), paracetamol-cysteine (1'-C) and paracetamol-mercapturate (P-M) were donated 
by Sterling Winthrop B. V. (Haarlem, the Netherlands). 
De-ionized water was further purified for H1'LC by passing it t1n'ough six filters (MilIi-
Q system, Millipore, Etten-Leur, the Netllerlands). . 
Standard solutions of paracetamol and its metabolites were in water. 
Procedure 
Calibration curves were prepared of 1', P-S and P-G. In a pilot study, p-M and P-C 
were not detected in urine samples of pretenll infants (collected in a plastic bag), 
therefore no calibration clUves were prepared ofP-C or P-M. 
Calibration curves were prepared by adding tile standard solutions of 1', p-G and P-S to 
a pooled sample of "blank" urine of pretenl1 infants, so that tile final concentrations of 
paracetamol in urine were 5-10-20-40 ~g/ml, p-G 5-50-100-200 Ilg/ml and P-S iO-
100-500-1 000 ~g/ml, respectively. 
Duplicate urine samples (100 ~l) were diluted with 900 ~l water and mixed, and 20 ~I 
was injected on tile column. 
The precision of tile lIIetllOd was determined by six replicate assays at two 
concentrations (of tile calibration cUlve) for 1', P-G and P-S. 
The specificity of tile method was detennined by assay of six independent urine 
samples of patients who received other dmgs (caffeine, gentamicine, carbamazepine, 
vancomycin, digoxin). 
Detection limits (signal/noise ratio: 3) and detenllination limits (signal/noise ratio: 5) 
were detennined. 
RecovelY of 1', 1'-G and P-S in urine were measured in duplicate for four different 
concentrations and compared to a direct assay in water. 
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Figure J HPLC delerminalioll of paraeelamo/ alld its melaboliles ill urille of a prelerm il!falll 
after a reela/Iy admillistered sillg/e-dose paraeelamo/ (20 mg/kg). 
(A) paraeelamo/-g/ucurollide (IR ~ 1.6 mil).), (B) paraeelamo/-sulfate (IR ~ 2.9 lIIill.), (C) 
paraeelamo/ (IR ~ 3.7 mill.) 
11.2.4 Results 
A chromatogram resulting from the analysis of urine from a preterm infant after a dose 
of20 mg/kg paracetamol (rectally) is shown in figure 1. 
HPLC determination of the metabolites of paracetamol in a pooled blank sample 
spiked with each of the metabolites (and an internal standard N-propionyl-p-
aminophenol, which was not used in the final assay) was perfonned. 
The retention times ofP, P-G, P-S, P-C, and P-M were 3.7, 1.6,2.9,3.3 and 8.0 
minutes, respectively. 
Standard graphs of P, P-G, and P-S showed good linearity between peak heights and 
concentration, calculated by regression analysis (1) always> 0.99). 
Validation results are given in the table. 
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detection detelmination recovelY (%) precision (%) 
limit (mg/l) limit (mglll 
Paracetamol 0.3 1.0 100 7 
Paracetamol· 2.3 3.2 95 3 
glucuronide 
Paracetamol· 6.3 10.1 95 3 
sulfate 
11.2.5 Conclusion 
The HPLC method described pennits the rapid detennination of paracetamol and its 
metabolites in urine. 
The preparation of urine samples prior to chromatography is simple since only one 
diluting step is required. Both the sensitivity and precision of the method are r,0od. 
ContralY to the methods described by others, which needed 1·5 ml urine,8.9. 0 we 
needed only 100 III for analysis, making tltis method suitable for use in research 
studies including phannacokinetics. 
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11.3.1 Abstract 
Aim: To investigate the pharmacokinetics, metabolism, and dose.response relation of a 
single rectal dose of paracetamol in pretenn infants in two different age groups. 
Methods: Preteml infants stratified by gestational age groups 28·32 weeks (group 1) 
and 32-36 weeks (group 2) IUldergoing painful procedmes were included in tItis study. 
Pain was assessed using a modified facies pain score. 
Results: Twenty-one infants in group 1 and seven in group 2 were given a single rectal 
dose of 20 mg/kg body weight. Therapeutic concentrations were reached in 16/21 and 
117 infants in groups 1 and 2, respectively. Peak senun concentrations were 
sigttificantly ltigher in group 1. Median time to reach peak concentrations was similar 
in the two groups. As serum concentration was still in the tIlerapeutic range for some 
infants in group 1, elimination half-life (T'/,) could not be detennined in all infants: Tv. 
was 11.0 ± 5.7 in II infants in group 1 and 4.8 ± 1.2 hours in group 2. Urinary 
excretion was mainly as paracetamol sulphate. The glucurOltide:sulphate ratio was 0.12 
± 0.09 (group I) and 0.28 ± 0.35 (group 2). The pain score did not correiate with 
therapeutic concenh·ations. 
Conclusions: A 20 mg/kg single dose of paracetamol can be safely given to pretenn 
infants, in whom sulphation is the major pathway of excretion. Multiple doses in 28-32 
week old neonates would require an interval of more tIlan 8 hours to prevent 
progressiveiy increasing selum concentrations. 
11.3.2 Introduction 
Even preterm neonates feel pain. I Soon after bUih, many paulful procedures may be 
required for routine neonatal intensive care, and there are few data on the lise of 
analgesics in pretenn infants.' In contrast to tIle use of paracetamol (acetaminophen, 
AP AP) Ul term neonates,3.4 the use of AP AP in the fITst weeks of life in pretel1n 
neonates is controversial, because its phannacokinetics, pharmacodynamics and 
metabolism in tltis age group remaul unknown. Safety concems may prevent its use in 
critically ill pretenn neonates. 
Tltis srudy aimed to investigate pharmacokinetic variables after a sUlgle dose of 
rectally adntinistered AP AP in pretenn infants, and to investigate whether there are 
any age dependent differences and any dose-response correlations between serum 
APAP concentrations and responses to pain duling pautful procedmes. 
II.3.3 Methods 
Twenty-eight inbom neonates who were admitted to the neonatal ultensive care IInit 
were included into the Shldy. Entry criteria were the need for ulsertion of at1erial and 
venous catIleters or other painful procedures, such as ulsertion of a chest drau!. The 
srudy protocol was approved by tIle etItical review committee atld infol111ed pat'ental 
consent was obtained. As phamlacokinetics atld dl11g metabolism change dmulg the 
last tlITee months of gestation",6 and pain sensitivity may be altered after 32 weeks,' 
the neonates were slratified into 2 gestational age groups: 28-32 weeks (gt·oup 1) and 
32-36 weeks (group 2). The gestational age of the neonates was estimated from 
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maternal menstrual history, by routine ultrasound examination during pregnancy, and 
from postnatal physical characteristics (Farr score). B Patients were excluded if they had 
congenital anomalies, if the mother received tocolysis with indomethacin, or if she had 
been given analgesics (other than local analgesia) within 24 hours before delively. 
None of the infants had sepsis or other congenital infections, or documented periods of 
shock. 
The infants were studied on the first two days after birth. Nasal intubation, if 
necessaly, was perfolmed in the de livelY room and the patient was transported to 
intensive care. In each patient heart rate, respiratolY rate, arterial blood pressure and 
oxygen saturation were monitored continuously, together with rectal and peripheral 
temperatures. According to standard procedures in intensive care, umbilical venous 
and arterial acceSs was obtained, and parenteral nutrition was stalied within 24 hours 
of bitth. 
All patients were given AP AP rectally after anival in itltensive care, within one hour 
of birth, the dose used being as close to 20 mg/kg as Ule available strengths of 
suppositolY (20 mg for birthweights 750·1249 g, 30 mg for 1250·1749 g and 40 mg for 
1750-2250 g) would allow. The nUl'ses ensured that the suppository was retained. 
Suppositories contained 20, 30 or 40 mg APAP (particle size <45 Illn), and hard fat 
(Witepsol H 15), a synthetic lnixture of mono·, di·, and triglycerides of the saturated 
fatty acids CIO·ClS. The suppositories were prepared and analysed for APAP content 
and content IUtif0l111ity by Ule quality assurance laboratory of the hospital phannacy. 
Before APAP was administered a 0.1 ml blood sample was taken from the arterial 
catheter. Subsequently samples were taken at 30, 60, 120 minutes, 4, 6, and 8 hours in 
the first 10 neonates, with an additional sample at 12 hours in 18 neonates. After 
collection serum was separated and frozen at ·20 °c, until assayed. Urine was collected 
for 48 hours using a plastic bag, and frozen itl separate (3 hours) aliquots until 
analysis. 
The assay was pelformed witltin a month of sample collection, using a modified high 
performance liquid clu'omatography (HPLC) method.9 Serum samples were exh'acted 
with perchloric acid and after centrifugation the supernatant was injected itlto the 
HPLC column. Urine samples were diluted with distilled water (1 :9) before injection 
itlto the column. Standards for senun APAP, and urine APAP, APAP'glucuronide 
(AP AP-G) and APAP·sulphate (AP AP-S) were injected at the stari arId the end of each 
nul, HPLC conditions, retention times, arId nlh'aviolet detection were as described 
before.' Untit of detection for selUllI AP AP was 0.2 mg/I, recovery was 96%, arId 
precision 2%. Detection limits in urine were 0.3, 2.3, arId 6.3 mg/l for AP AP, APAP· 
G, and APAP-S respectively; recovery for APAP was 100%, for APAP·G and APAP-
S 95%; and precision for AP AP was 7%, for AP AP-G and AP AP-S 3%. 
The values for each metabolite were converted to the equivalent weight of APAP, from 
wltich Ule metabolite was derived by con'ection for molecular weight. Starldard 
metabolites were a generous gift of Sterling Health ComparlY, Haarlem, The 
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Netherlands. The calibration curves were linear over the range 0.5-40 mg/I (AP AP) 
and 5-1000 mg/l (metabolites). 
Phannacokinetic data and variables were calculated from standard equations using the 
KINFIT program (Mediware, Groningen, The Netherlands). Concentration time curves 
were constructed to detet1nine peak serum concentration (Cm,,), time to reach Cm,x. 
time to reach therapeutic concentrations (adult values 10-20 mg/l),4,IO and sermll half-
life of the drug (T Yo). For Tv. a minimum of two time points in the elimination phase 
was used. Kinetic constants for AP AP elimination were calculated according to the 
two compaltment model as used by Miller. II For calculations a bio-availability of 90% 
was assumed. 
Because all infants were nW'sed in incubators with a relative ambient humidity of 60-
70% and temperatrne settings that aimed at a neutral temperature between 36.5-37.2'C, 
the anti-pyretic effects could not be measured. 
Pain was assessed by nurse pairs or nurse/doctor pairs with a modified five facies pain 
score, showing increasing levels of discomfOlt from 0 (no pain) to 4 (clearly/obviously 
in pain). ",13 
Data were analysed WiUl the Statistical Package for the Social Sciences, SSPS Inc., 
Chicago, Ill, USA I4 Student's I tests were used for not1llally distributed data and 
Marm-Whituey U tests for non-parametric data to compare the two groups. Least 
squares regression was used to evaluate linear correlation between variables. P values 
::,:0.05 (two tailed) were considered significant. 
Figllre 1 (A) APAP se/'llm cOllcelllraliolls jo/lowillg a sillgle reclal dose oj 20 mgikg, after 30 
millllles-8 hOllrs ill 10 hifallis (grOIiP I). (8) after 30 millllles-12 hOllrs ill 11 hifallis (grollp I). 
alld (C) after 30 lIIillllles-12 hOllrs ill 7 ilifollfs (grollp II). 
~r---------------------------------, 
Figllre IA 
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11.3.4 Results 
Of the 28 infants studied, 21 were in the 28-32 week group and 7 in the 32-36 week 
group. Demographic data are shown in table 1. 
SenlIll APAP concentrations are shown in fignres lA-C. 
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Matel1lal factors: 
HELLP/Preec1ampsia 
Solutio Placenta 
Bloodloss Plac. previa 
Sex: 
Male 
Female 
Method of delivery: 
Vaginal vertex 
Vaginal breech 
Ceasarean section 
Diagnosis at admittance: 
RDS 
SGA 
Pneumothorax 
Asphyxia 
Pretenn birth' 
Artificial ventilation 
Surfactant 
Birthweight (grams)" 
Gestational age (weeks)" 
Group I 28-32 weeks 
(n=21) 
6 
1 
1 
13 
8 
13 
1 
7 
7 
5 
-
-
2 
10 
3 
1280 ± 284 
30.21 ± 0.99 
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Group II 32-36 weeks 
(n=7) 
1 
-
1 
2 
5 
4 
-
3 
1 
-
1 
2 
-
5' 
2 
1786 ± 323 
33.57 ± 0.77 
Table 1. Demographic dala ofsilidy parlicipallis. 
HELLP Haemolysis, eiel'Oled liver flillCliolls, low plalelels. RDS RespiralOlY disll'ess 
sYlldl'ome, SGA Small for geslalional age . • as sale diagllosis, "meall±SD, ' aile ilifalll high 
freqllellcyoscillalioll 
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Analgesic therapeutic concentrations (adult values 10·20 mg/I),'iO were reached in 17 
infants, in 16 out of 21 in group 1 (76.2%), and in one out of 7 (14.3%) in group 2. 
Therapeutic concentrations persisted for 8 hofU's in 13 infants (12 group 1 and one in 
group 2) and for 12 hours in one infant. Cm" was mean 11.2 (SO 3.8) mg/I for all 
infants studied, data for groups 1 and 2 are shown in table 2; Cmox was significantly 
higher in group 1. For individual values there was a significant negative correlation 
between Cm" and gestational age (r ·0.50, p=0,007). There was a significant inverse 
linear regression between APAP concentrations at T60 (p<0.05), TI20 (p=0.008), and 
T240 (p<0.05) with gestational age (Figure 2) and no significant conelation between 
Tom, and gestational age. As serum concentrations were still in tile therapeutic range 
after 8 hours, T Yo could not be measlll'ed in 10 infants in group I because elimination of 
AP AP was not yet apparent (Figure IA). Therefore, T,;, could only be measured in 1 I 
infants in group I but it was measured in all infants iu group 2 (Table 2). 
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/'·0.49, P 0.008, Dashed lilies: 95 percelll cO/!fidellce Iilllits. 
In two infants only two pieces of data were available to calculate T",: in the other 16 
infants tln'ee or more time points were available. The area under tile serum 
concentration time curve (AUC) was determined by tile trapezoidal mle. The mean 
(SO) value in group 1 (95,1 (28.0) in II infants) was significantly higher than in group 
2 (71.7 (41.7); p=0.046). Clearance increased with gestational age showing a 
significant positive conelation (1=0.52, p=0.008)(Table 2). 
66 
11.0±5.7 
3.5 - 25.2 
95.1 ± 28.0 
29.0 - 160.6 
0.10 ± 
0.03 -
7.5 ± 4.0 
1.5 - 13.6 
5.1 
1.0 - 9.5 
4.8 ± 1.2 
3.6 - 6.8 
71.7 ± 41.7 
17.5 - 134.6 
ChaI1(cl'U3 
ns 
0.011 
0.046 
Table 2. Phal'l11Gcokillelic parameters oj pal'acetamo/ in preterJll neoltates ajler rectal single 
dose. 
CmlX. maximum concentration; '£110);, time to reach maximum concentration; T%, eiIillinatioll 
haif-life; AVC, Area IIl1del' the cOllcelltratioll-time curve; CI, clearance. 
Data are shown as mean ± SD O/' as mediall·, 
Due to the available strengths of the suppositories, individual doses ranged from 16.6-
26.6 mglkg in group I, and from 17.1-22.1 mglkg in group 2; the relation between 
AP AP dose and Cm" is shown in figure 3. All doses of more than 18 mglkg resulted in 
therapeutic concentrations in group I, but not in group 2. There was a significant 
correlation between the rectal temperature and time to reach therapeutic concentrations 
(1' -0.54, p<0.03), and no conelation between rectal temperature and Cm,,' 
~r------------------------------' 
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Figure 3 APAP peak serum concentration ill preterm in/ants in relation 10 fhe dose, ill two 
different age groups; group I 28-32 weeks (1I~21), group II 32-36 weeks (1I~7). TI/Crapeutic 
levels repl'esellt adult values. 
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No significant losses occurred duting urine collection, Of the rectal dose, 63.2 (24.4)% 
was recovered in the urine; 61.0 (24.4)% in group I and 74,2 (24,8)% in group 2 (NS; 
p=0,2), APAP was excreted mainly as AP AP-S and to a lesser extent as APAP-G, 
Very small amounts of free APAP, and AP AP-cysteine (APAP-C) were excreted and 
AP AP-mercapturic acid (APAP-M) was not detected, The glucuronide:sulphate ratio 
(G:S ratio) was 0,12 (0,09) and 0,28 (0,35) for groups 1 and 2, respectively (Figure 4), 
2 
23-32 w 32-38 Vi NeoR· Neon fI 8-D y' 12 Y f AHIttB 
Figure 4 APAP metabolism, glucurollide to sulfate ratio ill pretam in/allts ill this study 
compared with IeI'm lIeollales (* Levy el al 1975;55-6:818-2525), alld lertll lIeollales, older 
childrell alld adults (# Miller el 01 1976;19-3:284-94"), (* reproduced by permissioll of 
Pedialrics alld # reproduced by permissioll of Clillical Pharmacology alld Therapeutics) 
Facies pain score reflecting the infants' responses was scored at the time of blood 
sampling, Pain scores from ° to 2 were obtained in all infants and did not correlate 
with therapeutic concentrations, The reliability for the pain score was high; weighted 
Cohen's k=0,74, 
11.3.5 Discussion 
As far as we are aware tlus is the first study to provide data on the pharmacokinetics 
and metabolism of AP AP in preteI'm infants, As the rectal mode of delivelY results in 
less efficient absorption than the oral route, higher doses are needed in infants and in 
older children, After rectal doses of 16-26 mglkg none of our infants reached 
concentrations above 20 mgll, while toxic concentrations occur above 120 mgll at four 
hours after ingestion,15 In infants whose mothers ingested an overdose of APAP 
prenatally, high concentrations of APAP (75,5 and 260 mgll) were documented in 
neonates with no apparent hepatic or renal toxicity,16,17 The high therapeutic ratio in 
neonates may be related to reduced rates of metabolism by the cytochrome p 450 
system in the neonatal liver and neonates' increased ability to synthesise gluthathione 
relative to adults,18,19 YOIUlg mice have a fomfold greater glutllatione nUllOver and 
increased activity in the gluthatione peroxidase/reductase system than older mice,18,19 
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Renal toxicity is also prevented by the increased solubility of AP AP-S as compared to 
AP AP-G, the major metabolite in adults. 
We speculate that multiple doses of APAP would also be safe, in the pretenll infants 
studied. 
Peak senull concentrations were reached later in pretenll infants in our study than in 
tenll infants and adults,.·2o but most 28-32 week old infants did achieve therapeutic 
concentrations. All the infants in our study were IUlder 1 hour of age, and absorption 
Ulay increase with gestational and posolatal age. Individual differences in rectal 
temperature (range 34.7°C-38.4°C) at time of adminiso'ation of the suppository may 
alter the time needed for melting and absorption. A significant correlation occurred 
between rectal temperature and the time to reach therapeutic concentrations. Rectal 
temperature ranged from 34.8 to 36.8°C in 10 infants who did not achieve therapeutic 
concentrations (e: 10 mgll). Although no suppositories were expelled, differences in 
Cm" and T mox in individual patients may be due to the variability of venous drainage 
from the rectum. Drugs administered into the proximal rectum will be subjected to the 
hepatic first pass effect, whereas dmgs in the distal rectum will bypass the liver.' The 
inverse linear regression between AP AP concentrations and gestational age may be 
due to the larger extracellular space and thus greater volume of distribution (V d) with 
lower gestational age. 21 Although our samr,ling time was two to four tinles greater than 
the T Yo in adults and tenn neonates, 17. 2-24 senun concentrations remained above 
therapeutic concentrations for more than 8 hours, which made it impossible to assess 
T Yo in 10 pretenn infants. In infants where assessment was possible, the values 
indicated slow elimination, subsequent to a lower clearance and increased V d. 
Miller et al found shOlier T Yo in three term infants and one preterm infant than in older 
children and adults after oral AP AP.II Other sOldies fOlUld longer T Yo after rectal AP AP 
in infants compared WiOl oral doses in adults.,,22,23 Our Ty, values were 11 hours in 
infants 28-32 weeks of gestation and 4,8 hours in infants 32-36 weeks of gestation and 
were inversely related to gestational age, Tltis agrees with the published findings, with 
values of 2,7 to 4,9 hours in term infants in the first month of life and of 1.0 to 2.4 
hours up to the age of 1 year.1O Doses of 18 mglkg or more produced therapeutic 
concentrations in the 28 to 32 week gestation group, and doses up to 26,6 mglkg were 
given without any adverse effects, Because of the long Tv. we recommend that multiple 
doses should be given every 8 to 12 hours, 
The pain scores we used",13 did not conelate with the concentrations of APAP; 
probably because most of the infants scored low on the pain score indicating minimal 
or no pain, It may be that this pain score is not palticularly suitable for measuring pain 
in preterm infants or that it is only suited fur the assessment of acute severe pain, In the 
original sOldy tills pain score was used for older infants,12 and later modified for use in 
yowlger infants, 13 Mlllme et al showed tllat in older children simultlllleous assessment 
of pain by patients, nurses and parents showed comparable results," Postgestational 
age seems to be important when considering the pain response of inflllits less thllli 32 
weeks of age,26 
In several double blind cross over studies in healthy volunteers given normal 
therapeutic doses, analgesic effects occurred with concentrations <10 mgll. 20 
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If the same applies for the infants in our study, they were having suitable pain 
management and the pain score was appropriate. 
Exaggerated concems for overdosing and hepatotoxicity, or increased bilimbin 
concentrations have been tile main reasons for withholding AP AP fi'om neonates. 
Neonates are capable of metabolising AP AP, not by glucuronidation but also by 
sulphation, 11.".27 and there is no correlation with plasma bililllbin concentration." 
Limited data show that even when AP AP reaches toxic concentrations in pretenll 
neonates, detoxification by the mixed function oxidase system is sufficient, without 
any adverse effects. 16.17 Even when glucuronide and sulphate conjugation (phase II 
reaction) have reached their maximum capacity, tllis nonllally minor pathway 
metabolises AP AP as long as glutathione is not depleted. Part of the AP AP is not 
metabolised and excreted unchanged in the urine. 
Our findings that urinary excretion was primarily as AP AP-S, resulting in a low 
glucuronide to sulfate ratio, agree with the results of earlier studies. I 1.16.22 The values in 
our groups show a considerable decrease in G:S ratio WiUl earlier gestational age. 
Figure 4 shows tile comparison of G:S ratio in our study WiOl two other studies in older 
infants, children and adults."'" Our results are sup~orted by several studies showing 
decreased fetal and neonatal UDPG-T activity,",3 and by the presence of a well 
developed sulphalion pathway both in vivo" in term neonates and in vitro31 in fetal 
liver at 19-22 weeks of age. FUl1hermore, two other studies showed even higher 
sulphation rates than gluClU'onidation in children aged 7-10 years, compared with 
adults. 11.32 Our results differ from those of a recent study in which 2 to 6 day old, tenll 
infants ingested paracetamol in their motllers' breast milk in amOlUlts of 0.3-18.5 
mglkg, and excreted it mainly as AP AP_G.33 However, in this study urine sampling 
only took place for 3 hours; in other words with the longer T,;, in infants a substantial 
part was not yet excreted and maximal recovery of the ingested dose was 4.4%.33 
We fOlUld only minute amounts of APAP-C and no AP AP-M in the urine. As AP AP-
M was fOlUld in mine of a pretelID infant after matemal overdose,17 it might be tllat in 
pretenll infants AP AP-M is only fanned after doses higher tllan our dose or after 
prolonged multiple doses, or that it is merely a reflection of their mothers' excretion 
pattern. 
We conclude that rectally administered AP AP is safe in pretem1 infants as single dose 
treatment. As prolonged rectal absorption from tllis dose is evident, a higher dose 
might be needed to shorten the interval to reach tllCrapeutic concenh'ations. Prolonged 
rectal absorption and plasma clearance subsequent to developmental immatmity in the 
phase I and phase II pathways which govern AP AP clearance were evident. Rectal 
AP AP was apparently tolerated without any ove11 evidence of adverse effects. 
Sulphation is the major metabolic pathway, while G:S ratio is positively related with 
post conceptional age. Furthermore, our study provides new ways of using AP AP: in 
pretenll infants the choice is no longer sh'ong analgesics or no analgesic, but an 
intenllediate analgesic for moderate pain. 
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11.4.1 Abstract 
Objective: To investigate pharmacokinetics and pharmacodynamics of rectally 
administered paracetamol in tenll neonates directly after birth. 
MetllOds: In tllis prospective clinical trial, tenll neonates Witll painful conditions or 
who were undergoing painful procedures received multiple-dose paracetamol. Sennll 
concentrations were determined serially with an HPLC method, and phannacokinetic 
analysis was performed. Pain assessment was performed by means of a validated pain 
score. 
Results: Ten consecutive term neonates received folll' rectal doses of paracetamol, 20 
mg/kg body weight, every 6 holll's. Mean peak serWll concentrations (±SD) dm'ing 
multiple-dose administration were 10.79 ± 6.39 mg/I, 15.34 ± 5.21 mg/I, and 6.24 ± 
3.64 mg/1 for the entire group, boys, and girls, respectively. There was a significant 
difference between the boys and the girls (P~O.OI). No sennn concentrations 
associated with toxicity (> 120 mg/I) were found. Median time to peak se111m 
concenl1'ation was 1.5 hours after the first dose and 15 hours for multiple doses. Mean 
(± SD) half-life was 2.7 ± 1.4 holll's in eight patients. There was no con'elation 
between dose and se111m concentration or between pain score and sennn concenb·ation. 
There was a significant inverse relationship between the preceding pain score and peak 
serum concentrations. 
Conclusions In term neonates, mUltiple rectal doses of paracetamol, 20 mg/kg body 
weight, led to widely varying serum concentrations but did not result in therapeutic 
concentrations in all infants. Boys had higher peak concenb·ations. Because 
accumulation was not f01Uld, a dose of 30 mglkg followed by doses of 20 mg/kg at 6-
to 8- hour administration intervals are appropriate to reach therapeutic concenb·ations. 
A concenb'ation-effect relationship could not be determined 
II.4.2 Introduction 
Although little is known about the pharmacokinetics and pharmacodynamics, 
paracetamol (INN, acetaminophen) is frequently used by bOtll doctors and parents to 
treat minor and moderate pain in children. Fear of toxicity caused by accumulation in 
cases of multiple dosing has been the main reason that paracetamol has been refused to 
infants in the first days after birth. I•3 Its effectiveness in b"eating neonates and both 
older and younger iruants has not been clearly evaluated. In a recent Sbldy in pretenn 
infants, we showed that a single rectal dose of paracetamol can be given safely.4 
Moreover, it has been proven that metabolism of paracetamol in newbol1l infants is 
comparable to tllat docmnented irl older children and adults, not as a result of 
gluclll'onidation but because paracetamol is predominantly conjugated to sulphate.'·6 
The appropriate analgesic dose for term infants is not known, but sirlgle doses between 
10 mg/kg (oral) and 20 mg/kg body weight (rectal) that result in serum concenb'ations 
between 4 and 20 mg/I are reported to be sufficient to have an antipyretic effect.7-9 By 
taking this range and by combirling other data based on validated pairl assessment 
instruments and oral dose, the thera~eutic range for analgesia irl adults and cllildren 
(10-20 mg/I) has been extrapolated. ,10,11 In older iruants and cllildren, ti,e advised 
rectal dose is 20 mg/kg evelY 4 hourS. 12,13 This sbldy was therefore designed to 
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investigate the selUm concentrations resulting from multiple rectal doses of 20 mg/kg 
paracetamol in tenn neonates and to detennine the relationship between dose and 
effect and between concentration and effect. 
11.4.3 Methods 
Patients 
The study included 11 consecutive neonates who were admitted to the neonatal 
intensive care unit. Entry criteria were trawnatic delivery that resulted in hematoma, 
fraclmes, or scalp birth injuries or that resulted in the need for insertion of arterial and 
venous catheters or other potential painful procedures, such as insertion of a chest 
drain and subsequent drainage. The study protocol was approved by the ethical review 
committee of the Isala Clinics/Sophia Hospital (Zwolle, The Netherlands). Written 
infonned parental consent was obtained for each patient before enrolment. The 
gestational age of the neonates was estimated from maternal menstlUal history, by 
rouline ultrasowld examinalion during pregnancy, and by postnatal physical 
characteristics (Fan score ).14 Patients were excluded if they had major congenital 
anomalies, severe asphyxia (Apgar score :'03 after 5 lninutes), if their mother had 
received tocolysis with indomethacin (INN, indometacin), or if she had been given 
analgesics within 24 hours before delivery. 
The infants were studied during the first 2 days after birth. Nasal intubation, if 
necessary, was perfonned in the delivery room in a standardized fashion without 
administration of medication, and the patient was transpOlted to the neonatal intensive 
care ,mit. The heart rate, respiratory rate, arterial blood pressure, and oxygen salmalion 
of each patient were monitored continuously, together with rectal and peripheral 
temperatures. Patients were nursed under a radiant heater. In each patient, umbilical 
venous and arterial access was obtained, and parenteral or enteral nutrition was started 
within 24 hours after birth according to standard procedures in the neonatal intensive 
care unit. 
Within I hour of buth, patients were given paracetamol rectally. The dose used was as 
close to 20 mg/kg as the available strengths of suppository would allow (50 mg for 
birth weights 2500 to 2749 g, 60 mg for 2750 to 3249 g, 70 mg for 3250 to 3749 g, and 
80 mg for 2:3750 grams. Subsequent doses were given after 6, 12 and 18 hours. Care 
was taken by the nurses to ensure that the suppositOly was retained. Suppositories 
contained 50, 60, 70, or 80 mg paracetamol (particle size <45 ~lIn), and hard fat 
(Witepsol H 15), a synthetic mixture of monoglycerides, diglycerides, and 
triglycerides of the salmated fally acids CIO to C18. The suppositories were prepared 
and analyzed for paracetamol content and content unifonnity by the quality assurance 
laboratory of the hospital phannacy. 
Blood samples (0.2 ml) were taken at 30, 60, 90 minutes, and at 3, 9, 15, 21, 24 and 27 
hours after the first dose had been admulistered. After blood collection, sermll was 
separated and frozen at -20°C, until analysis. 
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Analytical procedures 
The assay was perfonned within a month of sample collection by a modified HPLC 
method, as described previously.',l' In short, senun samples were extracted with 
perchloric acid and, after centrifugation, the supernatant was injected into the HPLC 
column. Standards for serum paracetamol were injected at the stati and end of each 
run. HPLC conditions, retention times, and ultraviolet detection have been described 
previously.4,ls The limit of detection for serum paracetamol was 0.2 mg/l, the recovery 
rate was 96%, and the precision of the assay was 2%. The calibration curves were 
linear across the range of 0.5-40 mg/!. 
Pharmacokinetics and pharmacodynamics 
Phannacokinetic data and parameters were calculated from standard equations using 
the Multifit program (J.H. Proost, University Centre for Phannacy, Groningen, The 
Netherlands). Concentration-time curves were constrncted to detennine peak senun 
concentration (Cm,,), time to reach Cm" (T m,,), time to reach therapeutic levels (T,), 
and serum half-life of the drug (Tv.). The mean Cm" was determilled by averaging the 
maximum serum cOllcentrations, and the mean T mox was determined by averaging the 
times of peak senun concentration. Area under the concentration-time curve (AUe) 
was calculated WiOl the trapezoidal rule. For calculations of the quotient of clearance 
and bioavailability (ClIF), a bioavailability of90% was asstUned. 
Senull concentrations ranging from 10-20 mg/l were considered to be therapeutic. 
Because all infants were nursed under radiant heaters with temperature settings 
between 36.soC-37.2°C to achieve a neutral temperature, any atltipyretic effects could 
not be measured. All infants had repeated painful procedures, including suctioning, 
skin puncture, <h'essing change or tape removal, and discontinuation of intravenous 
lines. Pain was assessed at standard times I hom after each dose was given by nurse 
pairs or nurse-doctor pairs, with a modified 5 facies pain score that showed increasing 
levels of discomfolt from 0 (no pain) to 4 (clearly/obviously in pain), as described 
previously.',I' Observers were trained by video iustruction for 3 hours, resulting in a 
high inter-rater reliability (Cohen's FO,74) as published previously.' 
Statistical analysis 
Data were analyzed with SPSS-5 (SPSS Inc, Chicago, III). Student's t tests were used 
for nonnally distributed data and Mann-Whitney U tests for nonparametric data to 
compare the two groups. Least-squares regression was used to evaluate linear 
correlation between variables, and P values SO.05 (two-tailed) were considered to be 
significant. 
11.4.4 Results 
Eleven infants were included in the study; senun samples from one infant were lost. Of 
the remaining 10 infants, the lungs of nine were ventilated. Diagnosis at admittance 
was pneumonia in two infants and pneumothorax in two infants. The clinical details of 
these infants are shown in table I. 
Paracetamol was detected in the senun of all infatlts studied. Individual serum 
concentration-time ctU"Ves are shown in figure 1. 
Multiple-dose Pharmacokinetics of Rectally Admlnlsted Paracetamol in Ternt Infants 79 
30 
25 
20 
'§, 
E 15 
a 200 400 600 BOO 1,000 1,200 1,400 1,600 
minutes 
Figure 1 Paracetalllol serum COllcelltratiolls following multiple doses (at 0, 6, 12, alld 18 
hOllrs) after 30 minlltes - 27 hOllrs (n~10), 
Triangles: time of drug administration, ----- m'erage concelltratioll. 
Sex 
Male 5 
Female 5 
BiJih weight (grams) 3542 ± 777 
Gestational age (weeks) 39,34 ± 2,35 
Artificial ventilation 9 
Mode of delivery 
- Vaginal 5 
- Vaginal vacuum extraction I 
- Cesarian section 4 
Diagnosis at admittance 
- Pneumonia 2 
- Pneumothorax 2 
-PPHN I 
- Wet lun)!' (TTN) 5 
Table 1 Clinical characteristics of study participants, 
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Absorption of paracetamol after the first dose Was slow. Cm" was reached between 30 
and 180 minutes (median, 90). The C..,,,·after the ftl'st dose reached a mean (± SD) 
value of3.36 mg/1 ± 2.11 mg/!. Even after multiple doses, it took a considerable time 
to reach a Cm" within the therapeutic range (10-20 mg/I), with only the five boys 
reaching a Cmox that exceeded 10 mg/l during the total study period. 
There was a significant difference in the mean (± SD) Cm" between the boys (n=5; 
15.34 ± 5.21 mg/I) and the girls (n=5; 6.24 ± 3.64 mg/1; P = 0.01). The c'n" for all 
infants throughout the entire study period was 10.79 ± 6.39 mg/I (range 1.7 to 23.2 
mg/1; Figure 2). The coefficient of variation for all infants was 37.2 %. The median 
Tmox values after the first dose and during multiple dosing was 1.5 hours and 15 hours, 
respectively. 
25 
20 
All Boys' Girls 
Fiftltre 2 em"" (hatched bars) alld SD (error bars) durillg the study period for all i'i/allts 
(11=10), boys (11=5), alld girls (11=5). 
• P = 0.01 boys vs girls. 
The senun Tv. after the ftl'st dose could be calculated for eight patients only 
(elimination of paracetamol was not yet apparent in two patients) and was 2.7 ± 1.4 
hours. 
The Tt for the five boys was between 9 and 27 hours; tlus was reached after two, tlu'ee, 
or even folU' doses (n=2, 2 and I). After tile last dose, elimination seemed to be slower 
in four infants, with senUll concentrations remaining in the therapeutic range even 9 
hours after the last dose. 
Because of tile fixed strengtlls of tile suppositories, tile actual doses admitustered 
ranged from 16.6 to 21.2 mglkg. A correlation between dose and Cm" was not found. 
Almost all infants with a short T m" after tile ftl'st dose had a low Cm", but tltis 
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correlation (r -0.57) did not reach a significant level. After multiple doses, no 
correlation between T max and Cm" was observed. The T'/" area under the senlln 
concentration-time clu'Ve (AVC), clearance (Cl) for individual patients after all doses, 
and the quotient of clearance and bioavailability (ClIF) are shown in table II. 
Patient 
Gl 
Bl 
G2 
G3 
G4 
B2 
G5 
B3 
B4 
B5 
TYi 
4.9 
8.6 
3.8 
1.2 
5.3 
52.4 
36 
11.8 
AVC 
28.2 
461.8 
151.8 
115.2 
73.3 
397.2 
164.5 
229.8 
118.6 
160.4 
CI 
9.4 
0.8 
1.4 
3.9 
5.3 
OJ 
0.4 
1.2 
CVF 
8.46 
0.72 
1.26 
3.51 
4.77 
0.27 
0.36 
1.08 
Table II Pharmaeokilletie data of sttldy participallts. 
T", elimillatioll half life (h); AUC, area tlllder the eOlleelltratioll-tillle ell/ve (mg.hl/); CI, 
elearallee (//h); F, /raetioll of d/'llg absorbed; G, girl; B, boy. 
In all infants, pain assessment by means of the facies score, perfonned 1 hour after the 
dose was given before the infant's Cm,,,, showed a significant inverse linear regression 
in relation to the Cm" (r = -0.39, P = 0.023). 
There was no correlation between the pain scores and the serum concentrations: pain 
scores from 0 to 1 were obtained in the infants when semlll concentrations were >2.61 
mg/l. 
II.4.S Discussion 
As far as we are aware, tIils study is the first study to investigate both dose-
concentration and concentration-effect relationships of paracetamol multiple-dose 
phannacokinetics in term neonates. The phannacokinetic effect of a single dose has 
been studied after rectal and intravenous administration in infants <14 days of age, 16.17 
but there are still few data regarding multiple doses and analgesia. 18 
The antipyretic effect of paracetamol has been extensively studied in infants, 10.19.20 
clilldren,',1O,19.21 and adults.9,,, Plasma and senlm values between 4 and 20 mg/I are 
considered to be therapeutic,9 and by combining data from orally administered 
paracetamol that result in concentrations of 10 to 20 mg/l23 with data from a dose-
effect study,IO a therapeutic range for analgesia has been proposed but has not been 
validatedY Vsing tonsillectomy as a pain model Anderson et al24 found that 
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paracetamol (40 mg/kg orally) provided satisfactOlY analgesia for most children when 
plasma concentrations were within the range known to reduce fever, In the literatme, 
data on the effect of paracetamol on fever or analgesia in children are either dose-
concentrationl6,20,2S or dose-effect studies,26 
The values for em" in our study are comparable with results from previous single-dose 
studies with a 20 mg/kg rectal dose of paracetamol in both pretenn and term 
neonates,.·l6·" and with high-dose rectal paracetamol (30-45mg/kg) in children aged 3 
to 13 years,2S,,, In a recent study by Sanderson et al,29 plasma values at 24 hams in 
children aged 3,9 to 9,8 years old ranged from 6,8 to 20,9 mg/I after a scheduled 
dosing regimen of 20 mg/kg orally with a 6-holU' dosing interval. In comparison, we 
found values from 0,59 to 2004 mg/I at 24 hours, Olll' data with a dosing schedule of 20 
mglkg four times a day do not support the estimates made by Autret et al l7 for infants 
under 10 days of age, With computer simulations of 15 mg/kg propacetamol four times 
a day (Le. 30 mg/kg/day paracetamol) Autret et al l7 estimated that em" would reach 
concentrations fi'om 10, I to 22,9 mg/1 (mean ± SD, 17.46 ± 4,97 mg/I), whereas these 
values were reached in only half of our study infants with 80 mg/kg/day, We agree 
with Anderson et al" that with the large variability of results shown by the coefficient 
of variation of 40 %, which compares with our value of 37.2 %, we should be careful 
not to overstate the wOl1h of mean values when considering individual patients, and 
that this coefficient of variation implies that some patients may not achieve a 
therapeutic em", 
In all studies in infants, individual values vary widely, and when paracetamol is given 
rectally the T mox also varies widely and is seldom reached before 3 hams, This might 
be a result of the variability of venous drainage from the rectum, resulting in bypassing 
of the liver by dmgs delivered distally, whereas drugs delivered in the proximal rectnm 
will be subjected to the hepatic first-pass effect.'o 
Even after four doses, aCClllnulation was not observed in our patients, as was the case 
in one study of children from 6 months to 6 years old to whom oral doses between 10 
and 15 mg were administered,21 In adults, orally administered paracetamol exhibits 
linear pharmacokinetics for doses of 18 mglkg or less when given five times at 6-hours 
intelvals,31 In a computer model that simulated rectal dosing in children, a loading dose 
of 50 mg/kg followed by 30 mglkg at 6-hour intelvals achieved plasma concenh'ations 
of 9 to 18 mg/I, without accumulation,32 However, the effect of paracetamol given for 
more than 24 hams in this age group is not known, Nahata et al' found accumulation 
after 2 to 3 days in an older age group (2 to 8 yean) when given 22 to 27 mg/kg orally, 
whereas doses of 13,3 mg/kg or more may also accumulate after tlus period, The 
lughest sel1lm concenh'ation recorded in our shldy was 23,2 mg/I, wluch is still well 
below the concentration associated with toxicity in adults (> 120 mg/I).' However, 
elimination appeared to be slower after the last dose in our shldy, 
In some stndies witlt older children, a starting dose of 30 to 40 mg/kg has been 
proposed, but we refrained from following tlus schedule in tltis stndy because the 
metabolism in neonates is somewhat slower,4.11.28,32 The T.;, varies widely between 
individuals, and in our shldy on the first day of life it ranged between 1.2 and 52.4 
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hours but decreased with postnatal age, In term infants it is reported to be between 2,7 
to 4,9 hours in the first month of life and ranges from 1.0 to 2.4 hours up to the age of 
1 year,5,8 
On the basis of our study, a starting dose of 30 mg/kg is proposed, followed by 20 
mg/kg rectally at dosing intervals that increase from 6 to 8 hours, In this way, the 
maximum daily dose of 90 mg/kg, is not exceeded, 
Surprisingly, we found a significant difference in C "'" between the girls and the boys; 
the mean value for girls was lower than for boys, Clearance was no higher in girls than 
in boys, Although we have tried to collect urine by means of an adhesive urin8lY bag 
in five infants, too many samples were lost to give a reliable impression of the 
excretion and recovelY in the urine, Nothing is known about a gender-related 
difference in pharmacokinetics for any drug in tlus age group in humans, Data from 
our recent study in preterm infants do not show any difference:' Because our group is 
relatively small, this difference may become negligible when a larger sample group is 
taken, 
Senllll concentrations between 10 and 25 mg/l are suggested as the appropriate 
analgesic range,32 However, no studies have been performed to compare serum or 
plasma concentration with effect in the age group under study, Except for the study by 
Anderson et al,24 until now, therapeutic paracetamol concentration ranges have not 
been determined in inf8llts or in older cluldren 8lld adults, Studies in adults on the 
central analgesic effect propose tllat tile time course of paracetamol· in cerebral spinal 
fluid may parallel that of 8llalgesic effect because a time delay exists between serum 
concentrations and the anal~esic effect of paracetamolmeasured by means of the R-III 
nociceptive flexion reflex, 3,35 Painful procedures such as those experienced by the 
infants in our study are repOlted to generate painful responses 75-100% of the time and 
therefore seem to be equivalent to each other. 36 A dose-effect study showed that 20 
mg/kg oral paracetamol was ineffective for decreasing the pain from heel prick in tenn 
neonates,37 Recently Anderson38 stated that neonates may have altered 
phannacodynamics compared with older children, 
Although low sennn concentrations were found, low scores of pain assessment were 
determined, suggesting appropriate analgesia in all infants, This may be the result of a 
greater permeability of the blood-brain barrier in neonates, leading to greater central 
analgesia, Because there was no conelation between the pain scores 8lld the serum 
concentrations 8lld because values tllat exceeded 2,6 mg/l were associated with facies 
pain scores from 0 to 1, we are not able to indicate a therapeutic paracetamol 
concentration range for this age group, 
In conclusion, we found that paracetamol can be adnunistered safely to neonates on the 
first day of life in rectal multiple doses of 20 mg/kg, A higher stalting dose of 30 
mg/kg, as recommended for older children, is proposed because (I) therapeutic 
concentrations were not reached in all infants, (2) tile time to reach therapeutic 
concentrations was relatively long, and (3) accumulation was not found, Fluther 
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research with a longer sampling time is needed to detennine whether paracetamol 
given to neonates for periods exceeding 24 hours is effective and safe. 
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11.5 Effect of Rectally Administered Paracetamol on Infants Delivered by 
Vacuum Extraction. 
Based on the article: 
Effects of rectally administered paracetamo/ on Infants delivered by vacuum 
extraction. 
Richard A van Lingen, Coby ME Quak, HaImeke T DeinulIl, FraIlS van de Log!, Jim 
van Eyck, Albert Okken, Dick Tibboel. 
Eur J Obstetr Gynecol 2000; in press 
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11.5.1 Abstract 
Objective: To evaluate whether paracetamol 20 lllg/kg rectally relieves pain in infants 
delivered by vacuum extraction, and improves clinical condition. 
Methods: Prospective, randontised, double blind, placebo-controlled study. Infants 
delivered by vacuum extraction were randomised either to the study group (n=61) and 
given paracetamol 01' to the control group (n=61) receiving placebo. Pain assessment 
was performed by. a validated pain score and by scoring the clinical condition. Both 
scores and clittical symptoms in these groups were compared with symptoms in a 
reference group (n=66) WiOl lUlcomplicated pregnancy and de livelY in vertex position 
without vacuum extraction. 
Results: Paitl score did not differ between groups; clinical condition itl the study group 
improved only after the fll'St dose. There was a sigttificant difference (p<0.05) itl 
objective clinical symptoms itl the vacuum extraction groups, compared to the 
reference group. 
Conclusion: One dose of paracetamol given to neonates delivered by vacuum 
extraction improved significantly theit· clittical condition, but did not result in a 
sigttificant change in objective pain scores. Subsequent doses of paracetamol did not 
show any effect on the clinical symptoms or appearance of the neonates studied. 
II.S.2 Introduction 
Vacuum extraction is frequently perfol1l1ed when there is insufficient progress in the 
second stage of labor, 01' when fetal distress is presumed. I The incidence of this 
procedure in the Isala Clinics, consistitlg of the Sophia Hospital, a hospital with a level 
III neonatal itltensive care unit (NICU), and the Weezenlanden Hospital, is about 17%. 
Tlris is lrigher than the incidence in the past few years in Dutch hospitals (5%-10%), I 
as vacuum assisted delivelY is preferred over forceps delivelY in our hospitals. During 
vacuum extraction, traction of 0.8 kg/cm' (550-600 nunHg) is used to reach sufficient 
force and this aggravates the fOlmation of a caput succedaneum. 
Several reports show that complications after vacuum extraction are mostly due to cup 
displacement and vary from moderate complications such as scalp injuries (redness, 
abrasions, lacerations, ecchymoses, ablation, blistering) in 12.6%, cephalhematomas 
(10%), and subgaleal hematoma, to more severe injuries as intracranial hemorrhage 
(0.4-0.8%), skull fractures «0.1%) or mpture of the tentorium. I",3 Extrapolated to the 
Netherlands with about 200,000 births and 5-10% vacuum extractions, this would lead 
to a maximum of 2500 cases with moderate, and 160 with severe complications. 
Retinal hemon'hage after vaCuum extraction is fi'equently found (46.2%) arId is thought 
to result from a rise in intradural pressure; however, the progtlOsis with regard to 
vision at a later age is good. I 
Newbom infants are cafable of experiencing pain, as substantiated by data published 
over the last decade," but we still do not know under which condition neonates 
actually feel paitl. 6 
We hypothesized tllat infants delivered by vacuum extraction experience pain due to 
the suction and tile traction of the vacuum procedure, and that it may be relieved by the 
administration of paracetamol. 
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For this reason a prospective, randomized, double blind, placebo-controlled study was 
perfol1ned to evaluate whether paracetamol given in the recommended rectal dose of 
20 mglkg7•8 relieves pain in newbom infants after delivelY by vacuum extraction. 
Secondary endpoints were the changes in clinical symptoms, such as increased 
irritability, pain on handling, clying, vomiting, gnmting or poor feeding and abdominal 
distension, and the changes in overall clinical condition, when compared with infants 
given placebo. 
Moreover, both groups were compared with a (third) reference group, delivered in the 
vertex position wiUlOut vacuum extraction and matched for gestational age and 
birthweight, to test the hypothesis that the above clinical symptoms are significantly 
more fi'equent in infants who required vacuum extraction than in those who did not. 
II.S.3 Materials and methods 
Patients 
During a 15 month period uuants born Ul vertex position after vacuum extraction in 
two level 11 hospitals were enrolled in our study. One of those hospitals also includes a 
level III NICU. Vacuum extraction was performed with either a hard cup (Malmstrom 
Bird Egnell, Lameds, Utrecht) or intermittentiy (4 times) with a soft cup (Silk Cup 
Egnell, Lameris, Utrecht). huants were eligible for the study if they fulfilled the 
following enhy criteria: bUih weight >2500 grams, gestational age >36 weeks, Apgar 
score at 5 minutes ?:.7, and the absence of congenital anomalies of the newborn. Entry 
criteria related to the infants' mothers were: uneventful pregnancy, no matel1lal 
analgesics <24 hours before delivery, and no matemal drug abuse. Infants admitted to 
the NICU for artificial ventilation because of respiratOlY insufficiency were excluded 
from the study. Flllihermore infants were excluded during the evaluation phase of the 
study if data were incomplete, e.g. in case of early hospital discharge. 
The same inclusion criteria and exclusion criteria, except for the delivelY by vacuum 
extraction, applied to tlle uuants bom Ul vertex position in the reference group. 
Informed parental consent was obtained'prior to study entry. The study was approved 
by the hospital medical ethics committee. 
Procedure 
A computer-generated randomization procedure was canied out by one of our hospital 
phannacists (JTD) who had no knowledge of the clulical status of the neonates. The 
NICU staff and the nurses, responsible for patient management and tile nurses who 
perfolmed scoring had no knowledge of the group designation. Randomization to 
paracetamol or placebo was stratified by bUih weight. 
In the delivelY room separate numbered boxes were available for bU'tll weight 
categories, each containing 4 suppositories with either paracetamol suspended in 
Witepsol H-15 as fatty suppository base or a placebo with only Witepsol H IS base, 
The suppositories were prepared by the hospital phannacy. Suppositories contained 
50, 60, 70 or 80 mg paracetamol (Ph.Eur, particle size <45 lun). Hard fat Ph.Em 
(Witepsol HIS), a synthetic mixture of mono-, di-, and triglycerides of the satrll'ated 
fatty acids C I O-C 18 was used as a suppository base. The suppositories were prepared 
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in batches of 100; each batch was analyzed on content and content-unifonllity by the 
quality assnrance laboratory of the hospital phannacy. 
When an infant met all entry criteria the next numbered box for his or her birth weight 
category was used. Administration of the placebo or study drug was statted 
immediately after inclusion. All infants were given the suppositoty rectally, in case of 
the study drug the dose of paracetamol used was as close to 20 mg/kg as the available 
strengths of suppository (50 mg for birth weight 2500-2749 g. 60 mg for birth weight 
2750-3249 g, 70 mg for birth weight 3250-3749 g, and 80 mg for birth weight 3750 g) 
would allow. At 6, 12 and 18 honrs hereafter they received another suppositoty from 
the same batch. 
0(} 0(} 
o 4 
Fif{ure 1 Facies scale, rallge 0 (110 paill) - 4 (clearly in paill).)O (reproduced by permissioll oj 
the Dutch Natiollal Orgallizatiolljor Quality Improvement ill Hospitals, CBO Utrecht). 
Scoring 
Pain was assessed with a modified 5 points facies scale' (Figure 1) at 1, 7, 13, and 19 
honrs after the first suppository had been given, assuming a maximum effect of 
paracetamol for temlneonates between 30 and 60 minutes and a serum half life of 2-3 
hours.8 Scores ranged from 0 (no pain) to 4 (clearly in pain). Scoring was perfonned 
by nnrses from the obstetric and pediatric wards, who were blinded for the group in 
which the infant was included. Nurses were trained by video instruction for tln'ee 
honrs, which has been repotted to result in a high inter-rater reliability (Cohen's 
1('=0.74): In addition, nurses' perception of pain was noted at the same time and 
described as better, worse, or unchanged clinical condition, as compared to the clinical 
condition before administration, using tile indices of pain as reported by Pigeon et al. 10 
Clinical symptoms in the first 24 homs were assessed before and after administration 
of paracetamol or placebo and were defmed as shown in table I. In order to conect for 
symptoms due only to vacuum extraction, the same clinical symptoms were scored in a 
reference group of 66 tenn infants delivered after an uncomplicated pregnancy in 
vertex position without vacuum extracted head extraction. Two or more pain scores in 
the reference group were assessed at the same time points as in the other groups. 
The following clinical data were recorded for all patients: birth weight, gestational age 
from last menstrual date or, preferably, from early (1 0 weeks) ultrasound, Apgar score 
at 5 minutes, heart rate, passage of meconium, and voiding. Labor related parameters 
such as fetal distress defined by CTG, and insufficient progress of labor in the second 
stage of labour, the indications for vacuum extraction, were recorded as well. 
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Symptom 
Pain on handling 
Grunting 
IITitability 
Crying 
Poor feeding 
Bringing up 
Vomiting 
Abdominal distension 
Definition 
Noticing that the child dislikes to be handled, may cry 
with apprehension even when approached, but is quiet 
when left alone 
G11mting noise on expiration> 30 minutes after birth 
Hyperactive Mora reflex, increased muscle tone, 
restlessness, jittery even when undisturbed 
Excessive clying longer than I minute, or incessantly 
for repetitive periods 
Listlessness or disinclination to feed 
Retuming small amounts of feeding 
Retuming the whole amount of one feeding 
Increased abdominal circumference (by clinical 
impression from the nurse) in the time between 2 
feedings 
Table I Definition of clinical ,ymptoms scored in the first 24 hOllrs of life. 
Data analysis 
Data were analyzed using SPSS-5. In bivariate analysis, Student's t-tests were used 
when the data were normally distributed; otherwise, a nonparametric method (Mann-
Whitney U test) was used to compare groups. 
From OUl' clinical practice, we assumed a complication rate of approximately 25% in 
the placebo group. To detect a significant difference (at the 5% level) to be 80% 
confident of detecting a difference in propot1ion of complications of 25% in the 
control group versus 5% in the study group, 58 patients were needed in each group. 
Ten more infants were added to compensate for possible dropouts. P values <0.05 
(two-tailed) were considered significant.. 
Il.S.4 Results 
One IUUldred and forty infants entered the study, 122 of whom completed the study as 
designed. The first dose was administered within 1 hour after birth in all 140 infants. 
Eighteen infants were excluded since they failed to receive three or more doses of tlle 
study d11lg or placebo. Sixteen infants were discharged before all suppositories were 
given, and in two other infants the study was stopped on parental request. Sixty-one 
infants received paracetamol, 61 other infants entered the placebo group. The clinical 
data are presented in table II. There were no abnol1nalities in heart rate, passage of 
meconium, and voiding. No significant differences in group size, birth weight, 
gestational age, 5 minute Apgar scores or sex were observed. Indications for vacuum 
extraction were sintilar for the paracetamol and tlle placebo group. In both groups 2 
infants were delivered by means of a soft cup. Labor related parameters were not 
different between these groups. 
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The reference group consisted of 66 infants delivered in veltex position without 
vacuum extraction after a normal pregnancy. The clinical data of these infants are also 
shown in table II. There were no significant differences with either vacuum extraction 
group. 
Paracetamol group Placebo group Reference group 
: (n=61) In=61) I (n=66) 
Sex 
Male 30 29 32 
Female 31 32 34 
Birth weight (g) 3575 ± 464 3556 ± 440 3486 ± 495 
Gestational age 40.28 ± 1.20 40.16 ± 1.23 39.5 ± 1.5 
(wks) 
Admission to 2 1 . 
neonatal ward 
Table II Clillical dala of sludy paliellls. Dala are giVe/I ill lIumbers or as meall ± SD. 171ere 
were 110 significanl differences between groups (Sludelll 's 1·lesls) 
Pain assessment was performed in 66 infants in the reference group, in 59 infants in 
the paracetamol group and in 60 in the placebo group. In the reference group a facies 
score> 1 was never observed. There were no significant differences in facies score 
between study and placebo group at any of the assessment times T=I, 7, 13 or 19 
homs: scores in most infants were 0, I, or 2; 40 in the paracetamol group and 43 in the 
placebo group. In 19 infants in the paracetamol group and in 17 infants in the placebo 
group one or two of the scores were 3 or 4 at any of tlle time points. There was no 
relation between facies score and analgesic effect. 
There was, however, a significant difference in clinical condition between the 
paracetamol group and the placebo group as scored by subjective perception of nurses 
at T=\. In the paracetamol group the clinical condition improved in 33 infants, did not 
change in 5, and was worse in 21 as compared to that before administration. In the 
placebo group the scores were 21, 2, and 37, respectively (P<O.OI). 
In contrast, no difference in clinical condition between tlle paracetamol group and the 
placebo group at 7, 13 and 19 hours was observed. For individual patients the outcome 
at T= 1 or any of the other time points was not predictive for the clinical condition at a 
later time point. Clinical condition was stable in all infants in the reference group. 
Of the clinical symptoms, abdominal distension was scored only once in the placebo 
group. Excessive crying was noted in one case in tlle paracetamol group, and in 3 cases 
in tlle placebo group. Data for the other clinical symptoms are presented in Table III. 
There were no significant differences between tlle paracetamol and placebo group for 
any of the symptoms. 
Multivariate analysis with one or more symptoms did not show any differences 
between the paracetamol and the placebo groups. 
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When compared with the infants in the reference group, however, there were 
significant differences between the numbers of episodes of vomiting and poor feeding 
in both the paracetamol and placebo groups (Table III). The same holds true for the 
number of infants that grunted or showed irritability or pain on handling (Table III). 
Paracetamol Placebo Reference group 
(n=61) (n=61) (n=66) 
No. of times found 
- Bringing up 0.67 ± 1.00 0.90 ± 1.17 0.79 ± 1.12 
- Vomiting 0.48 ± 1.27 0.29 ± 0.59 0.12 ± 0.45' 
- Poor feeding 1.00 ± 1.61 0.86 ± 1.51 0.71 ± 1.05" 
No. of patients 
2' 
- Grunting 9 8 
- Irritability 8 10 O· 
- Pain on handling 8 11 0' 
Table III Clinical >ymploms 
Number of limes clinical symploms were found wilhin 24 hours of birlh (meall±SD) and 
lIumber of paliellls wilh clillical symploms wilhin 24 hours of birlh. 
, P< 0.05, reference group vs paracelamol alld placebo, ' P< 0.01, referellce group vs 
paracelamol and placebo (Manl1-Whillley U lest). 
II.S.S Comment 
We found that the administration of paracetamol directly after birth to infants bam by 
vacuum extraction did not relief pain as assessed by the validated modified facies 
score.7 The administration of one dose of 20 mg/kg pamcetamol rectally directly after 
birth significantly improved the clinical condition as perceived by nurses but ftlliher 
doses did not make any difference. 
Symptoms such as vomiting, poor feeding, gl'llnting, il1'itability, and pain on handling 
were fOltlld significantly more after vacuum extraction than after vertex delivelY 
without vacuum extraction, but did not diminish after administering paracetamol. 
Although major sequelae, such as scalp injuries, cephaUlematomas, inh'acranial 
hemorrhage and fractures have been repOlted in the literahlre, I,' minor complications 
or symptoms are not mentioned in pediatric, neonatal, or in obsteb'ics textbooks. Pain 
in relation to vacuum exh'action has not been mentioned before in the literahlre 
(Medline search) and guidelines for preemptive analgesia directly after a traumatic 
delivery or after vacuum extraction in particular are not given either. In a recent study, 
Shah et al" assessed the efficacy of paracetamol in 75 tenn neonates undergoing heel 
prick. Facial action scores did not differ between groups, indicating that paracetamol 
fails to alleviate the acute shall> pain h'iggered by heel prick in term neonates. 
In tlle present study we did not find differences in facies pain score between the 
paracetamol group and tlle placebo group. The results of 01U' validation and tlle high 
interobserver rate (Cohen's 1(=0.74) prove that the initial pain score was reliable.9 
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Labour related parameters did not differ between the paracetamol group and the 
placebo group. For 2 infants in the paracetamol group and one infant in the placebo 
group, who had been admitted to the neonatal ward because they 'were not doing well' 
after vacuum extraction, the vacuum extraction seemed to be the only cause for the 
symptoms. 
The facies score performed one hour after administration of paracetamol might have 
been too early to show pain effects. Previously we assumed that in term infants the 
maximal serum concentration is reached between 30 and 60 minutes, as shown by 
Hopkins et a18, but recentIy we showed that gestational age must be taken into aCCOlmt: 
in pretenn infants the maximal semm concentration is not reached lUltil after 3.9 
hours.' 
In a recent other study we found that the maximum senun concentration in tenn infants 
of 3.36 ± 2.11 mg/l is reached between 30 and 180 minutes after a rectal dose of 20 
mg/kg. l2 
In spite of the fact that appropriate analgesia has been reported,12 and Anderson et al 13 
recently snggested that neonates may have altered pharmacodynamics compared with 
older children, the given rectal dose of paracetamol might have been too small to show 
differences between tIle paracetamol and the placebo group. Higher starting doses of 
25-40 mg/kg in older infants and children,13.15 and one of 30 mglkg in term infants on 
the fll'St day of life have now been proposed." 
The above-mentioned symptoms might be expressions of pain caused by the vacuum 
extraction, considering they were fewer in tIle reference group, and no other causative 
factors have been identified so far. 
Even though the facies pain scores did not significantly differ between tIle paracetamol 
group and the placebo group, the nurses' perception of pain (in terms of better, 
unchanged or worse clinical condition), suggested that infants in the paracetamol 
group had less pain than those from the placebo gronp after the first, but not after 
subsequent doses. 
Although nurses' perceptions of palo are often based on subjective "feeling", signs and 
symptoms,IO·16.17 neonatal nurses have shown strong agreement (average 86%) on the 
indicators of neonatal pain. 1o 
In a study on assessment of acute pediatIic pain in older children, children's self-report 
and nurse ratings were significantly correlated, implicating that where observational 
coding is not possible, nurse ratings of acute pain may most closely approximate 
objective assessment of pain and distress behaviors." 
The difference after tlle first dose might have influenced our overall impression in 
scoring after the subsequent doses. The fact tllat no improvements were observed after 
tile second and following doses might be due to rapid improvement of tIle clinical 
condition after a vacuum extraction during the first hours after birth, or to the fact that 
the acute pain was not present anymore and our scoring method was not appropriate 
for ongoing pain. 
Although the endorphin system is completely functional in term infants,19 we believe 
that the influence of high, endogenously produced, ll-endorphlo levels in infants lo 
umbilical blood,20 is of little importance, as values in infants bom after vacuum 
extraction and tIlose bom after delivery in vertex position did not differ significantIy,20 
and because ll-endorphin has a short half life.21 
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We conclnde that clinical symptoms occwTed significantly more in babies delivered 
with vacuum extraction. Judging from the modified facies scale to assess neonatal 
pain, paracetamol did not significantly contribute in lowering the score in babies 
delivered by vacuum extraction 
Judging from the subjective nurses' perception score of the clinical condition, the 
clinical condition improved following one dose of paracetamol. 
Finally, we doubt tlrat subjective feelings of nurses and the facies scale are suitable to 
assess pain in infants bom after vacuum extraction, and suggest that multidimensional 
pain scores, which have recently become available, might be more appropriate.22•24 
As the clinical condition of most infants was shown to inrprove after one dose of 
paracetamol, it seems justified to await the clinical course in individual patients, and to 
apply a multidimensional pain score to assess the possible need of more medication. In 
case overt pain is present following delivery a higher starting dose of 30 mg/kg might 
be more effective. 
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III 
Pharmacokinetics alld Pharmacodynamics oj Morphine 
ill 
Ventilated Preterm Illjants 
"Then 1 prepared a drajl of Red Shepennfor him and made it as strong as 1 dared, 
for [ knew that pain could undo all my best efforts and destroy my patient as swijlly 
as a slip of my scalpel. "(Wi/bur Smith, River God, 1993) 
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111.1 Pain Assessment and Morphine Pharmacokinetics in Preterm 
Infants: The Usefulness of the Flnorescence Polarization Immnno 
Assay. 
Based on the article: 
Pain Assessment and Morphine Pharmacokilletics ill Preterm Illfallts: The 
Usefuilless of the Fluorescellce Polarizatioll Immullo Assay. 
RA van Lingen, B Greijdanlls, A Okken, DRA Uges. 
Submitted. 
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111.1.1 Abstract: 
Objective: To determine the concentration-effect relationship of continuous morphine 
in preterm infants in the ftrst days after birth using a validated pain score, both at rest 
and during endotracheal suctioning, and to investigate whether a rapid method for the 
detennination of morphine senun concentration, a modifted fluorescence polarization 
inllilUno assay can be useful to adjust morphine dose. 
Methods: In a prospective clinical trial, pretenll ventilated neonates in three different 
age groups, who were subject to several painful procedures, received continuous 
morphine (l0 Jlg/kg/h). Morphine selum concentrations were determined using a rapid 
Fluorescence Polarization Imiliuno Assay, and pharmacokinetic analysis was 
perfolmed. 
Pain scores before and after morphine, and during endotracheal suctioning, were 
assessed by a validated pain score. 
Results: Of24 infants included in the trial, 4 were aged <28 weeks, 14 between 28 and 
32 weeks, and 6 >32 weeks. Morphine could be detected in 75 to 84 % of the samples 
during the ftrst 10 days of life. Differences between the groups in mean morphine 
concentration were not signiftcant, although there was a trend for lower concentrations 
with older age in the ftrst 3 days. Mean morphine concentrations for all infants 
increased from 85.1 ± 33:4 on day 2 to 103.3 ± 70.8 Jlg/l on day 5. Except on day 2 
morphine concentration was not correlated to gestational age. Mean estimated 
clearance was 2.3 ± 1.1 ml/min/kg for the total group, and increased with gestational 
age. The difference between the groups was not signiftcant. 
Pain scores were signiftcantly higher before than after morphine (P <0.001) and also 
during than either before or after endotracheal suction (P <0.001), but were not related 
to morphine concentrations. 
Conclusion: Morphine concentrations can be detelmined by tlLis rapid method, but it 
can not be used for individual dosage adjustment. With tile dose used in tlris study 
appropriate analgesia as assessed by a pain score was achieved during ventilation, but 
no concentration-effect relationslrip was found. 
111.1.2 Introduction 
Morphine is the most widely used analgesic in neonates.!·2 It is used to alleviate and 
prevent pain and stress in case of invasive procedures in the neonatal intensive care 
IUrit (NICU), during and after interventions, and during assisted ventilation. During 
neonatal intensive care especially pretenn infants are subject to many rainful events, 
of which heelprick and endotracheal suctioning are the most common. FUl1hennore, 
llIorphine is reported to increase synchronous ventilation:! and llIay reduce the 
incidence of poor neurologic outcome in ventilated preteI'm infants. 5 
An intravenous loading dose of 50 to 100 Jlg/kg followed by continuous infusion of 10 
to 25 Jl~k~l is reported to provide good sedation and analgesia in tenn and pretenll 
infants .. 6.7· To prevent adverse effects it is recolllmended not to give doses in excess 
of 15 fig/kg/h." However, a more recent study repol1ed the administration of an 
intravenous loading dose of 50 Jlg/kg, followed by continuously given doses of 10-20 
fig/kg/hour to neonates without any observed adverse effects.!O The dose was even 
increased in case of inadequate cHlrical effect or when tolerance developed.!O Several 
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authors do not report side effects with serum concentrations varying from 10 to 210 
~Ig/I, at doses between 5 and 50 ~g/kg/h. 11·14 Adequate sedation was reported in 50% 
of patients with a morphine serum concentration> 125 ~g/l. 14 In adults, morphine was 
consistently effective at plasma concentrations of 40 ~g/I or greateL IS 
Morphine serum or plasma concentrations can be detennined by various methods.7.16 
Concentrations vary widely and detennination often takes days. Several groups 
investigated the phannacokinetic effects ofa single dose of mOll'hine,' 7·19 or of various 
continuous doses versus concentration or effect. 6.20 However, in contrast with studies 
in adults, the phannacokinetics and phannacodynamics in the newborn period were not 
studied. IS 
Phannacokinetic-phannacodynamic relationships of analgesia in pretenn and full tenn 
infants have been examined only in studies using fentanyl,21.23 and in one study using 
morphine as analgesic dlllg, and applying the Neonatal Facial Coding System as pain 
assessment instrument: The effect of morphine is generally only measured by means 
of a sedation score. 14 Tltis may be partly due to the absence of adequate methods to 
detennine morphine concentrations in blood, and partly to the lack of validated pain 
scores for bedside use in tltis age group. Several validated pain measure instmments 
have been developped in the past ten years?4 
If a correlation could be found between pain score and mOll'hine concentration, the 
clutical benefit of a method to detect concentrations within hours would be obvious. 
Thus tile objectives of tltis study were twofold: 1. To detennine a concentration-effect 
relationsltip Ul tile first days after birth using tile Neonatal Infant Pain Score (NIPS),2s 
as a validated pain score for tllis age group, both at rest and during a painful procedure, 
i.e. endotracheal suctioning (ET), and 2. To ulVestigate whether a rapid method for the 
detennll18tion of morphine serum concentration, a modified fluorescence polarization 
itmnuno assay (FPIA),26 can be used to adjust morphine dose in pretenn infants. 
111.1.3 Methods 
Patients 
The study included 28 inborn pretenn neonates who were admitted to the neonatal 
intensive care mtit in the period from January, 1996 through April 1997. 
EntJy criteria were the need for artificial ventilation (IPPV), need for sedation or 
analgesia as assessed by a validated pain score, the NIPS, and postnatal age <48 hours. 
The study protocol was approved by the etltical review committee of tile Isala Clinics 
(Zwolle, The Netllerlands). Written infonned parental consent was obtauled for each 
patient before enrolment. 
The gestational age of the neonates was estimated from maternal menstrual histOlY, by 
routille ultrasound examination during pregnancy, and by postnatal physical and 
neuromuscular characteristics (New Ballard score). 27 Patients were excluded if they 
had major congeltital anomalies, severe asphyxia (APGAR score :S3 after 5 InlllUtes), if 
tlley needed muscle paralysis for adequate ventilation, if their motller had received 
indomethacul or had been given analgesics (otller tllan local or epidural) within 24 
hours before delivelY. 
All uuants recieved appropriate fluid therapy and adequate nutJ"ition. 
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According to standard procedures in 'the NICU, central venous catheters and umbilical 
or radial arterial catheters were inserted. 
Infants were stratified into three different age groups: <28 weeks (group A), 28-31 
weeks (group B), and 32-37 weeks (group C). 
Morphine was administered as an intravenous loading dose (100 lIg/kg) in 5 minutes 
on day 1, followed by 10 tlg/kg of morphine continuously. 10 Extra morphine was given 
as the attending physician deemed it necessary. Total days on mO'llhine therapy and 
time and amount of additional morphine were noted. 
As the mean duration of artificial ventilation in our unit (level III NICU, no surgical 
patients) in general was between 7 and 8 days, we decided to study the 
pharmacokinetic and dynamic propel1ies of morphine during a period of 10 days, with 
regular intervals dlll'ing the time morphine was needed. 
According to Ole study protocol morphine infusion was stopped by Ole attending 
neonatologist under the following circumstances: 1. After successful extubation, 2. If 
ventilator settings allowed extubation within several hours, 3. If the patient was judged 
to be pain free. If morphine had been given for more than 5 days, morphine 
administration was decreased by 50 % one day before discontinuation of Ole infusion, 
according to standard procedures to prevent possible symptoms of opioid 
withdrawal.28 
Blood samples were taken at predetermined time points on days 2, 3, 5, 7, and 9 
together with sampling for routine laboratOlY investigation, and at 12 and 24 hours 
after ending administration of the drug. After blood collection, serum was separated 
and frozen at _20°C, until assayed. 
Clinical observations included continuous monitoring of heart rate, respiratOlY rate, 
arterial blood pressure, oxygen saturation, and rectal temperal1u·e. Cranial ultrasound 
was perfOl1lled routinely on days 1, 2, 3 and 5, and at the expected date of delivery. 
Analytical procedures 
For this sl11dy the assay was pelformed within a month of sample collection. A rapid 
(wiOlin one honr) and r<;prodncible method was used for Ole quantification of 
morphine wiOI Ole AxSym fluorescence polarization inlllUUlo assay (FPIA) analyser 
(Abbott Diagnostics Division, Amstelveen, The Netherlands) requiring 100 ttl of 
senun. 
In a polypropylene 111be, 100 III of senllll was added to 50 III solubilization reagent 
(Abbott 9797-30), and 150 III whole blood precipitation reagent (Abbott 9797-33), 
mixed and centrifuged. The supernatant of the senllll was transferred in a sample cup 
and analysed with the FPIA reagent for mOl]lhine in urine (Abbot1 9673-60), confolln 
the guidelines of Ole supplier, but using serum instead of urine. 
Limit of quantification was 25 J.lg/l. Inter-day variation was 4.8 % (C = 103 tlg/I; n = 
100). 
Cross reactivity for morphine-3-glucuronide (as given by the supplier) is 31-58 % 
depending on the concentration. 
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Pharmacokinetics 
Phannacokinetic data and variables were calculated from standard equations usinJl the 
KINFIT program of MWlPhann (Mediware, Groningen, The Netherlands)? An 
estimate of the individual serum clearance was obtained by dividing the moq)hine 
infusion rate by the apparent steady state mean sennll concentration of morphine at 
day 2.8 
Pain Assessment 
Pain was assessed by means of the NIPS by experienced nurses, before and after 
starting morphine, twice during every 8 hour shift, and once daily before, during and 2 
minutes after ET. Nurses were trained by means of a videotape to use the NIPS, lmtil a 
good interrater reliability was reached (Cohen's kappa >0.70). A score of 0-2 was 
considered as good analgesia, 3-4 as moderate pain, and 5-7 as severe pain. 
Inadequate analgesia (NIPS >3 at two consecutive controls or 2:5 once)30 was managed 
by the attending physician by administering an extra bolus of mOlphine (50 Ilg/kg), or 
if this failed to improve analgesia, by increasing the morphine infusion rate by 5 
Ilg/kg/h . 
Severity of illness was assessed by means of the clinical risk index for babies 
(CRIB)3!,,, which includes bil1hweight, gestation, and clilucal data up to 12 hours 
from bil1h, and rredicts mortality and morbidity, and nught predict the long-term 
clinical outcome. 3,34 
Statistical analysis 
Data were analyzed WiUl SPSS-8 (SPSS Inc, Chicago, Ill). Student's I tests were used 
for nOl1nally distributed data, Wilcoxon's Signed Rank tests for pail'ed data, and 
Friedman's test or Spearman's rank conelation for nonparametric data. Mann-Whitney 
U tests were used for nonparametric data to compare the tluee groups. P values :S0.05 
(two-tailed) were considered to be sigJuficant, except for the pain scores, for which P 
values :S0.01 (two-tailed) were considered to be significant. 
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111.1.4 Results 
Parental consent was denied for 3 (all group A) of the 28 infants eligible for the study. 
Samples from one infant were lost. Clinical data of the remaining 24 infants are shown 
in table I. 
Morphine was detected in 16/21 (76 %) samples on day 2, 16/19 (84 %) on day 3, 7/9 
(78 %) on day 5, 6/8 (75 %) on day 7, and 3/4 (75 %) on day 9. Twelve hours after 
discontinuation morphine was detected in 4/15 samples (range 38-57 1lg/1), and in 5/16 
samples (range 26-59 1lg/1) after 24 hours. All values were considerably lower than the 
preceding values during morphine administration. 
Morphine concentrations for individual patients are shown in figure I. 
Mean morphine concentration for Ole Ouee groups could be detennined on days 2 and 
3 only, in groups A and B on day 5 as well (Table 2). There were no significant 
differences between groups. 
In group B Ole mean morphine serum concentration on day 7 was 104.6 ± 60.0 flg/l (n 
= 5). In groups A and C insufficient data (0-1) were available after days 5 and 3 
respectively, as morphine administration was stopped on clinical indication. 
Mean morphine concentration did not differ significantly between groups on any day. 
A significant negative conelation between gestational age and mean morphine serum 
concentration was observed on day 2 (Spearman Rank r=0.50, P <0.05); on all other 
days no con'elation was found. 
Estimated mean clearance (± SD) on day 2 was 2.3 ± 1.1 lnl/min/kg (n=16) for the 
total group, and increased with gestational age, but the differences between the groups 
were not significant (Table 2). 
NIPS score and morphine concentration did not correlate at any time point. Pain scores 
before and after morphine administration are depicted in figure 2A.; tlley significantly 
decreased after morphine administration (P <0.001). 
Tluee infants needed an extra single morphine dose (50 Ilg/kg) after 3 days (one infant 
in group A, 2 in group B). 
Except for day 9, pain scores during ET were significantly higher than before or after 
ET (P < 0.001 on day 2, P = 0.001 on days 3 and 5, P <0.05 on day 7). Pain scores (n = 
19) during ET on day 2 are depicted in figure 2 B. 
Pain scores before and after ET did not differ significantly, and almost always ranged 
between 0 and 2. In only 3 of 51 pain scores (5.9 %) before ET, and 4 of 51 pain 
scores (7.8 %) after ET a value of 3-4 was scored. Tluee of those 4 high pain scores 
after ET were in Ole same infants that had a high score before ET. 
Severity of illness did not differ between the groups (Table 1). Two infants (one group 
A, one group B) died during the study period, for reasons not related to the study (both 
severe IRDS and persistent hypoxia). One other infant (group B) died at the age of 4 
months due to septicaemia and paralytic ileus, caused by streptococcus A. 
There were no significant differences in heart rate or mean arterial blood pressure 
between Ole groups after starting the mOlphine. In 14 infants hypovolemia and 
hypotension was already treated with volume expansion before morphine treatment 
was started, and in 7 infants (Table 1) inotropic SUppOlt was given either before or 
after morphine administration. 
Urinary retention as objectivated by ultrasound was found in I infant in group B. 
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Group A (n- 4) B (n - 14) C (n - 6) Total (n -24) 
Birthweight (g)' 865 ± 91 1200 ± 385 2044 ± 316 1355 ± 535 
Gestational age (weeks)' 26.5 ± 0.7 29.2 ± 0.9 33.8 ± 1.0 29.9 ±2.6 
Sex 
Male 2 11 5 18 
Female 2 3 1 6 
Diagnosis at admittance 
RDS 4 12 2 18 
Pnemnoniaisepsis 
-
I 2 3 
Asphyxia 
- -
I 1 
Pneumothorax 
- -
I 1 
Hypoplastic lungs 
-
I - I 
Surfactant 3 11 2 16 
Inotropic agents 2 4 1 7 
PIVH I-II - I - I 
PIVH III-IV/PVL 
-
2 
-
2 
Died S; 28 days I 1 - 2 
Died >28 days - I - I 
Artificial ventilation (days)' 22.0 ± 18.9 11.1 ±7.7 7.0 ± 6.1 11.9 ± 10.6 
Morphine (days)' 9.5 ± 6.5 6.2 ± 2.5 3.7 ± 2.2 6.1 ±3.7 
CRIB score' 6.0 ±4.3 4.2 ± 2.5 2.7± 1.6 4.1 ± 2.8 
Table 1. Clillical data of study partieipallis. Dala givell are lIumber of ilifallls, or • meall ± 
SD. No sigllifiealll differellees betweell groups exeepl for geslalional age group A vs Band C 
(P< 0.001), alld B vs C (p<O.OOJ), and birlhweighi A vs B(P<0.01) and C (p<O.OOJ). 
Cmax day 2 Cmax day 3 Cmax day 5 Clearance 
Group A 116.0 ± 43.6 (n-3) 73.7 ± 31.8 (n-3) 60.5 ± 43.1 (n-2) 1.6 ± 0.7 
Group B 87.7 ± 23.0 (n-9) 87.9 ± 44.6 (n-IO) 120,4 ± 76.0 (n-5) 2.1 ± 0.8 
Group C 56.3 ± 28.8 (n~4) 43.3 ± 23.0 (n~3) 
-
3.4 ± 1.2 
Total 85.1 ± 33.4 (11-16) 76.9 ± 41.3 (n-16) 103.3 ± 70.8 (n-7) 2.3 ± 1.1 
Table 2. Meallmorphine serulII cOlleenlralioll (Cmax) ± SD (pgll) and clearance (mllkg/mill) 
for all paliellis andfor differenl age grOl/ps. All differellces between groups 1101 significanl. 
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Figure 2. (A) NIPS scores before and after start of morphine administration (n~24) (P 
<0.001), and (B) before, during and after endotracheal suction on day 2 (n~I9) (P <0.001 
during vs before, and during vs after). 
111,1.5 Discussion 
The importance of analgesia in newbom infants in the NICU for their well· being, and 
improvement of shOli-tenn outcome is now widely known.4.'.35 In this context, it is 
important to find dose and administration schedules which are effective and safe. In 
this study we investigated the pharmacokinetics and phannacodynamics of ventilated 
newbom infants during the first week of life, in order to be able to adjust morphine 
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dosage following detel1nination of the selUm concentration and simultaneous pain 
assessment. 
We have demonstrated that morphine concentrations can be detected by the FPIA 
method. With a relative low dose of 10 Ilg/kglh morphine, selUm concentrations 
between 25 and 233 Ilg/l were detected in the majority of infants. 
A significant negative con'elation between morphine selUm concentrations and 
gestational age was detected on day 2, but on all other days cOlTelations were not 
found. 
Validated pain assessment scores showed good analgesia during continuous morphine 
administration, although without a cOlTelation between morphine serum concentration 
and pain scores. 
Differences between age groups were not significant. However, they could be 
detennined only for days 2 and 3 postnatally, because numbers of patients in groups A 
and C on the other days, were too low. 
In this study morphine was administered during the first 10 days of life, and 
phannacokinetics and phal1nacodynamics during tlus period have been determined. 
There are no other repOits of a sintilar study of tlus lengtll, which nught be due to the 
difficulty of obtaining dataj as not many infants need analgesia for a longer period. In a 
recent study by Scott et aI, 48 out of 496 eligible infants were studied during 3 days. It 
is obvious tllat only the most critically ill patients were studied. 
In 14 infants in our study, 2 or more serum concentrations could be detected, Widl 
values ran£in~ between 25 and 233 1lg/1. These are in line with data found after 
morplune6 .. 9,1 ,14 and diamorphine.36 
Comparable mean morplune concentrations were found in two studies using a 
continuous dose of 15 Ilg/kg/ll' and 20lllkg/ll,13 but our values were lower tllatl those 
found by Scott: with lugher infusion rates (20-30 Ilg/k~l), or lmtil adequate sedation 
was reached Widl infusion rates of 7.5 to 30 Ilg/kg/ll.l In a study compat'ing a 12.5 
Ilg/kg/ll continuous dose Widl a 50 Ilg/kg/ll continuous dose no clinical advantage in 
using the hlgher dose was reported.8 
The mean estimated clearance in our studr on day 2 is in range with the values as 
reported by others in pretenn infatltS,8,14,3 atld is considerably lower than in older 
children. This explains tile lugher meatl morphine concentrations in our study as 
compat'ed to tllOse in older cluldren. 16,38 
In chlldren mean selum concentrations of 16 atld 18 Illl were found at 24-40 hours 
after a continuous infusion of 20 llg/kglh.16 
After discontinuation of the morphine infusion, mOlphiue could still be detected in 
serum of 27 % and 31 % of the neonates after 12 and 24 hours, respectively. Whether 
tllis is still active morphine or eitller one of its metabolites is not cleat·, atld will be 
subject of ftuther study. 
The FPIA enables us to detelmine morplune concentrations in a relatively short time, 
and tlleoretically it can be used tile velY same day to evaluate our tllerapy. However, in 
clinical practice it offers no benefit in that regard, as no cOlTelation was found between 
morphine concentration and pain assessment score. 
We found appropriate analgesia with morphine concentrations that were lower than 
those proposed by Hartley. et aV9 who aimed at a minimum target plasma 
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concentration in the region of 100 flg/l. Even higher concentrations were reported by 
Chay et al,14 using individualised dosing, who found that a mean plasma concentration 
of 125 Ilg/I provided a desired comfort score in 50 % of babies. 
The morphine concentrations of >40 fig/I, repOlied to correlate with appropriate 
analgesia in adults using patient controlled analgesia, are more in line with our 
values. IS 
In two other studies pain was scored in relation to morphine administration. Scott et 
al,9 using the neonatal facial coding system (NFCS), found that facial activity discloses 
morphine analgesia, bnt is unrelated to morphine concentration, as in our study. 
Furthermore, the NFCS needs video taping and is in that respect not suitable for 
bedside use. Saarellmaa et al2J compared morphille and fentanyl, and found similar 
changes ill pain score for mOlphine and fentanyl administration, which compares to 
our results. However, as values were not reported it can not be concluded whether 
there was good analgesia or not?' Using our pain score tlris would mean tllat a 
decrease of 3 (moderate paill) to 0 (no pain) is equal to a decrease of 7 (severe pain) to 
4 (moderate pain), bnt still in pain. 
Severity of illness as measured by the CRIB score was not related to the analgesic 
effect of morphine as measmed by tile NIPS, dmation of morphine administmtion as 
expected, was longer in tile youngest age group, but was not related to severity of 
illness eitller. 
We conclude that morpltine concentrations can be determined by the FPIA method, but 
it can not be used for individual tailoring of dosage. With the dose nsed in this study 
appropriate analgesia as assessed by the NIPS was acltieved during ventilation, but no 
concentration-effect relationship was found. 
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111.2 Pharmacokinetics and Pharmacodynamics of Morphine and its 
Metaholites: The Effect of two Different Dose Regimens in Ventilated 
PreteI'm Infants 
Based on the article: 
Pharmacokinetics and pharmacodynamics of morphine and its metabolites: The 
effect of hvo different dose regimes in ventilated preterm infants. 
RA vall Lingen, B Greijdanus, W Grol, A Okken, DRA Uges, D Tibboel MD. 
Submitted. 
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111.2.1 Abstract 
Obiective: To investigate pharmacokinetics and pharmacodynamics of mOlphine and 
its main metabolites, morphine-3-glucuronide and morphine-6-glucuronide, in pretenn 
ventilated neonates in the first ten days of life in relation to gestational age. 
Design: Randomised controlled trial. 
Setting: Level III neonatal intensive care wut. 
Methods: In this prospective clinical trial, two groups preterm ventilated neonates 
stratified for gestational age, who were subject to several painful procedures, received 
continuous morphine in two different dose regimens of 10 (group A) or 15 ~lg/kg/h 
(group B). Serum concentrations of mOlphine and its metabolites were determined 
serially with a HPLC method, and phannacokinetic analysis was performed. Pain 
assessment was perrol1lled by a validated pain score. 
Results: Twenty-eight infants were randomised to either group A or B. Morphine 
could be detected in 80-100%, and mOlphine-3-g1uc\U'onide in 89-100% of the infants. 
The percentage of infants in whom morphine-6-g1ucuronide could be detected 
increased significantly from 41% to 90% over the first 9 days of life. 
Mean morphine concentrations for all infants increased from 58.1 ± 37.6 ~lg/I on day 2 
to 63.2 ± 29.1 ~lg/l 011 day 3 and decreased thereafter to 44.3 ± 16.3 ~lg/l on day 9. 
Morphine-3-glucuronide values increased sigruficalltly from 75.4 ± 41.0 ~g/l to 130.8 
± 66.7 flg/l on day 9, and mOlphine-6-glucuronide concentrations increased from 25.1 
± 10.0 to 38.4 ± 14.0 flg/l on day 9. On all postnatal days except day 7, there was no 
relation between gestational age and morphine or its metabolites. Twelve and 24 hours 
after discontinuation of the drug, morphine-3-g1ucuronide was still detected in 12/14 
(85.7%) and 13/17 (76.5%) infants in lower concentrations, but in the majority no 
mOlplune or morphine-6-glucuronide was foulld. Mean metabolite:molphine sel1un 
concentration ratios increased significantly during the first 7 days, the mean tllOlphine-
3-gluc\U'onide:mOlphine-6-gluc\U'onide ratio did not increase sigrlificantly. 
Mean estimated serum clearance was 3.64 mllmin/kg for all patients, without a 
significant correlation with gestational age. There was a sigruficantly higher clearance 
in group B than in group A. No influence of either inotropic drugs or severity of illness 
on clearance or morplune concentrations was present. Pain scores were sigluficantly 
higher before than after start of Illorphine administration. Appropriate analgesia was 
present before and after endotracheal suction, but pain scores were sigrlificantly lugher 
during suctiOlung (indicating moderate pain or distress). Pain scores did not correlate 
with morphine, tllorphine-3-glucuronide, or mOlphine-6-g1ucuronide concentrations at 
any time. 
Conclusion: While in pretenn infants morphine and morphine-3-g1ucuronide can be 
found after intravenous admitustration on all days, morplune-6-glucurolude can not be 
fOll11d itl all itliants in the first days after birth, though increasingly WiUl lugher 
postnatal age. 
No cOlTelation between 1ll00phine concentrations and paitl scores was found. Therefore 
we suggest an initial dose of 10 ~lg/kg/h morphine. If tolerance develops the lUOlphitle 
infusion should be increased by 5 Ilglkglh, preceded by 50% of the loaditlg dose. 
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III.2.2 Introduction 
For the last ten years morphine has increasingly been used as an analgesic in premature 
newborns. However, there are still insufficient data regarding its pharmacokinetic and 
phanllacodynamic properties in this age group. 1,2 
Because intubation and artificial ventilation are perceived to be sources of major 
discomfort and possible painful procedures, it is common practice to administer an 
analgesic dmg like morphine during mechanical ventilation in adults and older 
children.3 In the treatment of newborn infants one is reluctant to administer morphine, 
fearing adverse effects such as respiratory depression, constipation, tolerance, and 
withdrawal symptoms, and because of the difficulty of assessing pain in nonverbal 
patients.4 Consequently there is a lack of data regarding the safety and effectiviness of 
I . l morp nne. 
In children and adults pain relief is considered the most important target in the 
administration of analgesia, and side effects are of secondary importance.3 The same 
should apply to infants and newborns, and consequently efforts should be made to 
deternune the dose-concentration-response relationship. 
In the neonatal intensive care wut (NICU) babies are highly exposed to invasive 
procedures, such as heel prick and endotracheal suction, with 74% of the procedures 
performed on the 30% of infants born below 31 weeks gestation.6 
FUlihermore, pain sensitivity is higher in (premature) infants as a result of lower pain 
threshold,7 repeated injuries,' and an initial lack of inhibitOlY processes.9,IO In the most 
critically ill babies pain sensitivity nught be higher due to allodynia. 11 
Pain and stress are suggested to playa role in poor neurological outcome in pretenn 
infants when no analgesia is provided,12 possibly due to fluctuations in arterial blood 
pressure. 13 
Finally, pain experienced durin~ the neonatal period leads to different paill responses 
to subsequent painful events. 14,1 
The effects of morphine in pretenll infants have been evaluated. in several double blind 
randonused controlled trials,I2·16.19 phannacokinetic studies,20.26 and phal111acodynamic 
studies.22.24.26 
Most of these studies have evaluated single dose effects,20.21.2l short tellll «72 h) 
effects of continuous morphine,23,24,26 or different doses. 22 However, there is a lack of 
data for prolonged use of morphine. Moreover, a dose-concentration- response effect 
has been described considering only total morphine concentrations, with 
concentrations over a wide range suggested as being effective for analgesia."·27.28 A 
threshold value for tile concentration necessary to obtain analgesia has not been set. 
The morplune metabolite morphine-6-glucurolude (M6G) is considered to be 
responsible for most of tile tIterapeutic benefit of mOl]lhine,29 and the 
phannacokinetics of morphine and its metabolites change rapidly in tile first days of 
life. Consequently studies should include information about these metabolites 
mOl]llune-3-glucuronide (M3G) and M6G as well. For this reason phannacodynamic 
studies taking into account both M6G arId M3G might give a better understanding of 
tile mechanisms of pain relief.'o 
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As severity of illness might influence the effect of morphine, and inotropic support has 
been reported to decrease the clearance of morphine,3l these factors need to be 
considered, 
Therefore, we conducted a study with the following objectives: 1. To determine 
pharmacokinetics and pharmacodynamics of mOll'hine and its main metabolites M3G 
and M6G, following two different dose regimens in ventilated prematme newbom 
infants in the first ten days of life; 2, To investigate their effects in relation to 
gestational age; and 3, To evaluate the effects of the use of inotropic a§ents, and 
severity of illness as evaluated by the Clinical Risk Index for Babies (CRIB), 2 
III.2,3 Methods 
Patients 
The study included 30 inbol11 pretenn neonates admitted to the Isala Clinics neonatal 
intensive care unit in the period of May, 1997 through September, 1998, Enoy criteria 
were the need for artificial ventilation (IPPV), need for sedation or anal§esia as 
assessed by an objective pain score, the Neonatal Infant Pain Scale (NIPS), 3,34 and 
posolatal age <48 hours, The sOldy protocol was approved by the ethical review 
committee of the Isala Clinics (Zwolle, The Netherlands), Written infonned parental 
consent was obtained for each patient before enrolment, 
The gestational age of the neonates was estimated from matel1lalmenstrual histOlY, by 
routine ultrasound examination during pregnancy, and by posolatal physical and 
neuromuscular characteristics (New Ballard score)," Patients were excluded if they 
had major congenital anomalies, severe asphyxia (Apgar score :,:3 after 5 minutes), if 
they needed muscle paralysis for adequate ventilation, if their mother had received 
indomethacin (INN, indometacin), or if she had been given analgesics (other than local 
or epidmal) within 24 homs before delivery, 
The infants were studied during the first 10 days with regular intervals during the time 
morphine was needed, and 12 and 24 hours after discontinuation of the drug, 
According to standard procedures iil the NICU, central venous catheters and umbilical 
or radial at1erial catheters were inserted, and parenteral nuo'ition was stat1ed within 24 
hours ofbuih, 
After a loading dose of 1 00 ~g1kg mOll'hine intravenously, patients were ratldomised 
to a group receiving 10 ~g1kglh (group A) or 15 ~g1kglh (group B), As 
phannacokinetics atld drug metabolism Chatlge dming the last tlu'ee months of 
gestation,'6,,, and pain sensitivity may be altered after 32 weeks," the neonates were 
stratified into three gestational age groups: under 28 weeks, 28-31 weeks, and 32-36 
weeks, 
According to tlle study protocol mOll'hine ulfusion, blinded for the dosage given, was 
stopped by tlle attending neonatologists, under the followulg circumstatlCeS: 
1. after successful extubation; 
2, if ventilator settings allowed extubation witlml several hours, 
3, if they judged the patient to be paUl free, 
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According to standard procedures, it morphine had been given for more than 5 days, 
morphine administration was decreased by 50% one day before discontinuation of the 
infilsion, to prevent possible symptoms of opioid withdrawal. 
Blood samples (0.4 nu) were taken from the indwelling arterial catheter at 
predeteonined time points on days 2, 3, 5, 7, 9, and at 12 and 24 hours after ending the 
study medication. Total days on morphine therapy, possible additional morphine, total 
dosage, and total time of morphine administration were noted as well. After collection 
senl1n was separated and frozen at _20°C, until assayed. 
Inotropic drugs were started if the mean artedal blood pressure repeatedly (more than 
2 times) fell under the standard value for gestational age and did not react to volume 
expansion by cristalloid solutions or saline, according to hospital routine. 
Severity of illness was measured by CRIB,32 which includes birthweight, gestation, 
and clinical data up to 12 hours from bilth, and predicts mOltality and morbidity, and 
might predict the long term clinical outcome.'o 
Clinical observations included continuous monitoring of heatt rate, atterial blood 
pressure, and oxygen saturation of each infant. Cranial ultt'asomld was perfonned 
routillely on days 1, 2, 3 and 5, at Ule expected date of delivery, or more often 
whenever required by Ule clinical condition. 
Analytical procedures 
In a polypropylene tube 0.2 ml of serum and 0.4 ml of 0.01 M ammonium hydrogen 
carbonate (PH 9.3) were mixed and centrifuged. The supematant was applied on an 
equilibrated CB Bound-Elute (Merck, Dannstad, Germany) solid phase extraction 
column. After 5 minutes Ule column was washed with 0.01 M anunonium hydrogen 
carbonate, dried under vacuum, washed again with hexane and dded agaill. Morphine 
and its glucuronides were eluted with 0.5 ml of 0.05 M acetic acid in methanol/water 
(9/1 v/v) under vacuum for 20 s. The eluate was evaporated to dryness under nitrogen 
at room temperature. The residue was reconstituted in 150 fll of 0.05% (w/v) 
phosphoric acid. An aliquot of 75 JlI was injected onto a HPLC column (Merck 
Lichrocart 250-4 fitted WiOl a Merck Lichrocart 4-4 precolunm, both Licluospher 60, 
RP select B 5Jlm). These analytical colunills were eluted after 20 min. isocratic and 
Ulen WiOl a linear increasing gradient of 0 to 60% acetonitt;le ill 0.2 M potassiW11 
dihydrogen phosphate buffer (pH 3.0) in B tnin with a flow of 1.2 mVmin. Detection 
was with an extt'emely sensitive spectrofluorilnett'ic detector L-74BO (Hitachi/Merck) 
with an Bft1 flowceU, at excitation 210 nm, and emission 350 nm; response time 4 s. 
The lilnit of detection (signal to noise ratio >3) was for motphine, M3G, and M6G B, 
11, and 19 Jlg/l serum respectively and at 100 flg/l (n=5) the illter-day CV's were 1.1, 
6.3, and 2.5%, and Ule bias -5.23, -1.4, and -0.019% respectively. The extt'acts were 
stable in the autosampler at 4°C during at least 22 hrs. 
Phamlacokilletics 
Pharmacokinetic data and variables were calculated from standard equations using the 
KINFIT program (Mediware, Groningen, The Netherlands). An estimate of the 
individual senl111 clearance was obtained by dividing the morphine infusion rate by the 
apparent steady state selum concentration of mOlphine at day 2.23 
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Pain assessment 
Pain assessment was performed using a validated pain assessment instnlluent for this 
age group, the NIPS.3 The NIPS was done before and after starting morphine, daily at 
predetermined intervals, being at the start and end of the nlll'ses' shifts, and before, 
during and after endotracheal suctioning. A score of 0-2 was considered as good 
analgesia, 3-4 as moderate pain, and 5-7 as severe pain. 
Inadequate analgesia (NIPS >3 at two consecutive assessments or >5 once)34 was 
managed by the attending physician by administering an extra bolus of morphine 
(50~g/kg), or if this failed to improve analgesia, by increasing the morphine infusion 
rate by 5 ~gIkg/h. 
Statistical analysis 
Data were analyzed with SPSS-8 (SPSS Inc, Chicago, Ill). To compare the two groups 
Shldent's I tests were used for nonnally dishibuted data, Wilcoxon Signed Rank tests 
for paired data, and Friedman test or Spearman's rank conelation for nonparametric 
data. P values :0;0.05 (two-tailed) were considered to be significant, except for the pain 
scores where P values :0;0.01 (two-tailed) were considered to be significant. 
Group A (n= 14) Group B (Il- 14 ) 
Birthweight (g)* 1156 ± 387 1350 ± 783 
Gestational age (wks)' 28.25 ± 1.7 29.46 ± 2.2 
Sex 
Male 8 9 
Female 6 5 
Diagnosis al admittance 
RDS 13 13 
PnelUlionia 1 1 
Surfactant 11 11 
Inotropic agents 8 7 
PIVH I·II 6 3 
PIVH lII-IVIPVL 4 2 
Died :0; 28 days 1 3 
Died> 28 days 0 1 
Artificial ventilation (days)' 14.9 ± 13.9 15.4 ± 10.5 
Morphine (days)* 8.5 ± 6.5 8.1 ± 4.9 
CRIB score* 4.7 ± 3.4 5.6 ±3.0 
Table 1 Clinical data of sludy participants. Data given are IItlll/ber of ill/anls. 
or • meall ± SD. Differellces between groujJs Jor all data given are not signijicalll. 
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III.2.4 Results 
Thirty-five infants were eligible for the study, but in five cases parental consent was 
denied, Thirty infants were included in the study; serum samples from one infant were 
lost and one infant was withdrawn from the study after initial parental consent, None 
of the infants died during the study period, Clinical data of the remaining 28 patients 
are shown in table I and revealed no significant differences for all the items evaluated, 
For all infants mean birth weight (± SD) was 1253 ± 614 g, and mean gestational age 
28,85 ± 2,0 weeks, 
Duration of morphine administration varied from 24 hours to 23 days (median 7 days), 
Blood samples were obtained in 27 infants on day 2 (1 missing sample), 22 infants on 
day 3 (2 missing samples, 4 morphine stopped), 19 infants on day 5 (3 missing 
samples, 6 morphine stopped), 17 on day 7 (I missing sample, 10 morphine stopped), 
and 10 infants on day 9 (2 missing samples, 16 stopped), Morphine could be detected 
in 80-100%, and M3G in 89-100% of the infants (Figure I), The percentage ofinfants 
in whom M6G could be detected increased significantly from 41 % on day 2 to 90% on 
day 9 (P <O,OI)(Figure I), 
'/, 
2 3 5 
days 
fJ Morphine 
o M3G 
o M6G 
7 9 
Figure 1 Percelltage of illfallts ill whom morphine Clnd its metabolites could be defected 
durillg Ihe sludy, M3G lIIolphille-3-glucurollide, M6G 1II0'1J!lille-6-glucurollide, 
Mean senllll concentrations of morphine, M3G, mId M6G for the total group are 
shown in figure 2, 
Mean morphine concentrations increased fi'om58,1 ± 37,6 Jlg/I on day 2 to 63,2 ± 29,1 
Jlg/I on day 3 mId decreased thereafter to 44,3 ±16,3 fig/Ion day 9, 
M3G values increased significantly fi'om 75.4 ± 41.0 Ilg/l to 130,8 ± 66,7 Jlg/I on day 
9 (P ~0,016), and M6G concentrations increased from 25,1 ± 10,0 Ilg/l to 43,0 ± 11.7 
Jlg/l, and 38.4 ± 14,0 fig/Ion days 7 and 9, respectively (Figure 3A, B, C), 
Differences between the groups A and B in mean sennll concentrations for morphine, 
M3G, mId M6G were !lot significmlt (Figure 3 A,B,C), 
124 
160 
120 
m 
e 80 
u 
E 
40 
0 
:=: 
2 3 4 5 6 
days 
7 
o Morphine 
o M3G 
II M6G 
8 9 
Figure 2 Mean l1101phille, lI10lphine-3-glucurollide 011lIlJlOlphil1e-6-glucuronide 
COllcentrations 011 consecutive daysjor the total group. 
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Because only 3 infants bom after 32 weeks were included, differences between age 
groups were only determined for the group <28 weeks (lFIO) and the group 28-32 
weeks (n=15). Mean concentrations of M3G were significantly higher in the.older age 
group on days 3 (P<O.05) and 9 (P=O.007), mean M6G concentration was significantly 
higher in the older age group on day 9 (P=O.007). 
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Figure 3. (AJ Meallll/O/phille cOllcelllraliolls, (BJ l/Iea/1I/101phille-3-glucurollide 
concentrations, and (C) mean lJIOlphine-6-glucurollide cOlleentrations in groups A and B. 
Differellces 1101 significalli. 
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Extra morphine was given in 7 infants; one infant (group B) needed only one bolus 
(day 2), in 3 infants (1 in group A on day 6, 2 in group B on days 3 and 7) the infusion 
rate was increased by 5 Ilg/kg/h, and in the remaining 3 infants (2 group A, 1 group B) 
an extra bolus was administered because of reintubation after accidental extubation. 
After discontinuation of the dl1lg, M3G was still fOlllld in 12/14 (85.7%) and 13/17 
(76.5%) infants in concentrations of 41.0 ± 19.3 J.lg/I after 12 homs and 34.0 ± 27.4 
Ilg/I after 24 hours respectively. There was no significant difference between groups A 
and B. In the majority of infants no morphine or M6G could be detected. 
There was no difference between infants in whom the morphine dose was decreased by 
50% before ending and those in whom it was stopped immediately. 
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Morphine concentrations on days 2 and 7 were significantly lower with higher 
gestational age (Spearman's rank correlation pO.55, P<O.OI, and 1=0.64, P<O.OI 
respectively). On all other days there was no relation shown between gestational ages 
and morphine. 
Mean M3 :morphine, and M6:morphine senun concentration ratios increased 
significantly during the first 7 days (P <0.05), the mean M3G:M6G senun 
concentration ratio did not change significantly, although the ratio decreased Ii'om 4.1 
on day 1 to 3.5 on day 9. There was no correlation of birthweight and gestational age 
with either ratios. 
The estimated mean senun clearance on day 2 was 3.64 mllmin/kg for all patients, 
without significant c011'elation with gestational age. Mean senUll clearance was 
significantly higher in group B (3.99 mllmin/kg) than in group A (3.37 ml/minlkg) (P 
=0.023). The use of inotropic agents was equal in both groups, and had no effect on the 
clearance in any dose compared to infants who did not receive inotropic agents. 
Pain scores were significantly higher before than after start of morphine administration 
(P=O.OOI). There was good analgesia before and after endotracheal suctionillg, but 
pain scores were significantly higher during suctioning (indicating moderate pain or 
distress), compared to those before and after suctioning (P<O.Ol). 
Pain scores did not con'elate with morphine, M3G, or M6G concentrations at any time. 
Severity of ilhless, as measured by the CRIB, did not differ between groups. Neither a 
con'elation between CRIB and morphine concentrations was found. 
Incidence ofPIVH grade I1I·IV or PVL was not significantly different between groups 
A and B. 
Heart rate, and mean aIierial hlood pressure were comparable between groups; as over 
50% of the infants had inotropic support, with no difference between groups A and B, 
the effects of morphine on heali rate and blood pressure could not be detennined. 
Decreased gastrointestinal motility was not found in our study. Urinary retention as 
objectified by ultrasolmd was found in 3 infants in group A, aIld in 1 infant in group B 
(ns). 
III,2.5 Discussion 
To our knowledge, this is the first study investigating both the pharmacokinetics and 
phanllacodYllamics of mO'1Jhine and its major metabolites M3G and M6G in pretenll 
infants. We have demonstrated that a dose· dependent effect, for the doses used, was 
absent, and a correlation with gestational age could neither be detenllined. 
In preteI'm newb011l infants morphine lUld M3G can be fmUld in sennll after 
intravenous administration on all days; M6G was not detected on the first days after 
bilih, but its appearance in senUll increased with postnatal age. After discontinuation 
of the infusion, morphine and M6G disappear quickly, but M3G can be found in low 
concentrations after 12 and 24 hours. Although appropriate analgesia, as determined 
by a validated pain assessment inSO'ument was present, no correlation between 
concentrations of eitller morphine or M6G, aIld pain scores was fOlmd. In only 4 
infants possible adverse effects were fOUlld. Severity of illness as determined by the 
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CRIB score, did not influence the analgesic effect of morphine, and the use of 
inotropic drugs did not have an effect on morphine concentrations either. 
The effects of continuous morphine taking into account both mOIphine and its main 
metabolites, their concentrations, and the relation to pain scores during a prolonged 
period, i.e. 7-14 days, in critically ill, ventilated pretenn infants deserve great attention 
in detenllining objective guidelines for Hle use ofmOIphine in Hus age group. 
In the literatme different doses of mOIphine and diamorphine have been reported for 
analgesia in p,retenn infants, with continuous doses ranging fl'om 5 to 100 
flg/kg/h.l2,2],27, 2,43,44 Doses of 10 and 15 flglkg/h are commonly used, which prompted 
us to investigate these dose regimens prior to a double blind placebo controlled 
multicenter trial. Initiallugher doses offer no benefit, as no better analgesia is reported, 
and excessive doses might lead to adverse effects. 
The mean senun concentrations of morphine (58.1 ± 37.6 fig/I) and M6G (25.1 ± 10.0 
fIg/I) we have fOtUld at 24 homs compare to the values reported in the literature; 24-96 
11g/I,2l,24,27,42,43,4l,46 and 19-48 flg/I,2,42,43,4' respectively. Our values of M3G at 24 
hours are higher than those reported after continuous mOlplune (33.3-62 Itg/I),2l,4l but 
drastically lower than those found after administration of diamOIphine.'2,43 
Diamorphine is repOlied to have a more rapid onset of action and potency, probably 
due to its greater water solubility." 
MOlphine concenb'ations between 58.1 and 63.2 fig/I were detel111ined after 24-72 
homs. Higher values of 64-1 18 fig/I were again found after diamolphine 15 Itg/kg/h,43 
and values between 108.4 and 207.1 fig/I, after morphine in doses of 20 to 30 
IIg/kglh,26 which is twice the amount we used. The difference with the latter study 
might also be due to the determination of total morphine, where we measured 
unchanged morphine and its metabolites separately. After several days mOIphine 
concentrations will decrease, as more mOlphine is metabolized to M6G. 
MOlphine is metabolized to M6G and M3G, and to a lesser extent to morplune-3-
sulphate, and mOlphine-6-sulphate, AlUlOugh sulphation is Hle predominant paHlway 
for acetaminophen in neonates and infants,47 sulphation minimally contribntes to the 
metabolism of morphine. 48 
The M3G:M6G concentration ratios show that the contribution of M6G to M3G 
remains Hle same, which is in agreement WiUl the ratio fomld in urine,'9 and 01U' values 
in pretenll infants are comparable WiUl Hlose in full tenllneonates.'o 
BoHl Hle M3G:molphine concentration ratio and the M6G:mo'1lhine ratio sigluficantly 
increase with the increasing glucmonidation capacity of tlre neonate in tlle first few 
days of life, M6G:morphine concentration ratios are consistent with repolied ratios in 
newborns at 0.8,42 and in infants at 1.9-2,1." 
Data from a recent review support the presence of a single glucuronidation enzyme 
after tlle neonatal period,s2 but with different isoenzymes for tlle 3- and 6-positions.5J 
Assuming that this applies to neonates as well, tlus might explain why M3G 
glucuronidation develops velY rapidly, i,e. within hours, and M6G gluClll'onidation 
increases in a few days, whereas tlle M3G:M6G concentration ratio remains constant. 
Contraty to Hartley et al,45 who repOlied increased conversion to M3G and M6G with 
increasing bit1hweight, we did not fmd a con'elation with birthweight or gestational 
age, 
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Contraty to adults and children, in both of whom concentrations in blood exceed those 
of unmetabolized morphine,30,49 M6G, the most powerful metabolite is reported to be 
scarcely or not present at all in the ftrst few days of Iife.22•30,52 However, several other 
studies 23,45,50 have shown a rapidly increasing ability to glucuronidate morphine, 
apparently independent from gestational age, fttting with our results, During our long-
term observations we fmUld a correlation between concentrations atld postnatal age. 
M6G concentrations did not exceed those of utlllletabolized tIlOlphine, but equalled 
values on days 7 and 9, and it might be that after a longer period of tIlorphine 
administration, or at an older age, M6G concentrations exceed tllOse of morphine. 
The high values of M3G from tile rust day onwat'ds, might relieve tile feat· for 
respiratory depression, as this metabolite has a strong respiratory stimulating effect. 54 
Moreover, it was observed that respiratory derression occurs only in the ftrst few 
homs after the start of morphine administration, and has the same risk for neonates as 
for infants and children.5\ A retrospective study of the use of opioids revealed that 
apnoea and respiratory depression occun'ed in 13% of all cases, but none were 
attributable to morphine,56 although conb'oversy still exists.43,,, When mOlphine is 
used in ventilated infants, tllere is no reason to be afraid of respiratory depression, as 
ventilatory support can be increased temporarily, and several studies have failed to 
show respiratory depression'>',46,,, 
Afraid of respiratory depression or apnoea, many clinics are accustomed to stop 
morphine before extubation, but as can be extracted from am data, mOlphine and M6G 
disappear rapidly, whereas M3G is still detectable in most serum samples, 
As morphine seHUlI concentrations approach steady state values after 24 homs,·5 we 
used our values at day two to detennine the apparent steady state clearance. Clearance 
in am groups is better than the estimated values of 2,2 ± 0.7 mllmin/kg,1 but are in 
agreement with values of 2,16-4.6 mllmin/kg reported by several others, althou,llh 
these studies included teI1II infants or preterm infants between 32-36 weeks.",23" ,42 
Surprisingly, clearatICe was higher in group B infatlts. 
AlUlOugh matty children received inotropic dIllgs, we fOlUld no effect on clearatlce. 
Our values were higher than those of Dagan, who reported lower values due to 
inotropic drugS.31 However the groups are not comparable due to differences in 
gestational and postuatal age, underlying disease, and the reasons for admission, i.e. 
d· d' d d' 31 car lac Isease an post car lOsurgery, 
As M6G is found in relatively small amounts or not found at all during the ftrst few 
days of life, this may accolUlI for a higher need of morphine for analgesia in early 
age." Another explanation may be a diminished sensitivity of tile ~I receptors, which 
are responsible for the analgesic effect of morphine in the neonatal period. A 
difference in levels of the fI opiate receptor expression as a result of variation at the 
fIOR gene locus in individuals, as recently proposed, might be another interesting 
possibility that needs further research. 59 
Recently steady state concentrations of 74.2-207.1 fig/I were shown to diminish pain 
as measured by facial expression, but no relation with morphine concenb'ation was 
found. 26 We fOlUld good analgesia after mOI]lhine in pretenn neonates jUdging from 
the NIPS, but without a correlation between analgesia and total morphine senun 
Morpbine and Its Metabolites in Pretcrm Infants 129 
concentration either. 41 In the present study we found good analgesia after the start of 
mOlphine administration, but again were not able to detennine a con'elation with 
morphine serum concentrations or with M6G serum concentrations. 
As the pain assessment by means of the NIPS resulted in comparable values, we 
assume that during artificial ventilation for 1-9 days overall analgesia as assessed by 
the NIPS was adequate, with the exception of the moment of endotracheal suction, 
which is considered a strong pain and/or stress stimulus. Therefore, the reconullended 
doses of 2 llg/kg/h, as calculated in a recent review,2 are in our opinion to low to give 
adequate analgesia in the clinical setting. 
Due to the absence of differences between the two dose regimens, there is no need to 
use the higher dose initially. Higher doses leading to higher serum concentmtions are 
reported to cause adverse effects such as bradycal'dia, arterial carbon dioxide retention, 
and urinary retention." ContralY to that study, we found few adverse effects, which 
might be attributable to the fact that our senUll concentrations are well under the value 
of300 llg/l associated with adverse effects." 
Different doses of morphine for analgesia in pretenn infants have been studied, with 
loading doses between 50 and 200 Ilg/kg, followed by 5 to 50 llg/kg/h 
continuously.",26,44 However, dose regimens higher than 12.5 llg/kg/h" offer no 
clinical advantage. 
Recently, fentanyl was Rroposed to be superior to mOlphine during the first 2 days of 
life in newbol'll infants. 9 However, long term use was not evaluated and is associated 
with tachyphylaxis, raf.id tolerance, chest rigidity, and greater likelillOod of having an 
abstinence syndrome, I ,60,61 
As sicker infants, especially those with sepsis or meningitis, might react differently to 
pain stimuli due to hyperalgesia and allodYllia, we evaluated the cOlTelation between 
morphine concentration and severity of ilhless. 
Severity of ilhless as measured by the CRIB score was not related to the allalgesic 
effect of morphine as measured by the NIPS. Kalm et al62 found Ulat narcotics were 
used most frequently for the sickest patients, as measured by the score for neonatal 
acute physiology. This might be true for our NICU population as well, but in the 
present groups all infants were administered morphine, so no comparison could be 
made. 
From our findings we conclude Ulat an initial dose of 10 llg/kg/h is appropriate. If 
tolerallCe develops as shown by validated pain assessment instnllllents, Ule morphine 
infusion should be increased by 5 llg/kg/h, preceded by 50% of the loading dose. 
III.2.6 Acknowledgements 
We gratefully acknowledge U,e contribution by the nurses from intensive care to the 
collection of data, Willem Grol for his statistical advice, Ko Hagoort for his help in 
preparing Ule mallUscript alld Add Vall Zoeren for skilful drawing of U,e figures. 
130 Chaptcrill.2 
llI.2.7 References 
L Kart T, Cluisbup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children 
based on a literature review: Part l~Pharmacokinetics. Paediatr Anaeslh 1997;7:5·11. 
2, Kart T, Christrup LL, Rasmussen M, Recommended use of morphine in neonates, infants and children 
based on a literature review: Pm1 2~lin.ica1 use. Paediatr Anaesth 1997;7:93-101. 
3, Ambalavanan N, Carlo \VA. (Editorial), Analgesia for ventilated neonates: Where do we stand? J Pcdiatr 
1999:135:403-5. 
4. Hllijer Abu-Si\ad H, Bours GJJW, Stevens B, Hamers JPH. Assessment of pain in the neonate. Scm 
Perif41t 1998;22:402-16. 
5. Kennedy KA, Tyson Jll. Narcotic analgesia for ventilated newborns: Are placebo-controlled trials 
necessmyl JPedialr 1999;134:127-9. 
6, Barker DP, Rutter N. Exposure to invasive procedures in neollatal intensive care unit admissions. Arch 
Dis Child 1995:72:F47-8. 
7. Fitzgemld M, Shaw A, MacIntosh N. Postnatal development of the cutaneous flexor reflex: comparative 
study ofpretenn infants and ne\'i'born rat pups. Dev Med Child Neurol 1988;30:520·6. 
8. Fitzgerald M, Millard C, MacIntosh N. Hyperalgesia in prematme infants. [Letter] Lancet 1988;i:292. 
9. Fitzgerald M, Developmental biology of inflanunatol)' pain, Brit J Anaesth 1995;75:177·85. 
10, Fitzgemld M. Development of pain pathways and mechanisms. In: Anand KlS, McGrath Pl (cds). Pain 
in neonates. Amsterdam: Elsevier, 1993. 
11. Ma Q.-P, Allchorne Al, Woolf CJ. Morphine, the NMDA receptor antagonist lv1K 801 and the 
tachykinin NKI receptor antagonist RP 67580 attcnuate the developmcnt of innammation- induced 
progressive tactile hypersensitivity, Pain 1998;77:49-57, 
12, Anmld KJS, McIntosh N, Lagerkranlz H, Pelausa E, Young TE, Vasa R. Analgesia mId sedation in 
prelerm neonates who require ventilator), support. Arch Pediatr Adolesc Med 1999;153:331-8. 
13. Goldstein RF, Bmzy JE. Narcotic sedation stabilizes arterial blood pressure fluctuations in sick 
premature infants. J Perinato11991;XI:365-71. 
14. Taddio A, Katz J, I1ersich AL, Koren G. Effect of neonatal circumcision on pain response during 
subsequent routine vaccination, Lancet 1997;349:599~03. 
15. Johnston CC, Stevens BJ, Experience in a neonatal intensive care wtil affects pain response. Pediatrics 
1996:98:925-30. 
Morphine and its Metabolites in Preternt Infants 131 
16. Quinn MW, Otoo F, Rushforth JA, Dean HG, Puntis JWL, Wild J, Levcne MI.Effect of morphine and 
pancuroniull1 on the stress response in ventilated preterm infants. E..'lfly Hum Dev 1992;30:241-8. 
17. Quinn MW, Wild J, Dean HG, Hartley R, Rushforth JA, PuIHis JWL, Levene MI.Randomised double-
blind controlled trial of effect of morphine on catecholamine concentrations in ventilated pre-term 
babies. Lancet 1993;342:324-7. 
18. Dyke MP, Kohan R, Evans S. Morphine increases synchronous ventilation in pretenn infants. J Paediatr 
Child Healtll 1995;31: 176-9. 
19. Saarennma E, Huttuncn P, LepplHuolo J, Mereloja 0, Fellman V. Advantages offenlanyl over morphine 
in analgesia for vcntilated newborn infants after birth. J Pediatr 1999;134:144-50. 
20. Bhat R, Chari G, Gu1ati A, Aldana 0, Velamati R, Bhargava H. Pharmacokinetics of a single dose of 
morphine in prctenn infants during the first week oftife, J Pediatr 1990;117:477-81. 
21. Bhat R, Abu-Harb, Chari G, Gulati A. Morphine metabolism in acutely ill preterlll newborn infants. 
Pediatr 1992;120:795-9. 
22. Chay pew, Duffy BJ, Walker JS. Phannacokinelic-pharmacodynamic relationships of morphine in 
neonates. Clin Pharmacol TIler 1992;51 :334-42. 
23, Hartley R, Grecn M, Quinn M, Levenc MI. Phannacokinelics of morphine infusion in premature 
neonates. Arch Dis Child 1993;69:55-8. 
24. Farrington EA, McGuinncss GA, Johnson GF, Erenberg A, Leff RD. Continuous intm\'Cnous morphine 
infusion in postoperative newborn infants. Am J PerinatI993;10:84-7. 
25. Mikkelsen S, Feilberg VL, Christensen ca, Lundstrom KE. Morphine phannRcokinetics in premature 
and mature newbom infants. Acta Paediatr 1994;83: 1025-8. 
26. Scott CS, Riggs W, Ling EW, Fitzgerald CE, Hill ML, Gronau RVE, etal? Solimano Aj Craig KD. 
Morphine pharmacokinetics and pain assessment in premature newborns. J Pcdiatr 1999; 135;423-9. 
27, Barrett DA, Elias-Jones AC, Rutter N, Shaw PN, Davis SS, Morphine kinetics after diamorphine 
infusion in prelllature neonates. Brit J Clin Phannac 1991;32:31-7. 
28. Olkkola KT, Maunuksela EL, Korpela R, Rosenberg PH. Kinetics and dynamics of postoperative 
intravenous morphine in children. Clin Phamlacoi Thee 1988;44: 128-36. 
29. Osborne R, Thompson P, Joel S, 'frew D, Patel N, Slevin M. 111e analgesic acth<ity of morphine-6-
glucuronide. Br J Clin Phanllac 1992;34: 130-8. 
132 Chapter m.2 
30. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of 
morphine administration: Demonstration of tile importance of the active metabolite lllorphinc-6-
glucuronide. elin PIlm-macoi TIler 1990;47: 12-9. 
31, Dagan 0, Klein J, Bohn D, Barker G, Koren G. MOiphine phannacokinetics inchildren following cardiac 
surgery: Effects of disease and inotropic support. J Cardiolhor Vase Anesth 1993;7:396-8. 
32. The International Neonatal Network. TIle CRIB (clinical risk index for babies) score: a tool for assessing 
initial neonatal risk and comparing performance ofneonalal intensive care units. Lancet 1993;342: 193-8. 
33, Lawrence J, Alcock D, McGrath P, Kay J, MacMurray SB, Dulberg C. TIle development of a tool to 
assess neonatal pain. Neonatal Network 1993;12:59-66. 
34. Guinsburg R, Cassia Berenguel R, de Cassia Xavier R, Branco de Almeida MF, Kopelman BL rue 
behavioural se.'l.les suitable for pretenn and term neonatal pain assessment? In: Jensen TS, Turner JA, 
Wiesenfeld-Hallin Z (cds). Proceedings of the 8U\ world congress on pain. Seattle: IASP Press, 1997. 
35. Ballard JL, Khoury Je, Wcdig K, Wang L, Eilers-Walsma.ll BL, Lipp R. New Ballard score, expanded to 
include extremely premature infants. J Pediatr 1991;119:417-23. 
36. Morselli PL, Franco-MorseHi R, Bossi L. Clinical pharmacokinetics ill newborns and infants. Age 
related differences and therapeutic implications. Clin Phannacokinet 1980;5:485-527. 
37, Van den Anker IN, Schoemaker Re, Hop WeJ, van der Heijden AJ, Weber A, Sauer PJJ, ct al. 
Ceftazidimc pharmacokinetics in preterm infants: effect of renal function and gestational age. Clin 
Pharmacol TIler 1995;58:650-9, 
38, McIntosh N. Pain in the newborn, a possible new starting point, Eur J Pediatr 1997; 156: 173-177. 
39. De Courey-Wheeler RHB, Wolfe CDA, Fitzgerald A, Spencer M, Goodman IDS, Gamsu HR. Use of Ute 
CRIB (clinical risk index for babies) score in Ule prediction of neolk1tal mortality and morbidity. Arch 
Dis Child Neon Fet Ed 1995;73:F 32-<5, 
40. Rautonen J, Mitkelfi A, Boyd H, Apajasalo M, Pohjavuori M. CRIB and SNAP: assessing the risk of 
deaUl for pretenn neonates. Lancet 1994;343:1272~3. 
41. Scottish Neonatal Consultmlts Collaborative Study Group and Ule International Neonatal Network. 
CRIB(clinical risk index for babies) mortality, and impainnent after neonatal intensive care. Lancet 
1995;345:1020·22. 
42, Barrett DA, Barker DP, Rutter N, Pawula M, Shaw PN. Morphine, morphine-6-glucuronide and 
morphinc-3-glucuronide pharmacokinetics in ncwbom infants receiving dimnorphine infusions. Br J 
Clin PhanllacoI1996i41:531-7. 
Morphine and its Metabolites in Preterm IMa'nb 133 
43, Barker DP, Simpson J, Pawula M, Burrett DA, Shaw PN, Ruiter N, Rrutdomized, double blind trial of 
two loading dose regimens of diamorphine in ventilated newborn infants, Arch Dis Child 1995;73:F22-
6, 
44, Rutter N, Richardson I A survey of the use of analgesia in ncwbom intensive care, Jnt J Pharm Pmct 
1992;1:220-2, 
45, Hartley R. Quillli M, Green M, Levene I. Morphine glucuronidalion in premature neonates, Br J Clin 
Phannac 1993;35:314-7 , 
46, L)'1Ul AM, Slattery JT, Morphine phann3cokinetics in early infancy, AnesUlesiol 1987;66: 136-9, 
47, Van Lingen RA, Grcijdanus B, Okken A, Uges DRA, Rapid morphine assesssment by FPIA in pretenn 
infants in relation to pain assessment by the ne<matal infant pain score, [Abstract] Pediatr Res 
1997;42:405, 
48, Choonara I, Ekbom Y, LindstrMl B, Rane A. Morphine sulpitation in children, Br J Clin Phanll 
1990;30:897-900, 
49, Choonara lA, McKay P, Hain R. Rane A. Morphine metabolism in children Br J Clin Pharm 
1989;28:599-604, 
50, Choonara I, LawrenceA, Michalkiewicz A, Bowhay A, Racliffe 1. Morphine metabolism in neonates and 
infants, Brit J ClinPhann 1992;34:434-7. 
51. Lynn A, Nespeca MK, Bratton SL, Strauss SG, Shell DD, Clearance of morphine in postoperative 
infants during intravenous infusion: TIle influence of age and surgery, Anesth Analg 1998;86:958~3, 
52, Faura ce, Collins SL, Moore RA, McQuay HI. Systematic review of factors affecting the mtios of 
morphine and its major metabolites. Pain 1998;74:43-53. 
53, Hartley R. Levene MI. Opioid phannacology in Ule newborn, Balliere CHIl Paediatr 1995;3:467-93. 
54, Gong QL, Hedner T, Hedner J, Bj6rkman R. Nordberg G, AntinociceptiYe and ventilatory' effects of the 
morphine metabolites: morphjne~·glucuronide and morphine-3-glucuronide. Enr J Phanu 1991;193:47-
56, 
55, Lynn AM, Nespeca MK, Opheim KE, Slattery IT. Respiratory effects of intmvenous morphine 
infusions in neonates, infants and children after cardiac surgery. Anesth Analg.I 993;77:695-70 1, 
56, Purcell-Jones G, Donnan F, Swnner E. TIle use of opioids in neonates, A retrospective study of 933 
cases, Anaesthesia 1987;42: 1316-20. 
57, Hasselstrom I, Berg U, L6fgren A, Sawe J, umg lasting respiratory depression induced by Hlorphine-6-
glucuronide? Br J Cliu Pharmac 1989;27:515-8. 
134 Chapte .. 1II.2 
58. Koren G, Butt W. Chinyanga H, Soldin S, Tan Y, Pape K. Postoperative morphine infusion in newborn 
infants: assessment of disposition characteristics and safety. J Pedialr 1985; 107:963-7. 
59. Dill GR, SOfa I, Wang Z. The J1 opiate receptor as a candidate gene for pain: Polymorphisms, varialions 
in expression, nociception, and opiate responses. Proc NaIl Acad Sci USA 1999;96:7752-5. 
60, Katz R, Kelly HW. Pharmacokinetics of continuous infusions of fentanyl in critically ill children. erit 
Care Med 1993;21 :995-1000. 
61. Shapiro C, Pain in the neonate: Assessment and intervention. Neon Netw 1989;8: 17-21. 
62. Kalm DJ, Richardson DK, Gray JE, Bednarek F, Rubin LP, 8h,111 B, Frantz ill, Pursley DM. Variation 
among neonatal intensive care units in lmrcotic administmtion. Arch Pediatr Adolesc Med 
1998;152:844-51. 
IV 
General Discussion and Future Developments: 
To a Tailored Pain Management 
De pijnboom groeil 
hij heefi geen pijn 
ofsoms 
dal moel van hel ontharsen zijn. 
General Discussion and Future Developments: To a Tailored Pain Management 
IV.1 General Discussion and Future Developments: To a Tailored Pain 
Management. 
137 
Appropriate phannacological and non-phannacological management of pain has been 
the subject of study throughout the ages. Following beliefs that certain types of pain 
could not be cured as they were a punislunent of the Gods, a change took place in the 
16th and 17th century. From that point on pain was seen as a result of both wOlU1ding 
(tissue damage) aneVor as a signal of disease of certain organs, alUlOugh the cause and 
mechanism was not always clear. I 
Today in many circumstances the causes and mechanisms of pain are known, and 
consequently the choice of appropriate analgesia. However, in celiain patient groups 
such as pretenn infants, children less than 3 years of age, and severely mentally 
handicapped children in which selfreport is unreliable or not possible at all, there are 
still problems to be solved and myths to be unraveled. The age groups presented in this 
thesis represent one of the most difficult fields of pain assessment and management in 
the critically ill newbol1l infant. 
Until about 20 years ago pain in neonates was believed to be non-existent, as pain 
pathways were not yet functional.'·3 Following studies on the development of the pain 
pathways, indicating that neonates were velY much capable of feeling pain, even when 
born prematurely,' new problellls became cleaL Nothing was known about both pain 
assessment and pain management during the first days and weeks of life. 
As a result many clinicians were reluctant to provide analgesia. As a consequence, 
although they believed and knew that there was pain, clinicians did not even prescribe 
analgesics. This practice still exists in Illany clinics, and until now clinicians in the 
United States perform circumcision on newbom infants without analgesia or with 
insufficient analgesia. 5•6 In contrast, a good and easy method of analgesia, as the dorsal 
penile nerve block is used in Europe for a long time, and has been studied and 
reconunended as early as 1983 in the United States as well.'-9 Whether tlus attitude is 
due to ignorance or love of ease as it takes extra time, is not clear. 
The clinical significance of pain and stress in the pretenn neonate is recently 
summarized by Anand,1O who stated that they have an increased sensitivity to pain, and 
that acute painful stimuli lead to prolonged periods of hyperalgesia. Repetitive painful 
experiences are associated with some of the neurobehavioral and developmental 
sequelae, observed after long tenn stay in neonatal intensive care units of babies."· l2 
Tllis may lead to an altered development of the pain system associated with decreased 
pain tlu'esholds during development in neonatal rat pups. 13 Postoperative mOliality and 
morbidity in infants was decreased when potent anaesthetic agents were used. 14 
At the start of our studies foUl' main problems were not solved. 
1. In the first place a validated and reliable instnunent to assess pain in the 
newboI1l infant was not available. Many tools were developed based on 
instruments in older children and adults and were mostly tested in 
circlUnstances of acute sharp pain, following minor smgery or procedures as ti,e 
heel prick. 15-17 The so-called faces scales used in different settings were 
developed and tested in small studies without llllifornuty. This is demonsh-ated 
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in the different faces scales with for example even differences in the direction 
of the scale from no pain to worse pain in a Finnish scale. 18.20 The significance 
of unidimensional and multidimensional scales for pain assessment is clear as 
far as they can be related to self repOli. hi contrast it is not clear in non-verbal 
subjects if it is related to effect only, and not to concenh·ations of analgesics. 
2. The majority of (~'ugs used in children and infants, is not officially tested and 
approved for tltis age group,2!.22 As drug metabolism (sulphation, 
glucuronidation) is different especially in the first period of life this subject 
needs thorough investigation in the near fulnre. 2J.24 Some slndies on antimycotic 
and antibiotic drugs have already shown the difference in pharmacokinetics and 
metabolism in newbom infants/' ·'6 but for analgesics only velY few studies 
were perfonned.27.]0 Most slndies describe either dose effect or dose 
concentration relationship. Most important however is the fact tllat analgesic 
tlierapeutic ranges become known by correlating concentration to effect as 
measured by validated pain assessment instnunents, and controlling whether 
existing therapeutic ranges in adults apply to children as well. Another 
important source of information comes from self repOli and shldies in 
vohmteers using a pain stimulus as laser stimulation and the nociceptive flexion 
reflex tlueshold RIIl.]!·3J 
3. Following tile results of laboratOlY experiments, involving repeated pain stimuli 
in newborn rats, changes in the brain due to hyperalgesia and plasticity,34)l the 
role of specific receptors and long term effects of pain in the neonatal period 
need to be studied in a clinical setting. 
4. Doctors attitudes need to be changed: possibly due to changing views, studies 
reported in tile literature, and more interest in pain in children, the attitudes are 
changing slowly, but still have not changed enough.36." There was and 
apparently still is a need for practical guidelines that can be used in elittical 
practice. 
Tltis tllesis focusses on the phannacokinetics and phannacodynamics of the two main 
analgesic dmgs used in neonates: morphine and paracetamol, in correlation with 
validated pain assessment instruments, such as a modified facies scale and the 
Neonatal Infant Pain Scale (NIPS). 18.39,40 
The phannacokinetic and pharmacodynamic effects of single doses of the above 
mentioned analgesic dmgs were itlVestigated whenever nothing was yet known in that 
particular age group. Whenever information was available about single doses, the 
phannacokinetic and pharmacodynamic effects of multiple or contitmous dmg 
a(~ninistration itl relation to both gestational age and postnatal age was shldied. 
IV,2 Pain assessment 
The faces scale proved to be a reliable instrument when validity was tested, but did not 
correlate with the concentrations of paracetamol in two studies (chapter II.3 and 
H.4)4!,42 for several reasons. Most of tlle infants scored low on tlle pain score 
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indicating minimal or no pain. It may be that this pain score is not particularly suitable 
to measme pain in pretenn and tenn newbom infants or that it is only suited for the 
assessment of acute severe pain or moderate prolonged pain. Therefore, we were 
unable to pinpoint the therapeutic paracetamol concentration range for these age 
groups. 
Although nurses' perceptions of pain are often based on subjective 'feeling', signs and 
symptoms;'-4' neonatal nurses have shown strong agreement (average 86%) for the 
indicators of neonatal pain.43 
In a study on assessment of acute pain in older children, children's' self-report and 
nlll'se ratings significantly cOITelated, implicating that in case observational coding is 
not possible, nurse ratings of acute pain may closely approximate objective assessment 
of pain and distress behaviours.46 
This observation does not solve the problem of the absent conelation between pain 
scores and senlln analgesic levels. 
However, following vacuum extraction paracetamol did not significantly contribute in 
lowering tlle pain score, but judging from the subjective nurses 'perception score of tlle 
clinical condition, tile clinical condition improved following one dose of paracetamol 
(chapter 11.5). 
According to Pigeon et al,43 there is less discrimination of the behaviours on the basis 
of intensity of pain. The utility of behavioural signs as clying, limb movement, 
agitated state, and tachycardia for the assessment of pain in "chronic" conditions in 
neonates, such as sepsis or necrotizing enterocolitis is questionable, as it is possible 
that such behaviomal indicators Illay habituate to long-term pain.43 
Multidimensional pain scores, which have recently become available, are probably 
more appropriate in this respect. 40,47,48 
Therefore, in two studies on the use of morphine (chapter fIl), a multidimensional 
validated pain score, the NIPS was used.40 
Although appropriate analgesia was found, as shown by a significant decrease of the 
pain score after administration of morphine, a correlation between pain scores and 
morphine sennn concentrations was not fomld. Our findings are in agreement with the 
results from other studies, WiOl morphitie infusions of 20-30 l1g/kg/h.2&.49.50 This might 
be influenced by the cut off point used in the different studies to detennine the 
presence of pain using the NIPS." 
Fut1her development of the NIPS score bra extending the number of items or the use of 
the premature infant pain profile (PIPP) & score or comparing these pain scores with 
the much more detailed, (but not usable for bed-side scoring), Neonatal Facial Coding 
System (NFCS),17 is now mlder study evaluating the use of sucrose following heel 
prick pain, and might be of help in the future. 
IV.3 Pharmacokinetics and pharmacodynamics of paracetamol and mOl'phine. 
Although paracetamol has been used as an analgesic for over 100 years, 52 its use in the 
paediatric ropulation is based on data extrapolated from adults, 53 as occurs 
frequently.2 
The tllCrapeutic range of paracetamol of 10 -20 mg/l that we and others used in om 
studies was almost the same as that used to obtain an antipyretic effect. 54 A review of 
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the literature (chapter Il.!) clearly shows that this recommended therapeutic range is 
not supported by randomized controlled trials providing level I evidence. However, 
recent reports indicate that anal~esic efficacy may be obtained when blood 
concentrations range from 5-25 mg/l!·33.41.42.55.58 
The commonly accepted loading doses of paracetamol of 10 mg/kg for oral 
administration and 15-20 mg/kg for rectally administration are not sufficient in 
alleviating paill and should be increased to 30 and 40 mg/kg for the oral and rectal 
route respectively.55.59 
In neonates the metabolism of paracetamol is slower, but still adequate due to 
increased sulphation, provided that paracetamol is not used for periods exceeding 48 -
72 honrs.30.4!.6o 
In clinical studies using rectal paracetamol no toxic senun levels were reached after 
multiple doses and no accumulation was found. 42•61";3 Until fmiher studies show 
otherwise, the daily dose should not exceed 90 mg/kg, and dose interval in neonates 
should be between 8 and 12 hours. 
Morphine is the most widely used analgesic in neonates,37. ... but consistency in 
prescribing is not yet achieved. Recently a 28.6-fold variation among NICUs in 
narcotic administration was shown.38 Major differences in concentrations ranging from 
10 to 422 [lg/l after doses between 2 and 100 flgfkg/h, are presumed to result in 
adequate allalgesia. Adverse effects after higher doses are commonly reported,27.64 but 
it seems to OCCur after high doses (30-100 [lg/kg/h) and probably result from altered 
phannacokinetics and decreased clearance. If given for a longer period tolerance 
develops and higher doses should be given without an apparent increase in adverse 
effects. As part of the adverse effects occurs after discontinuation of morphine, when 
used for periods of 5 days or more, slow weaning of the patient over a prolonged 
period is required.65,66 
As described in this thesis (chapters Ill.! and III.2) and supPol1ed by other studies an 
initial dose of 10 [lgfkgfh provides adequate analgesia/7.68 however without a 
cOITelation between pain scores and concentration. Tltis correlation is not achieved 
using ltigher doses either.49.69 
Beneficial effects of mOlfchine other tllall analgesia alld stress reduction are increased 
synchronous ventilation, 0 stabilization of a!terial blood pressure,7l and a reduced 
ineidence of intraventricular hemorrhage and periventricular leukomalaeia.72 
Morpltine may also prevent abnormal behavioural and physiological responses to 
subsequent painful events. 
The importance of simultaneous pain assessment and analgesia to evaluate whether 
starting or continuation of analgesia is indicated, is stressed by a recent study in 
newb011l rats, where morphine given in the absence of pain resulted in a decreased 
sensitivity for morphine ill adulthood." Administration of opiates (and barbiturates 
and nih'ic oxide as well) during labour to mothers resulted in a higher prop0l1ion of 
infants that hl11led into opiate addicts as adults, as compared to their unmatched 
siblings.74 In the only study available in which the outcome at 5-6 years of prematurely 
bom cltildren who received morphine as neonates was evaluated, McGrefor et al did 
not find any adverse effects on intelligence, motor function, or behaviour. 7 
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Now that the proper initial morphine dose (10 ~Iglkg/h) is established, it is time for 
double blind placebo controlled randomized trials, in order to evaluate and eventually 
develop new pain assessment instnnnents, together with the prolonged use of 
analgesics. This should lead to correlations between the most commonly used 
analgesics and pain scores. A multi centre study supported by the Dutch Research 
Council (NWO) is now in progress. 
Moreover in the US the so-called NEOPAlN study evaluates the reduction of the 
incidence of poor neurologic outcome after preemptive morphine in pre term neonates, 
after encouraging results in a pilot study." 
The long term effects on infants, especially for neurodevelopmental outcome and pain 
response under standard conditions i.e. vaccination,II,12 evaluating of the reaction to 
pain, are of paramount importance. 
As more and more infol1l1ation is available on the central effects of morphine, but 
recently also of paracetamol,32.76 the relationship between drug concentrations in 
cerebrospinal fluid and neurophysiological parameters as elechical activity and 
changes in blood sh'eam velocity, need to be shldied. 
Phalmacodynamics of analgesics still pose an en0l1110US problem, especially in case of 
(continuing) chronic pain. In the field of phannacokinetics good progress has been 
made, and more studies on a wide range of (hugs are fOlthcoming with rhe growing 
interest both in the Netherlands,77 and intemationally.21 
For paracetamol the bioavailability after rectal and oral administration needs to studied 
in more detail, as it is hampered by elTatic absorption due to the variability of venous 
dainage from the rechnn" and by slow gastric emptying in (critically ill) newbom 
infants?s.78 Studies with for instance propacetamol, an intravenous pro drug of 
paracetamol are walTanted. A randomised t1'ial comparing the pharmacokinetics and 
phannacodynamics of oral versus rectal paracetamol after craniofacial surgely in a 
cohort of 40 children (mean age 8 months) is just finished. 
Much research on the effects of paracetamol is perfol1ned by Andersons7,58.79.8o, and 
we agree that still a lot about paracetamol is not known and needs flllther Shldy.81 First 
of all a study is warranted to determine the objective therapeutic range. 
IV.4 From laboratory to clinical research 
Two recent studies have shed new light on the way morphine works. Matthes et al82 
showing that mice lacking the fl-opioid receptor do not show any of the normal 
responses to morphine, as both the analgesic and additional euphoric effect are 
completely absent. This also indicates that the 0- and K-opioid receptors, are not 
involved in mediating the analgesic effect at the spinal level, as had been assumed 
previously.83 
In this context, Uhl et al84 postulated the existence of polymorphisms of the fl-opioid 
receptor, explaining tile differences between human individuals and mouse strains in 
levels of fl-opioid receptor expression, and consequently the responses to painful 
stimuli, and to opiate drugs. Along the line of progress of the human genome project it 
is possible in the neal' future to "map" each individual, and as a consequence tailoring 
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of analgesia will become a possibility. A new study has started recently combining the 
analgesic effects of morphine and paracetamol to alleviate postoperative pain in 
infants, to evaluate the mOlllhine sparing effect of paracetamol as suggested in adults. 
Although this thesis focussed on phanl1acological ways to manage pain, preventing 
pain and non-phannacological pain management should not be forgotten. 
Reducing stress by lowering noise, light and the huge number of potential painful 
procedures on the NICU, on average 14 daily," and caregiving (by nurses) by means 
of individualized developmental care, may improve medical and neurodevelopmental 
outcome. 86 Non-nutrive sucking and administration of sucrose87.92 are cheap and easy 
applicable methods in case of minor procedural pain, but might also be used as 
adjuvant therapy to well known analgesic agents. 
IV.S Attitude and education 
However, none of the research published in this thesis, in jOlIDlals or in textbooks, has 
any impact as the clinicians are not convinced tilat pain is present or will be expected 
in individual patients. 
Educating the nurses and above all, educating the physicians by theoretical and 
practical insltllctions, providing them with validated tools for pain assessment, and 
guidelines for pain assessment and pain management, is the first condition to achieve 
better analgesia in newborn infants. In my opinion nobody can state that a neonate has 
no pain as long as no pain assessment has been performed. Pain assessment should be 
part of normal routine in the care for newborn infants, much in the same way as 
counting tile heart rate, and measuring blood pressure. 
Together with the proper use of analgesics, and personal "mapping" of drug 
metabolism, tailored pain management will be the fultrre. 
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V.I Summary 
Newboms admitted to the neonatal uitensive care mut aIe subject to a large number of 
pauliul, invasive procedures, Pain can be present both in neonates where problems 
have occulTed dm'ing delivelY resulting Ul hematomas 01' fractmes, and in neonates 
admitted to high care muts or neonatal wards, In tlus thesis entitled "Pain management 
and analgesia in the newborn, an integrated approach" the pharmacokinetics and 
phannacodynanucs of two cOlllmonly used analgetic drugs - paracetamol and 
morphine - is presented, 
To understand how analgetic dnlgs affect the neonate, a thorough understanding of 
pain and development of pain pathways in utero and during the transitional period 
from intrauterine to extrauterule life is needed, This is presented in chapter Ll. 
Fmthennore, the goals of tllis thesis are specified: to investigate the phannacokinetics, 
metabolism, and dose-response relation of single and multiple rectal doses of 
paracetamol and continuous intravenous doses of morphine in pretenn and term 
infants, 
The period before, dmulg and shMly after birth is a period in which lllany changes 
occur in a relatively short period, As a result of pretenn birth, several physiological 
and metabolic processes are not fully equipped to cope Witll extrauterine life, for 
example tile metabolic processes of ti,e liver, Other processes, such as the nonnal 
growth of lungs, are ah'eady extended to the extrauterine period, even after nonnal 
full-term buih, 
Pain is one of the senses and is incorporated in a multidimensional process of 
development, togetller with touch, hearing, smell, taste and sight. As these are ongoulg 
processes and fetal development can be uilluenced by intrauterule and extrauterine 
behavioural reactions as well as by physiological, honnonal and metabolic processes, 
the development of tile senses is described in chapter 1.2, 
In chapter II, the pharmacokinetics and phannacodynamics of paracetamol are 
investigated, 
FU'stly, the literature was reviewed to test the evidence that blood concentrations of 
paracetamol between !O and 20 mg/l represent tllCrapeutic analgesic values, and to 
determine the conelation between dose and/or concentrations and validated pain 
assessment scores (chapter 11.1), This was done by means of a meta-analysis of studies 
from the literature and an inquuy among pharmaceutical compalues, 
Of 78 studies on both antipyretic and analgesic effect, 35 studies described analgesic 
effects, When stratified for age, 9 contauled data on infants, 21 on children aged 1-17 
years, and 7 on adults, The majority of these were dose-effect studies only, while in 10 
studies bOUI concentration and effect were studied, 
The sUlgle doses used UI children (7,5 to 40 mg/kg) by different routes of 
administration, were lugher than those advised on ti,e label ulstmctions, They resulted 
in lUean maximum blood concentrations from 5,5 to 22,5 mg/I, wlule concentrations 
between 5,8 and 55,9 mg/I in adults resulted from single doses of 500-1500 mg. 
Multiple doses were investigated scarcely, 
Pain assessment was performed by several different pain measurement scores, either 
by objective validated pain measurements in preverbal children, or by self-report in 
adults and older children, FUlally, appropdate analgesia was reported for 
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concentrations of 5.9-29.8 mg/J in adults and of 7.5-22.5 mg/l in infants and children, 
which is a wider range than the previous generally accepted range. 
Therapeutic ranges reported in the literature are not based on randomised controlled 
trials. Our analysis showed that it is not the range of 10-20 mg/l that may indicate 
analgesic efficacy as previously repOl1ed, but a wider range from 5-25 mg/l. 
For the puqloses of this thesis, the range of 10-20 mg/l was used. 
To detenlline paracetamol concentrations in our OWIl patient group, a reliable and fast 
method was required. As earlier published methods were too labour-intensive, a 
modified high-performance liquid chromatography (HPLC) method was developed, 
enabling us to determine paracetamol and its metabolites in both senllll and urine. 
With a retention time for the different metabolites valying liOln 1.6-8.0 minutes, and 
calibration CUlves showing good linearity, it proved to be an effective method (chapter 
!l.2). 
In chapter 11.3, the results of a study investigating the effects of rectally administered 
paracetamol in preterm neonates are described. This drug, although in use for over 100 
years, had not been studied in this nuumer in these age grouJlS before. 
Twenty-eight infants, stratified for gestational age of 28-32 weeks (n~21) and 32-36 
weeks (n~7) received a single rectal dose of paracetamol of 20 mg/kg body weight 
(range 16-24 mg, due to available strengths). The mean maximal serum concentrations 
were between 1.5 and 18 mg/l. The mean maximal serum concentration in the 28-32 
weeks group was 12.5 ± 2.9 mg/I and 7.5 ± 4.0 mg/! ill the older age group. When 
doses were> 18 mg/kg, most of the infants in the under 32 weeks age group had 
concentrations in the therapeutic range. 
Metabolism in preterm infants appeared to be adequate, not by glucuronidation but 
mainly by sulphation as was seell from the velY low Glucuronide:Sulphate ratio with 
earlier post conceptional age. During childhood, the significance of the contribution of 
glucuroni<iation to paracetamolmetabolism increases, but it is not till after the age of 
7-10 years, that it exceeds sulphation. 
As excretion is slow, the administration of multiple doses in preterm infants would 
require an intelval of>8 hours to prevent accumulation. 
Extending our research of paracetamol to term infants, we investigated the 
phannacokinetics and pharmacodynamics of rectally administered paracetamol in term 
neonates directly after billh (chapter 1I.4), and the effects of mUltiple dose paracetamol 
after a procedural painful event i.e. a vacuum extraction (chapter II.5) in two 
prospective clinical trials. 
Ten consecutive term neonates suffering from painful conditions, or who were 
undergoing painful procedures, received multiple-dose paracetamol. Serum 
concentrations were determined serially using an HPLC method, and pharmacokinetic 
analysis was perfonned. Pain assessment was pelfonned using a validated faces pain 
score. 
Ten consecutive term neonates received 4 rectal doses of 20 mglkg body weight evelY 
6 homs. Mean peak serum concentrations (SD) during multiple dosing were 10.79 
(6.39) mg/I, 15.34 (5.21) mg/l, and 6.24 (3.64) mg/I for the whole group, boys and 
girls respectively. There was a significant difference between the boys and the girls (P 
~O.OI). No serum concentrations associated with toxicity (> 120 mg/I ) were found. 
The median time to reach peak semm concentration was 1.5 hoUl's after the first dose 
and 15 hours for multiple doses. Mean Tv, (SD) was 2.7 (1.4) hours in8 patients. There 
154 Chaptel'V.l 
was no correlation between dose and serum concentratioll, or between pain score and 
serum concentration. However, a significant inverse relationship between the 
preceding pain score and peak senun concentrations was found. 
In term neonates, multiple rectal doses of paracetamol 20 mg/kg bodyweight resulted 
in widely varying senUll concentrations, but did not result in therapeutic 
concentrations in all infants. As accumulation was not found, a dose of 30 mg/kg 
followed by doses of 20 mg/kg at 6-8 hour intervals of administration are appropriate 
to reach therapeutic concentrations. These new recommendations are in line with those 
recently published in tile literature for older infants and children. 
Pain after a procedural intervention was investigated in 122 infants delivered by 
vacuum extraction. The rationale for this study was the fact that in clinical practice 
paracetamol was often given or often not allowed, both without objective data to 
support the action taken. In a prospective, randomised, double-blind, placebo-
controlled study paracetamol 20 mg/kg or placebo was given rectally to evaluate 
whether pain in infants delivered by vacuum extraction is relieved, and whether it 
improves clinical condition. Infants delivered by vacuum extraction were randomised 
eitller to the study group (n=61) and given a maximum of 4 doses of paracetamol or to 
tile control group (n=61) receiving placebo. Pain assessment was performed by a 
validated pain score, a so-called faces score and by rating the clinical condition. In 
these groups, both scores and clinical symptoms .such as vomiting, clying, and pain on 
handling were compared with symptoms in a reference group (n=66) with 
uncomplicated pregnancy and delivelY in vertex position without vacuum extraction. It 
was found tllat pain scores did not differ between the vacmun extraction groups, while 
tile clinical condition in the study group improved only after the first dose of 
paracetamol. There was a significant difference (P<0.05) in objective clinical 
symptoms in the vacuum extraction groups, compared to the reference group. 
It was concluded that one dose of paracetamol given to neonates delivered by vacuum 
extraction improved their clinical condition significantly, but did not result in a 
significant change in objective pain scores. Subsequent doses of paracetamol did not 
show any effect on the clinical symptoms or appearance of the neonates studied. 
Consequently, tile guidelines for paracetamol administration after vacuum extraction 
were changed to adminiso'ation of one dose of paracetamol to all infants, and that 
depending on the pain score, subsequent doses should be administered. 
In chapter III is described how the pharmacokinetics and pharmacodynamics of 
morphine was investigated in ventilated pretenn infants. 
Firstly, we investigated the effect of a continuous infusion of 10 llg/kg/h in different 
age groups, and tile usefulness of a rapid method to deteonine selUm concentrations to 
adjust the dosage (Chapter III. I). The objectives of the study were to detelmine the 
concentration-effect relationship of continuous morphine in preterm infants in the [ll'st 
days after bilih using a validated pain score - the NIPS - both at rest and during 
endotracheal suctioning, and to investigate whether a rapid method for the 
detelmination of morphine semm concentration, a modified Fluorescence Polarization 
IllnnmlO Assay (FPIA) can be useful when adjusting morphine dose. 
In a prospective clillical trial, ventilated preteon neonates ill Ull'ee different age groups 
«28 weeks, 28-32 weeks, and 32-37 weeks), who were subjected to several pailrful 
procedures such as insertion of intravenous catheters or cannula, endotracheal suction, 
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and elective reintubation, received continuous morphine (10 ~rglkglh), Morphine serum 
concentrations were determined using a rapid FpJA, and pharmacokinetic analysis was 
performed, 
Pain scores before and after morphine, and during endotracheal suctioning, were 
assessed using the NIPS, 
Of 24 infants included in the trial, 4 were <28 weeks, 14 between 28 and 32 weeks and 
6 >32 weeks, Morphine was detected in 75 to 84 % of the samples during the first 10 
days of life, and in some infants also at 12 and 24 hours, Differences between the 
groups in mean morphine concentration were not significant, although a trend was 
observed for lower concentrations with the older age groups in the first 3 days, Mean 
morphine concentrations for all infants increased from 85,1 ± 33.4 ~rgll on day 2 to 
!O3,3 ± 70,8 [rgll on day 5, No relation between morphine concentration and 
gestational age, except on day 2, was found, Mean estimated clearance was 2,3 ± 1. 1 
mllmin/kg for the total group, and increased with gestational age, No differcnces were 
found in clearance between the age groups, 
Pain scores were significantly higher before mor]lhine than after (P<O,OOI) and during 
endotracheal suction than either before or after (P<O,OOI), but were not related to 
mOl]lhine concentrations, 
Morphine concentrations can be determined by this rapid method, but as there was no 
correlation with pain scores, it is not suitable for individual adjustment of dosage, With 
the dose used in this study appropriate analgesia as assessed by a validated pain score 
was achieved during mechanical ventilation, but no relationship between concentration 
and effect was found, 
As studies on the effect of the metabolites of morphine increasingly indicated the 
importance of mOl]lhine-3-giucuronide as a stimulating substance for respiration and 
the importance of the analgesic properties of 1ll0rphine-6-glucuronide, we studied the 
pharmacokinetics and pharmacodynamics of morphine and its metabolites in another 
prospective randomised' controlled trial. The effect of the two most commonly used 
dose regimens were compared in ventilated pre term newborn infants, The aim of this 
study was to investigate pharmacokinetics and pharmacodynamics of morphine and its 
main metabolites mOl]lhine-3-g1ucuronide and m0'1)hine-6-g1ucuronide in the first ten 
days after birth, Furthermore, the effects of the use of inotropic agents, and the severity 
of illness were also studied, 
Ventilated pretenn neonates (n=28) who were subject to several painful procedures, 
received continuous morphine in two different dose regimens of 10 (group A) or 15 
flg/kg/h (group B), Senan concentrations of morphine and its metabolites were 
determined serially with an HPLC method, and pharmacokinetic analysis was also 
perfonned, Pain assessment was performed by a validated pain score, the NIPS, 
MOl]lhine was detected in 80-100%, and mOI]lhine-3-glucuronide in 89-100% of the 
infants, The percentage of infants in whom mOI}lhine-6-glucuronide was detected 
increased significantly from 41% to 90% over the first 9 days after birth, Differences 
between the groups in mean sennn concentrations of morphine and its metabolites 
were not significant. 
Mean morphine concentrations for all infants increased from 58, I ± 37,6 [rgll 011 day 2 
to 63,2 ± 29,1 flgli on day 3 and decreased thereafter to 44,3 ± 16,3 flg/l on day 9, 
Morphine-3-g1uclH'onide values increased significantly £i'om 75.4 ± 41.0 [rgll to 130,8 
± 66,7 ~gli on day 9, and morphine-6-g1ucuronide concentrations increased from 25,1 
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± 10,0 to 38.4 ± 14,0 [rgll on day 9, Morphine concentrations were significantly higher 
with higher gestational age on day 7; while on all other days, there was no relation 
between gestational ages and morphine, or its metabolites, Twelve and 24 hours after 
discontinuation of the w1lg, morphine-3-glucuronide was still detected in J 2 of 14 
infants (85,7%) and 13 of 17 infants (76,5%) in lower concentrations, but in the 
majority of infants, no morphine or 1ll0l1lhine-6-glucuronide was found, Mean 
llletabolite:morphine semm concentration ratios increased significantly during the first 
7 days indicating a maturation of the metabolic pathways of morphine, The mean 
morphine-3-glucuronide:mOlllhine-6-glucuronide ratio did not increase significantly, 
Mean estimated senUll clearance was 3,64 mllmin/kg for all patients, with no 
significant con'elation with gestational age, There was a significantly higher clearance 
in group B than in group A, No influence of either inotropic dmgs or severity of illness 
on clearance or morphine concentrations was foulld, There was a good analgesic effect 
of m0l1lhine as shown by the fact that pain scores were significantly higher before the 
start of morphine administration than after. Appropriate analgesia was observed before 
and after endotracheal suction, but pain scores were significantly higher during 
suctioning (indicating moderate pain or distress), Pain scores did not con'elate with 
morphine, mOIllhine-3-glucuronide, or morphine-6-glucuronide concentrations at any 
time, 
In this study the dose-concentration-effect relationship of m011lhine in this age group 
during a period exceeding 72 hours was investigated for the first time, We concluded 
that in pretenn infants, morphine and morphine-3-g1ucuronide can be found after 
intravenous administl'ation on all days, and that mOIllhine-6-glucllronide can not be 
found in all infants in the fll'st days after birth, but tllis increases with higher postnatal 
age, 
Although there was good analgesia, there is no correlation between concenh'ation and 
pain scores, An initial dose of 10 ~rglkg/h is appropriate, If tolerance develops the 
morphine infusion should be increased by 5 ~rglkglh, preceded by 50% of the loading 
dose, to maintain the analgesic effect. Apart from urinary retention in 3 infants, no 
adverse effects were fOlUId, 
In chapter IV, the results of our studies are discussed in relationship to studies 
perfolmed by others, The results contribute substantially to our understanding of the 
assessment and management of pain in newborn infants, Fuhlre studies are warranted 
to extend our knowledge of pharmacokinetics and pharmacodynamics of analgesic 
dmgs in newborn infants, New studies to validate pain assessment scores are now in 
progress, and may, together with the above-mentioned studies, result into con'Clations 
between the most commonly used analgesics and pain scores, The reduction of the 
incidence of poor nemological outcome after preemptive morphine in pretenn 
neonates, and the follow-up of infants for long-term effects, especially for 
neurodevelopmental outcome and under standard conditions (e,g, vaccination), 
evaluating of the reaction to pain, are of paramount importance, 
The relationship between dmg concellh'ations in cerebrospinal fluid and 
neurophysiological parameters, mechanisms of morphine (opioid) receptors and the 
existence of polymorphisms of the ~r-opioid receptor are interesting in regar'd to our 
hope of personal "mapping" and, as a consequence, tailoring of analgesia, 
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V.2 Samenvatting 
Pasgeborenen die opgenomen zijll op de neonatale intensive care afdeling ondergaan 
een groot aantal pijnlijke invasieve halldelingen en ingrepen. Pijn kan ook aanwezig 
zijn bij pasgeborenen, geboren na een moeizame gecompliceerde bevalling zoals 
bijvoorbeeld na een schollderdystocie, een vacuiimextractie of een tangverlossing. 
Tenslotte kan pijn ook optreden bij pasgeborcnen die opgenomen worden op de 
gewone zuigelingen afdeling, omdat de pasgeborenen ook daar, zij het in mindere mate 
pijnlijke handelingen, zoals een hielprik of infllus inbrengen, ondergaan. 
In dit proefschrift, over pijnbeoordeling en behandeling bij de pasgeborene, wordt een 
gelntegreerde aanpak gepresenteerd van de manier waarop de twee meest gebmikte 
pijnstillende medicijnen paracetamol en morfme werken. Hierbij wordt onderzoek 
beschreven omtrent de wijze waarop deze medicijnen worden opgenomen, omgezet in 
een werkzame vonn en vervolgens worden lIitgescheiden. Daamaast wordt het effect 
op pijn bestudeerd. 
Om te begrijpen hoe pijnstillers werken bij de pasgeborene is een globaal begrip van 
hoe pijn gevoeld wordt en de wijze waarop de pijnontwikkeling bij de ongeborene en 
gedurende de overgangsfase van intra-uterien naar extra-uteri en leven vedoopt, nodig 
(hoofdstuk L I). 
In de inleiding worden de doelstellingen van dit proefschrift geformuleerd. Deze zijn 
het bestuderen van de farmacokinetiek, het metabolisme en de dosis-effect reIatie van 
enkelvoudige en meervoudige rectale doseringen van paracetamol en continue 
intraveneuze doseringen van morfine in zowel te vroeg geboren als op tijd geboren 
zuigelingen. 
De peri ode voor, tijdens en kort na de geboorte is een peri ode waarin veel 
veranderingen optreden in een relatief kort tijdsbestek Ten gevolge van de te vroege 
geboorte is een aantal ontwikkelingen van organen nag niet voltooid. Deze organen 
zijn niet in staat te functioneren, zoals bij op tijd geboren baby's, de rijping van de 
lever is bijvoorbeeld nog niet voltooid. 
Andere processen, zoals de nonnale uitgroei van de longen, worden zelfs na een 
nonnale II terme geboorte gedurende de eerste levensjaren voItooid. 
Pijl! is een van de zintnigen en maakt deel nit van een multidimensioneel proces van 
ontwikkeling, samen met gevoe!, gehoer, smaak, tastzin en gezichtsvennogen. De 
ontwikkeling van de zintuigen wordt beschreven in hoofdstuk 1.2. De ontwikkeling 
van de ongeborene is tijdens het leven in de baarmoeder een continue proces en kan 
belnvloed worden door gedragsmatige reacties en fysiologische, honnonale en 
metabole processen. 
In hoofdst1lk II wordt een aantal onderzoeken naar de fannacokinetiek en -dynamiek 
van paracetamol besprDken. Er werd een litteratunronderzoek verricht om aan te tonen 
dat serumconcentraties van paracetamol t11ssen 10 en 20 mgll, de werkzame spiegel 
van paracetamol representeren en om de correlatie t11ssen de dosis en/of 
serumconcentraties en gevalideerde pijnscores te bepalen (hoofdstuk ILl). 
Deze studie be staat uit twee delen, een meta-analyse van in de Iitteratunr verschenen 
studies over paracetamol en een euquete gehollden onder de fannaceutische firma's die 
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pameetamo!, of een combinatie van paracetamol met andere medicijncn, vervaardigen 
en/of distribueren. 
Van 78 studies waarin het koortsverlagende (antipyretische) en/of het pijnstillende 
(analgetische effect) werd vermeld, werel in 35 gevallen gekeken naar het effect op 
pijn. Na indeling in leeftijdscategorieen, bleken 9 ollderzoeken gegevens te bevatten 
ovcr zuigelingen, 2! over kinderen tussen ! en 17 jaar ell 7 onderzoeken bevatten 
gegevens over volwassenell. Meestal waren dit dosis-effect studies, ill 10 gevallen 
werdell zowel de concentratie als het effect bestudeerd in relatie tot de dosis. De 
hoogte van de eemnatige dosering die gebl1likt werd bij kinderell varieerde van 7,5 tot 
40 mg/kg, waarbij paracetamol rectaal, oraal of intraveneus werd gegeven. Deze 
dosering was hoger dan de dosis geadviseerd in de bijsiuiters. De doseringen gaven 
gemiddeide maximale serumcollcentraties van 5,5 tot 22,5 ll1g/1, telwijl bij 
volwassenen, na een eelll11alige dosering tussen 500 en 1500 mg, serulllconcentraties 
tussen 5,8 en 55,9 mg/l werden gevonden. Het bepalen van de aanwezigheid van pijn 
of wei het scoren van pijn werd gedaan met behulp van diverse pijnllleetinstl1l111enten. 
Bij kinderen die nog niet goed konden aangeven waar zij precies pijn hadden (onder 3 
jaar) werd geb1uik gell1aakt van objectieve gevalideerde pijnll1etingen, te"vijl bij 
oudere kinderen en vo!wassenen meestal zelf-rapportage werd gebl1likt. In die 
gevallen waarbij naal' de senullconcentratie en het effect werd gekeken, bleek 
afdoende pijnbestrijding te bestaan bij concentraties van 7,5 tot 22,5 mg/l bij 
zuigelingen en kinderen en bij concentraties van 5,9 tot 29,8 mg/l bij volwassenell. In 
beide gevallen was de therapeutische breedte groter dan de tot nog toe geaccepteerde 
breedte, die zoals eerder vermeld tussen 10 en 20 lng/I gelegen is. Therapeutische 
spiegels die in de literatuur worden vermeld, zijn niet gebaseerd op gerandomiseerde 
gecontroleerde ouderzoeken. 
Uit de meta-analyse blijkt, dat niet de voorheen geaccepteerde therapeutische breedtes 
tussen 10 en 20 lng/I, maar een paraeetamolseramspiegel tussen 5 ell 25 mg/l de 
werkzame pijnstillende spiegel aangeeft. 
Voor de studies in dit proefschrift (die zijn verricht voordat de meta-analyse was 
verricht) werd de therapeutische spiegel van 10 tot 20 Ing/! aangehouden. 
Om de paracetamolspiegeis in ouze eigen patientengroep te kUllllen bepalen, was een 
betrouwbare en snelle methode no dig. Aangezien de tot nog toe gepubliceerde 
methoden te arbeidsintensief waren, werd een gelllodificecrde High-Performance 
Liquid Chromatografie (HPLC) methode ontwikkeld. Op deze wijze konden 
paracetamol en de metabolieten in zowel senun als urine bepaald worden. Deze 
methode bleek goed te zijn, getuige de retentietijd van de verschillende metabolieten 
die 1,6 tot 8,0 minuten bedroeg en de verkregen kalibratiecurven, waarin een goede 
lineairiteit wenl gevonden (hoofdstuk !l.2). 
In hoofdstuk 11.3 worden de resuitaten beschreven van het onderzoek Haar de effeeten 
van een paraeetamolzetpil bij te vroeg geboren kinderen. Alhoewel paraeetamol at 
meer dan 100 jaar gebruikt wordt, werd nog nooit op deze wijze en in deze 
leeftijdsgroep onderzoek verricht. 
Achtentwintig kinderen werden, naar de zwangersehapsduur, ingedeeld in twee 
groepen; een groep van 28-32 weken (N=21) en een groep van 32 tot en met 36 weken 
(N=7). Zij kregell een eenmalige rectale dosis paracetamol van ongeveer 20 mg/kg 
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lichaamsgewicht met een spreiding van 16-24 mg/kg ten gevolge van de beschikbare 
sterktes van de zetpi!. Een dosering van meer dan 18 mg/kg gaf bij het merendeel van 
de kinderen in de jongste leeftijdsgroep maximale serumconcentraties die 
"therapeutisch" waren, 
De verwerking, omzetting en uitscheiding van paracetamol in deze groep te vroeg 
gebmen kinderen bleek adequaat te zijn. Dit gebeurde voornamelijk door slilfatering 
en niet zoals bij volwassenen het geval is door gllleul'Onidering, gehlige de lagere 
G(lucuronide):S(ulfaat) ratio bij kOltere zwangersehapsdulil'. Tijdens het verdere leven 
neemt het aandeel van de gilicuronidering toe, maar pas na de leeftijd van 7-10 jaar is 
het aandeel VillI de glucuronidering in de omzetting van paracetamol hoger dan dat VillI 
de sulfatering. 
Omdat blijkt dat de uitscheiding van paraeetamol in de urine laag is, moet men bij 
evenhlele toediening van meerdere doses paraeetamol bij te vroeg geboren baby's een 
doseringsinterval van meer dan 8 lIur aanhouden om eventuele ophoping in het bloed 
te voorkomen. 
Uitbreiding VillI ons onderzoek van paracetamol naar kinderen die op tijd geborell 
werden, leidde tot onderzoek naar de fill111acokinetiek en farmacodynamiek van 
meervolldige rectale toedielling aan kinderen in deze groep direct na de geboOlte 
(hoofdshlk I1A). Tevens werd het effect onderzocht van een meervoudige dosis 
paracetamol na een invasieve han de ling tijdens de geboorte, namelijk de 
vacuumextraetie (hoofdshlk 1I.5). Beide shldies waren prospeetieve' klinische 
onderzoeken. Tien op tijd geboren baby's die opeenvolgend werden opgenomen op de 
afdeling en die pijn hadden of die pijnlijke handelingen of illgrepen ondergillgen, 
kregen 4 x daags eell dosering paracetamol. De sennllconcenh'aties werden in serie 
bepaald door middel vall eerder genoemde HPLC methode ell fannacokinetische 
analyses werden uitgevoerd. 
De pijnllleting werd verricht door middel van een gevalideerde pijnscore, een 
zogellaamde geziehtiesschaal, met gezichtjes die geell pijn uitdl1lkken varierend tot 
gezichtjes die el'ge pijll uitdlUkkell. De tien pasgeborenell kregen 4 zetpillen van 20 
mg/kg lichaamsgewicht, elke 6 UUI'. De gemiddelde maximale serumcollcenh'aties 
(stalldaarddeviatie) tijdens meervoudige toediening waren 10,79 (6,39) mg/I, 15,34 
(5,21) mg/I en 6,24 (3,64) mg/l respectievelijk voor de he Ie groep, voor jongells ell 
voor meisjes. Er was eell significant verschil hlssen de jOllgells en meisjes (P=O,Ol). 
Wij hebbell geen senllllcollcentraties gevollden die geassocieerd zijn met vergiftigillg 
(meer dan 120 mg/l). De gemiddelde tijd die nodig was am de maximale 
serumconcentratie te bereiken, was 1,5 UUl' lIa de eerste <losis ell 15 UUI' voor aIle 
doseringell. De gemiddelde halfwaardetUd (SD) was 2,7 (1,4 um ill 8 van de 10 
patienten). Er bleek geen correlatie te bestaan hlssen de doses ell de 
senlIllconcentraties en evcnmin tussen de pijnscore en de sennncollcentraties. Er was 
een significant omgekeerde verhouding tussen de voorafgaande pijnscore ell de 
maximale serumcolleentraties. Meervoudig rectale doseringen van paracetamol in een 
doserillg van 20 !llg/kg lichaamsgewicht leidden bij it terme geboren pasgeborenell tot 
wijd uiteenlopende senullconcentraties, maar leidden niet tot het bereikell vall 
therapeutische spiegels bij aIle kinderell. Aangeziell er geen accumulatie werd 
aallgetoond, is een dosis van 30 mg/kg gevolgd door doseringen van 20 mg/kg met eell 
doseringsintervai van 6-8 UUl', de optimale doserillg om therapeutisehe waardell te 
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bereiken, Deze nieuwe aanbevelingen komen overeen met recent gepubliceerde 
aanbevelingen voor ondere zuigelingen en kinderen, 
Pijn na een procedurele interventie, wcrd onderzocht in een groep van 122 kinderen 
die werden geboren na een vacuihnextractie, In de klinische praktijk werd paracetamol 
in een aantal ziekenhuizen vaak gegeven, echter in andere ziekenhuizen niet 
toegestaan, In beide omstandigheden waren er geen duidelijk objectieve redenen aan te 
voeren voor het wei of niet geven van paracetamoJ. Daarom werd een prospectieve 
gerandomiseerde dubbelblinde placebo-gecontroleerde studie verricht, met 
paracetamol in een dosering van 20 mgJkg rectaal elke 6 um, in vergelijking met een 
placebo, Hierbij werd geevalueerd of paracetamol de pijn verlicht, dan weI bestrijdt, 
bij pasgeborenen die geboren zijn na een vacuiimextractie, Daamaast werd onderzocht 
of de klinische toestand verbeterde, Kinderen die geboren werden na een 
vacntlmextractie, werden at random ingedeeld in de studiegroep (N=71) en kregen 
maximaa14 doses paracetamol rectaal, Of in de controlegroep (N=71) waarbij zij een 
placebo kregen, De beoordeling van de pijn werd ven-icht door middel van een 
gevalideerde gezichtiesschaal en door de klinische conditie te scoren, Beide scores en 
klinische symptomen zoals spugen, huilen en pijn bij het verzorgen van deze kinderen 
werden vergeleken met symptomen bij de kinderen in een referentiegroep (N=66), 
Deze referentiegroep bestond uit kinderen die geboren waren na een ongecompliceerde 
zwangerschap en een nonnale bevalling (d,w,z, met het achterhoofd voor) zonder 
vacuiimextractie, Het bleek dat de pijnscores niet verschilden tussell de twee 
vacuiimextractiegroepen, De klinische conditie in de studiegroep verbeterde aIleen na 
de eerste dosis paracetamol in vergelijking met de placebogroep, Er was eell 
significant verschil (p < 0,05) in objectieve klillische symptomen in de beide 
vacUUmextractiegroepen in vergelijking met de referentiegroep, Wij cOllc1udeerden dat 
een eelunalige dosis van paracetamol bij pasgeborenen, geboren na een 
vacuumextractie de klinische toestand duidelijk verbeterde, Dit resu!teerde evenwel 
niet in een significante verandering in objectieve pijnscore, Het geven vall herhaalde 
doses paracetamol had geen effect op de klinische symptomen of de klinische toestalld 
van de pasgeborene, De in deze studie gebruikte dosis paracetamol en de methode die 
gebruikt werd voor de beoordeling van pijn, lieten geen enkel analgetisch effect van 
paracetamol bij pasgeborenen, geboren door middel van een vacuUmextractie, zien, De 
paracetamol verbeterde lum klinische conditie echter weI. Naar aanleiding van de 
snldie werden de richtlijnen voor toediening van paracetamol na een vaclJiimextractie 
veranderd in toediening van een dosis paracetamol aan aIle kinderen vlak na de 
vacuumextractie; afilankelijk van de pijnscore kan evennlele aanvullende therapie 
worden gegeven, 
In hoofdsnlk III worden de onderzoeken naar fannacokinetiek en fannacodynamiek 
van morfine bij de premature pasgeborene beschreven, 
In de eerste plaats werd het effect onderzocht, van een continue toediening van 
morfine in een dose ring van 10 flg/kg/nm, bij kinderen nit verschillende 
Ieeftijdsgroepen en we I'd de bmikbaarheid van de snelle methode om 
sennnconcenn'aties te bepalen onderzocht, lllet ais doel de doseringen aan te kUllllen 
passen (hoofdstuk lIU), De doelstellingen van de snldie waren het bepalen van de 
concentratie-effect relatie van continue lllorfine in te vroeg geboren kinderen in de 
eerste dagen na de geboorte met gebruikmaking van een gevalideerde pijnscore, de 
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NIPS. De scores von den plaats zowel gedurende een periode dat geen interventies 
plaatsvonden als gedurende endotracheaal (door de beademingshllis heell) llitzuigen, 
Daamaast werd onderzocht of een snelle, gemodificeerde Fluorescentie Polarisatie 
lmuno Assay gebnlikt voor het bepalen van morfine serumcollcenh'aties, van nut kan 
zijll om de morfinedoses aan te passen. 
In een prospectief klinisch onderzoek kregen premature beademde neonaten continue 
morfine (10 ~g/kg/llur). Deze pasgeborenen werden verdeeld ill drie leeftijdsgroepen 
«28 weken, hlssen 28 en 32 weken, tussen 32 en 37 weken), AIle kinderen 
ondergingen verschillende pijnlijke procedures, zoals o.a. percutane intravenellze 
catheters of infusen, endotracheaal uitzlligen, en electieve rei'ntubatie. De morfine 
sel1l111concenh'aties werden bepaald met gebmikmaking van een snelle Fluorescentie 
Polarisatie Immuno Assay en vervolgens werd farmacokinetische analyse ven-icht. 
Pijnscores v66r en na het begin van de morfinetoediening en gedllrende endotracheaal 
uitzuigen, werden bepaald met behlllp van de NIPS. 
Van de 24 kinderen die werden gei'llcludeerd in het onderzoek, waren er 4 jonger dan 
28 weken, 14 tussen 28 en 32 weken en 6 ouder dan 32 weken postconceptionele 
leeftijd. 
Morfine werd gevonden in 75-84% van de monsters gedurende de eerste tien 
ievensdagen, en bij sommige kinderen ook nog 12 en 24 uur na staken van de morfine. 
Alhoewel er gedurende de eerste drie dagen een tendens was van lagere cOllcenh'aties 
in de oudere graepen, waren de verschillen in de gemiddelde morfineconcenh'aties 
tussen de graepenniet significant. 
De gemiddelde morfineconcentratie voor aile kinderen nam tae van 85,1 ± 33,4 llg/L 
op dag 2 naar 103,3 ± 70,8 flg/L op dag 5. Behalve op dag 2 werd geen relatie van de 
morfmeconcentratie met de postcanceptionele leeftijd gevonden. De gemiddelde 
geschatte klaring was 2,3 ± 1,1 mVmin/kg voor de totale groep en nam toe met de 
postconceptioneie leeftijd. Er werden geen significante verschillen gevonden in klaring 
tussen de verschillende leeftijdsgroepen. De pijnscares waren significant hoger v66r, 
dan na morfme (p <0,001), en eveneens significant hoger tijdens uitzlligen dan voor of 
2 minutenna endoh'aeheaal uitzuigen (p <0,00 I). De pijnscores waren niet gerelatcerd 
aan de morfineconcentraties. 
Morfineconcentraties kunnen bepaald worden met behulp van deze snelle methode, 
maar aangezien er geen conelatie was met pijnscorc is deze methode niet gesehikt 
VOOl' een individuele aanpassing van de dosering. Pijnmeting door middei van een 
pijnscore liet zien dat er in deze studie met de gebruikte doses goede analgesie werd 
verkregen gedurende de periode van beademing, maar dat er geen concentratie-effeet 
relatie bestond. 
Een toenemend aantai onderzoeken naar het effect van de metabolieten van morfine 
toonde aan, dat morfine-3-gIUCllronide en morfine-6-g111curonide respectievelijk van 
groat belang zijn als stimulerende stoffen voor de ademhaling en vanwege de 
pijnstillende werking. Daarom bestudeerden wij de fannacaldnetiek en 
fannacodynamiek vatl morfine en zijn metabolieten in een prospectieve 
geralldomiseerde geconh'oleerde studie. Het effect van de twee meest geblllikte 
doseringsvormen werd vergeleken in beademde premature pasgeborenen. Doel van het 
onderzoek was om farmacokinetiek en farmacodynamiek van morfine en zijn 
belatlgrijkste metabolieten morfme-3 en morfine-6-glucuranide te onderzoeken bij 
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kinderen in de eerste tien levensdagen. Daamaast werden de effecten van het gebruik 
van cardiotonic a (middelen die de werking van het hart ondersteunen en de bloeddruk 
verhogen), onderzocht, evenals het effect van de mate van 'ziek-zijn'. Achtentwintig te 
vroeg geborell, beademde kinderen die verscheidene pijnlijke handelingen of 
interventies ondergingen, kregen continue morfine toegediend in een dosering vall 10 
(greep A) of 15 (groep B) I!g/kgluur. Gedurende een aantal opeenvolgende dagen 
werden de serumconcentraties voor morfine en zijn metabolieten bepaald met behulp 
van een HPLC-meUwde en werden farmacokinetische analyses velTicht. De mate van 
pijn werd bepaald door middel van een gevalideerde pijnscore, de NIPS. Morfine werd 
gevonden in 80-100% van de monsters en morfine-3-g1ucuronide in 89-100% van de 
senunmonsters. 
Het percentage kinderen, bij wie morfine-6-glucurollide werd gevondell in het semm, 
nalll significant toe van 41 % tot 90% gedmende de eerste 9 levensdagen. Verschillen 
tussen de groepen in gemiddelde serumconcentraties voor morfme en de metabolieten 
waren niet significant. De gemiddelde morfineconcelltratie voor de totale groep nalll 
toe van 58,1 ± 37,6 l!glL op dag 2 tot 63,2 ± 29,1 l!glL op dag 3 en nam hiema af tot 
44,3 ± 16,3 Ilg/L op dag 9. De waarden van morfine-3-glucurenide namen significant 
toe van 75,4 ± 41,0 Ilg/L op dag 2, tot 130,8 ± 66,7 f!glL op dag 9 en morfine-6-
glucuronide concentraties tenslotte namen toe van 25,1 ± 10,0 [!gIL op dag 2 tot 38,4 ± 
14,0 ~g/L op dag 9. Op dag 7 waren de lllorfineconcentraties significant hoger bij een 
hogere postconceptionele leeftijd, op aile andere dagen was er geen relatie tussen de 
postconceptionele leeftijd en' morfine of de postconceptionele leeftijd en de 
metabolieten van lllorfine. 
Twaalf en vierentwintig uur na staken van de morfinetoediening werd in het merendeel 
van de kindel'en geen mOl'fme of morfine-6-glucuronide meer gevonden. Morfine-3-
glucuronide daarentegen wenlna 12 UUl' nog gevonden in 12 van 14 monsters (85,7%) 
en na 24 uur in 13 van 17 monsters (76,5%), echter in lagere concentraties dan de 
laatste waarden gedurende lllorfinetoediening. De gemiddelde metaboliet:morfine 
serumconcentra(ie ratio nam significant toe gedurende de eerste 7 dagen, hetgeen een 
aanwijzing is voor rijping van het morfinemetabolisme. De gellliddeide morfine-3-
glucuronide:morfine-6-g1ucuronide ratio nam niet significant toe. 
De gemiddelde geschatte senunklaring was 3,64 mlllllin/kg voor de totale groep, 
zonder dat er een significante correlane bestond met de postconceptionele leeftijd. Er 
was een significant hogere klaring in groep B dan in groep A. Zowel het toedienen van 
cardiotonica of de emst van de ziekte waren nie! van invloed op de morfineklaring of 
op de mOl'fineconcentraties. 
Er was een goed analgetisch effect van morfine. Pijnscores waren v66r het starten van 
de morfinetoediening significant hoger, dan na staIten. Er was eveneens een goede 
pijnbestrijding v66r en na endotracheaal uitzuigen, maar tijdens uitzuigen waren de 
pijnscores significant hoger,hetgeen eell aanwijzing kan zijn vom matige piju of voor 
onwelbevinden. Pijnscores waren niet gecol1'eleerd met lllorfine, morfine-3-
glucuronide of morfine-6-glucol'onide concentraties op enig tijdstip. 
Dit is het eerste onderzoek naar de dosis-concentratie-effect relatie VaIl morfine bij 
kindereu in deze leeftijdsgroep gedurellde een peri ode die laIlger is daIl 72 UUI'. Wij 
kwamen tot de coucInsie, dat ua intravelleuze toedielling aan premature pasge borenen 
morfine en morfine-3-glucurollide gedurende aile dageu aangetoond kau worden in het 
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serum, maar dat morfine-6-g1ucuronide niet bij alle kinderen in de eerste Ievensdagen 
gevonden kan worden. 
De mate waarin lllorfine-6-g1uClU'onide kan worden aangetoond, neernt toe Illet hogere 
postnatale Ieeftijd. 
Daamaast concluderen wij, da! ondanks het feit dat er goede pijnbestrijding leek te 
bestaan, er geen correlatie was (ussen de concentratie van lllorfine en de pijnscore. Eell 
aallvangsdosis vall 10 flg/kg/uUl' is voldoende. Jndien tolerantie optreedt, moet om het 
pijnstillend effect te waarborgen de lllorfinetoediening worden verhoogd met een 
hoeveellleid VillI 5 ~tg/kg/uUl', voorafgegaan door 50% VillI de oplaaddosis. 
Behoudens het optreden van een blaasretentie bij dde kinderen, werden geen 
bijwerkingen gevonden. 
In hoofdstuk IV worden de resultaten van dit proefsclnift besproken in reIatie tot 
andere in de littera(uur verschenen artikeIen. De resultaten van dit proefsclnift dragen 
in belangrijke mate bij aan ons begdp van pijnbeoordeling en pijnbestrijding bij 
pasgeborenen. VervoIgstndies zijn nodig om onze kennis over de farrnacokinetiek en 
de farrnacodynarniek van analgetica bij pasgeborenen te vergroten. Nieuwe studies met 
als doel de pijnscores te valideren, zijn reeds begonnen en zouden samen met de eerder 
genoemde onderzoekell knunen leiden tot correlaties tussen de meest gebruikte 
analgetic a en pijnscores. Van bijzonder belang is daarbij de preventie van een slechte 
neurologische uitkomst, door al vroeg morfine te geven aan te vroeg geboreneu. 
Daarnaas! is het goed de ontwikkeling van de kinderen te volgen, om eventuele lange 
tetmijn effecten op te sporen. Dit kan onderzocht worden (ijdens een standaardsitnatie, 
bijvoorbeeld tijdens vaccinatie, waarbij de reactie op pijn wordt bepaald. 
De relatie tussen de geneesmiddelenconcentratie in de liquor cerebrospinalis 
(herseuvocht) en ueurofysiologische parameters, alsmede de interaktie russen het 
mechanisme van morfine receptoren en het bestaan van polymorfismen van de fl-
opioid receptor, zijn belangrijke onderwerpen van huidig onderzoek. De huidige 
ontwikkelingen doen ons hopen, dat het in de toekomst mogelijk zal zijn om te komen 
tot het in kaart brengen van de pijngevoeligheid per individu en zo tot een aangepaste 
pijnbestrijding. 
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Abbreviations 
APAP 
AUC 
CI 
ClUB 
CST 
DC 
DCE 
DE 
EEG 
ERG 
ET 
F 
FI-IR 
FLACC 
FPIA 
HELLP 
HPLC 
IUGR 
MEG 
M3G 
M6G 
NFCS 
NICU 
NIPS 
NST 
OPS 
PIPP 
PTD 
Acetaminophen, paracetamol 
Area under the serum conceno·ation-time cmve 
Peak senIln concentration 
Clearance 
Clinical risk index for babies 
Contraction stress test 
Dose-Concentration 
Do s e-Con ceno·a ti on -EIT e c t 
Dose-Effect 
Electroencephalogram 
Electroretinogram 
Endoo·acheal suctioning 
Fraction of drug absorbed 
Fetal heart rate 
Faces, legs, activity, ely, consolability 
Fluorescence polarization immuno assay 
Haemolysis, raised liver functions, low platelets 
High-performance liquid chromatography 
Intrauterine growth restriction 
Magnetoelectroencephalogram 
Morphine-3-glucufOnide 
Morphine-6-glucuronide 
Neonatal facial coding system 
Neonatal intensive care unit 
Neonatal infant pain score 
Non-so·ess test 
Objective pain score 
Premature infant pain profile 
Pain threshold difference 
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RDS Respiratory distress syndrome 
SGA Small for gestational age 
Tmox Time to reach peak senUll concentration 
T~ Serum half-life of the dmg 
T, Time to reach therapeutic levels 
VAS Visual analog scale 
VAS Vibroacoustic stimuli (1.1) 
VE Vacuum extraction 
VEP Visual evoked potential 
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